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Summary
Sensitive, high-throughput, in vitro assays for the detection of potential rat CYP4A1 and rat 
CYPlAl inducers have been developed using reporter gene technology. Large numbers of 
compounds can be rapidly screened with these assay systems, using only small quantities of test 
compound.
A 102bp peroxisome-proliferator responsive element, isolated from the 5’-flanking region of 
CYP4A1 by Aldridge et al. (1995), was shown to be responsive to several peroxisome proliferators 
and 9-cis retinoic acid in transiently transfected human hepatoma HepG2 cells. Co-transfection of 
an expression plasmid encoding mPPARa was found to be required for this response. Initial 
transfections were carried out using a chloramphenicol acetyl transferase (CAT) reporter gene 
construct containing the rabbit (3-globin promoter upstream of the 102bp CYP4A1 element. In order 
to maximise sample throughput, subsequent transfections were performed using a secretory alkaline 
phosphatase (SEAP) reporter gene construct, which allowed reporter gene expression to be 
measured in small samples of cell culture media. The 102bp CYP4A1 element has been cloned into 
the SEAP reporter gene construct upstream of a SV40 early promoter. The response of the CYP4A1 
element was not altered by the change of promoter and reporter gene. Upon exposure to a range of 
compounds, that included known peroxisome proliferators, PPAR activators and a number of 
cytochrome P450 inducers, the assay was able to differentiate between inducing compounds and 
negative controls.
The first 1171bp of the rat CYPlAl promoter was cloned upstream of the SV40 early promoter into 
a SEAP reporter gene construct. SEAP reporter gene expression was induced specifically by (3- 
naphthoflavone in HepG2 cells that had been transiently transfected with the CYPlAl reporter gene 
construct. Unidentified factors present in foetal calf serum were observed to reduce p- 
naphthoflavone induced reporter gene transcription. PD98059, a specific inhibitor of mitogen-
activated protein kinase kinase (MEK) (Dudley et a l, 1995; Alessi et a l, 1995) was also found to 
modulate 7-reporter gene transcription.
In conclusion, the CYP4A1 and CYPlAl reporter gene assays that were developed have been 
found to be specifically responsive to their respective inducing compounds in a reproducible 
manner. These systems could potentially be used in the toxicological screening of novel 
compounds in the development of therapeutic drugs.
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1. Introduction
1.1 Preface
During the course of a life-time, both animals and man are exposed to a wide variety of foreign 
compounds. Exposure to these foreign compounds, better termed xenobiotics (‘xeno’ meaning 
foreign and ‘biotic’ meaning relating to living things), can be acute or chronic. Xenobiotics are 
encountered in foodstuffs in the form of additives such as preservatives, colourings, sweeteners and 
flavourings. Foods are also contaminated with chemicals used as herbicides, pesticides, fertilisers 
and growth promoters. Industrial chemicals and environmental pollutants, products of modem 
civilisation, are important sources of xenobiotic exposure. Xenobiotics are also used for 
therapeutic (e.g. anaesthetics, analgesics, anti-convulsants) and recreational (e.g. nicotine, alcohol) 
purposes. Living organisms are equipped with efficient defence mechanisms in order to convert 
xenobiotics into products that are more readily excreted (Gibson and Skett, 1994). Attention has 
focused on the toxicological importance of the enzymes involved in biotransformation in an attempt 
to dissect the mechanisms of toxicity. With the advent of molecular biology and the cloning of 
genes coding for the enzymes of biotransformation a new understanding of the biological roles and 
evolutionary history of these enzymes is being achieved (Waterman and Johnson, 1991; Josephy, 
1997).
Cytochrome P450 enzymes are the principal enzymes involved in the activation and detoxification 
of xenobiotics and play a major role in the biotransformation of endogenous compounds (Gibson 
and Skett, 1994; Josephy, 1997). Traditionally the toxic effects of a compound have been predicted 
by investigation of the activities of particular cytochrome P450 enzymes. Such studies are usually 
carried out using the livers of rats that had been dosed with test compound.
There is an ever increasing demand for new therapeutic agents to combat disease. New antibiotics, 
for example, must be developed in order to defeat the resistant strains of bacteria that have emerged 
due to the widespread use of antibiotics. It is now possible to synthesize vast numbers of novel 
compounds, any of which may possess therapeutic properties. Rapid high-throughput screening 
systems for the detection of potentially toxic compounds are therefore invaluable tools for the 
pharmaceutical industry, allowing toxic compounds to be identified at an early stage of drug 
development. In vitro molecular approaches to toxicity screening have several advantages over in 
vivo analysis: results are usually obtained in a shorter period of time, the use of experimental 
animals is reduced and only small quantities of test compound are required.
1.2 Cytochromes P450
Cytochromes P450 are a superfamily of haem-containing monooxygenases, that have been subject 
to intensive study for their physiological importance in the pharmacodynamics and detoxification of 
a very large number of structurally diverse drugs and other xenobiotics, as well as in the activation 
of environmental procarcinogens through their biotransformation into electrophilic genotoxic 
compounds (Gonzalez, 1992). A number of cytochromes P450, expressed in specialised tissues, are 
involved in the oxidative, peroxidative and reductive metabolism of endogenous compounds such 
as steroids, bile acids, fatty acids, prostaglandins, leukotrienes and biogenic amines (Nebert and 
Gonzalez, 1987; Nelson, Kamataki, Waxman et a l, 1993).
1.2.1 Nomenclature
The term ’cytochrome P450' is not the preferred term for these proteins which are more accurately 
described as 'heme-thiolate proteins' by the International Union of Biochemistry (Nelson et a l, 
1993). Yet this term has remained in use since 1961 when Sato and Omura suggested 'cytochrome 
P450' as a temporary name for the then newly characterised carbon-monoxide binding pigment, that 
exhibited an unusual visible absorption spectrum at 450nm in its carbon-monoxide-reduced 
difference spectrum (Omura and Sato, 1964).
In 1989 Nebert reported that the P450 superfamily was known to contain more than 78 members, by 
1993 this figure had risen to a total of 221 P450 genes and 12 pseudogenes classified into 36 gene 
families (Nelson et al, 1993). An updated list has been more recently published and contains 481 
P450 genes and 22 pseudogenes from 74 gene families that have been described in 85 eukaryotic 
species (including vertebrates, invertebrates, fungi, and plants) and 20 prokaryotic species (Nelson 
et al, 1996). All of these genes within their given families contain the same number of exons and 
similar intron-exon boundaries. It is interesting to note that the greatest increase in new P450 genes
since the Nelson et al (1993) update has come from invertebrates, plants and bacteria which may 
signify that there are few mammalian P450 genes yet to be discovered.
The existence of multiple isoforms of P450 with broadly overlapping substrate specificities and 
differential inducibilities means that classification of the isoforms according to substrate specificity 
is inappropriate. In efforts to dispel confusion caused by the use of trivial names for P450s a 
nomenclature system based on divergent evolution of the superfamily was devised, defining P450s 
by their amino acid sequence similarities (Nelson et a l, 1993). Cytochrome P450s are named using 
the root GYP (Cytochrome P450) followed by an Arabic numeral denoting the P450 family. 
Names of genes are written in italics. The cDNAs, mRNAs and enzymes in all species (including 
mouse) are written in capital letters without italics or hyphens. It was arbitrarily assigned that P450s 
with amino acid sequences showing >40% identity belong to the same family. Where mammalian 
P450 amino acid sequences show >55% identity they are assigned to the same subfamily and if two 
or more such subfamilies exist they are designated by a letter following the family number. The 
individual P450 form is specified by a number after the subfamily letter (Nelson et a l, 1996). For 
example, the enzyme CYPlAl belongs to the cytochrome P450 family 1, subfamily A and is 
identified as form number 1.
The definition of a P450 family has unexpectedly turned out to be useful; in the cases examined so 
far, genes within a defined subfamily have been found to be non-segregating (Nelson et a l, 1993). 
The rat CYP2D "gene cluster" is such an example where CYP2D1, CYP2D2, CYP2D3, CYP2D4 
and CYP2D5 genes are located adjacent to each other on the same chromosome, i.e. non­
segregated. It is most likely that these gene clusters have occurred via gene duplication events, 
mostly during the last 400 million years (Nebert and Gonzalez, 1987; Nelson and Strobel, 1987; 
Gonzalez and Nebert, 1990; Nebert and Nelson, 1991).
The trivial names of some P450 proteins, for example 11-p, 17-a, and c-21, are appropriate for the 
position of the carbon atom that they hydroxylate. These proteins are now designated CYPllB, 
CYP17 AND CYP21 respectively, in keeping with their trivial names (Nebert et a l, 1991).
1,2.2 Evolution of the P450 Gene Superfamily
The P450 gene superfamily is very ancient in origin, the ancestral gene having existed more than
3.5 billion years ago at about the time that the P450 substrate, oxygen, began to be present in the 
atmosphere; this was long before drugs, animal-plant interactions and combustion of organic matter 
occurred (Gonzalez and Nebert, 1990; Nelson et a l, 1993). To get a perspective on this kind of 
time scale it is interesting to note that humans and rats are believed to have diverged from common 
ancestors just 80 million years ago, and rats and mice diverged from each other less than 20 million 
years ago (Nebert et a l, 1988). Construction of phylogenetic trees from protein sequence 
alignment data show P450 genes to be an example of divergent evolution with divergence between 
bacterial and eukaryotic P450s occurring 2.1 billion years ago (Nelson and Strobel, 1987). All of 
the major P450 families had evolved by the time multicellular organisms had developed. About 
500 million years ago there was a noticeable increase in xenobiotic metabolising P450 forms, in 
particular the CYP2 family, corresponding to a time in evolution when land dwelling vertebrates 
appeared and plants were undergoing a period of diversification (Gonzalez and Nebert, 1990; 
Gonzalez, 1992; Kemper, 1993).
Interspecies variation in the catalytic activities of P450s, which can give rise to problems when 
trying to model human xenobiotic metabolism, may be explained by evolutionary events. Random 
non-synonymous base changes, gene duplication and gene conversions can give rise to new P450 
forms, some of which may be stabilised within a population. It is thought that natural selection 
would favour the progeny of individuals possessing certain enzymes advantageous for survival in
new habitats and on exposure to previously unencountered dietary toxins. P450's that are no longer 
required for survival may accumulate mutations and become inactive (Gonzalez, 1992).
1.2.3 P450 Gene Structure
There is a great diversity in the structure of mammalian cytochrome P450 genes, which range in 
size from the CYP21 genes which are 3.2 kb long to the human aromatase genes (CYP19) which are 
larger than 70 kb (Kemper, 1993). These large size differences are even seen within a single 
family, in particular CYP2D is small at only 4.5 kb compared with the 35 kb size of CYP2C. The 
sizes of the mRNA for each P450 gene are similar, the difference in the size of the genes 
themselves arises from changes in intron length. A good illustration of this are the rat CYP2B1 and 
the closely related rat CYP2B2 gene which differ in size by 9 kb due to a large change in just one 
intron (Suwa et ah, 1985). The mammalian P450s also show variation in the number of introns, 
with 6 introns in the CYPl family compared to 12 in the CYP4 family (Kemper, 1993).
Between mammalian P450 gene families only a small fraction of intron insertion sites are 
conserved, examples being the CYP2 and CYP4 families which share three intron sites. Yet within 
a single gene family the intron sites are completely conserved, with the exception of the CYP4 
family, where an intron in the 3’ untranslated region of CYP4A1 is not present in CYP4A2 or 
CYP4B1. Also, the first intron of CYP4A1 appears to have migrated two codons from the site of 
the first intron in CYP4B1 (Kemper, 1993).
1.2.4 Cytochrome P450 Reactions
Cytochrome P450 enzymes are b-type haemoproteins with an identical thiolate-bound haem 
prosthetic group and mechanism of catalysis, but they have a variety of endogenous and xenobiotic 
substrate specificities, reflecting their widely different apoprotein structures (Oritz de Montellano,
1986). P450 is often thought of principally as a 'hepatic detoxification system' but the central role 
of P450 enzymes in many crucial cellular biosynthetic pathways, along with their capacity to 
metabolise virtually all drugs and chemical carcinogens, is now more widely known. It has been 
postulated that fundamental cellular processes such as differentiation, apoptosis, growth, 
homeostasis and neuroendocrine functions involve P450 enzymes (Nebert and McKinnon, 1994, 
Gonzalez et a l, 1995; Ma and Whitlock, 1996).
Cytochrome P450 along with the flavoprotein NADPH-cytochrome P-450 reductase and a lipid 
component, phosphatidylcholine, constitute the mixed-fimction oxidation (MFO) reaction (see 
Equation 1-1) which plays a primary role in Phase I metabolism of drugs and xenobiotics. Phase I 
or ‘functionalisation’ reactions introduce, or unmask a suitable functional group into the foreign 
compound and hence in most cases render a more polar compound that is more readily excreted. 
The P450s involved in Phase I metabolism include mainly members of the CYPl, CYP2, CYP3 and 
CYP4 families, see Table 1-1. Some Phase I products act as substrates for Phase II metabolism in 
which conjugation with an endogenous group such as a glucuronide produces a more highly water 
soluble and polar product which can then be more readily excreted or eliminated from the body 
(Gibson and Skett, 1994).
Equation 1-1. Stoichiometry of the MFO Reaction
NADPH + +O2 + R H -------------------------►NADP^ + H2O + ROM
Cytochrome P450
Table 1-1. Selected Hepatic Xenobiotic Metabolising Cytochrome P450s
P-450 Family Enzyme Substrates Reaction Inducing agents
1 C Y P lA l
C YP1A2
ethoxyresorufin
2-acetylaminofluorene
7-ethoxyresorufin O -  
deethylase, aryl 
hydrocarbon 
hydroxylase
Y-hydroxylation
PAH, TCDD, P- 
naphthoflavone
Isosafrole, TCDD
2 CYP2A1 testosterone 7a-hydroxylase phénobarbital
CYP2B1
CYP2D6
CYP2E1
phénobarbital,
hexobarbital
debrisoquine, sparteine 
dimethylnitrosamine
xenobiotic metabolism
phénobarbital
non-inducible 
ethanol, isoniazid
3 CYP3A4 nifedipine xenobiotic and steroid 
metabolism
steroids,
dexamethasone
4 CYP4A1 fatty acids,
prostaglandins Ei and 
P2a
«-hydroxylase peroxisome
proliferators
Adapted from Josephy, 1997; Simpson, 1997; and Gonzalez, 1992.
The MFO reaction catalyses the hydroxylation of a large range of structurally diverse drugs whose 
only common feature is a degree of lipophilicity. Cytochrome P450 haemoprotein serves as both 
the substrate- and oxygen-binding locus for the MFO reaction and with NADPH-cytochrome P450 
reductase, undergoes cyclic oxidation and reduction of the haem iron that is required for catalysis of 
the reaction (Gibson and Skett, 1994). The catalytic cycle of cytochrome P450 is illustrated in 
Figure 1-1.
Figure 1-1. Catalytic Cycle of Cytochrome P450
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NADH, reduced nicotinamide adenine dinucleotide; NADPH, reduced nicotinamide adenine 
dinucleotide phosphate; RH, oxidisable substrate; ROH, hydroxylated metabolite. (1) oxidisable 
substrate (drug) binds to the oxidised form of cytochrome P450, (2) reduction of substrate-bound 
ferric cytochrome P450 to the ferrous form of the haemoprotein, (3) binding of molecular oxygen to 
the ferrous cytochrome P450-substrate adduct, (4,5 and 6) these stages are thought to involve 
electron rearrangement, introduction of a second electron and subsequent oxygen insertion and 
hydroxylated metabolite release, * may provide a source of the second electron for some P450s and 
substrates. (Taken from Gibson and Skett, 1994)
1.2.5 Role of P450s in Drug Toxicity and Carcinogenesis
As already discussed the P450s are an essential component of the MFO reaction, which plays a 
primary role in the Phase I metabolism of xenobiotics. Together with Phase II metabolism. Phase I 
metabolism usually results in the detoxification of xenobiotics. However, oxidation of these 
foreign compounds by P450 enzymes can generate more reactive and more electrophilic 
intermediates. These intermediates are capable of reacting covalently with biological
macromolecules, proteins, nucleic acids or lipids and are hence implicated in toxicity and 
neoplastic change (Guengerich, 1988; Soucek and Gut, 1993; Nebert and McKinnon, 1994).
Certain classes of chemicals are activated by specific cytochrome P450 forms, for example 
polycyclic aromatic hydrocarbons are activated by CYPlAl (Parke et a l, 1988), nitrosamines by 
CYP2E1 and aromatic amines by CYP1A2 and CYP2E1. Rat CYPlAl, 2A1, 2B1, 2B2, 2C11, 
2C12, 2E1, 3A1 and 3A2 have all been demonstrated to form mutagenic or carcinogenic 
metabolites (Soucek and Gut, 1992).
The majority of chemical carcinogens are activated by a limited number of cytochrome P450 
species, namely CYPlAl, CYP1A2, CYP2E1 and CYP3A. Research into human lung cancer has 
postulated that functionally linked inter-individual differences in the CYPlAl gene may be 
important in susceptibility to lung cancer, although there remains considerable debate on this topic 
(Ingelman-Sundberg, Johansson, Persson et al, 1992). The association between the human high- 
inducibility CYPlAl phenotype and cigarette smoking-induced lung cancer was first suggested 
over twenty years ago (Kellermann et a l, 1973). Due to difficulties encountered with the 
phenotyping assay, support for this data was not published until ten years later (Kouri et a l, 1982). 
Since then the results published contain conflicting data; Japanese studies show a correlation 
between a 1.9 kb allele and lung cancer susceptibility (Hayashi et a l, 1991) but this has not been
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found in other ethnic populations which include Norwegian (Tefre et a l, 1991), American whites 
and blacks (Shields et a l ,1992), and Finish (Hirvonen et a l, 1992). It has been suggested that, 
'among human populations, interindividual-enhanced risk secondary to h i^  CYPlAl inducibility 
might reflect differences in factor(s) affecting CYPlAl transcription, such as the regulatory AH 
receptor (AHR) gene, rather than the structural CYPlAl gene itself (Nebert and McKinnon, 1994).
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1.3 Molecular Mechanisms of P450 Gene Regulation
Adaptation to the increasing diversity of xenobiotic challenge during the evolution of the P450 
superfamily has resulted in responsive isoforms, in many cases expression is inducible by 
endogenous and/or exogenous molecules (Gonzalez, 1992). Considering the responsiveness shown 
by P450s and that in most instances expression is tissue specific, it is not surprising that a variety of 
regulatory mechanisms have been reported. These mechanisms include post-transcriptional and 
post-translational regulation but P450 regulation is predominately at the level of transcription 
(Goldfarb, 1990).
1.3.1 Basic Aspects o f Gene Expression
In the nucleus of a eukaryotic cell DNA is found bound with both histone and non-histone proteins 
in the form of chromatin. To be available for expression a gene must be in the activated state in 
order that transcription can take place (Goldfarb, 1990). Changes in chromatin structure are 
associated with activation of the expression of a gene brought about by a combination of gene- 
specific déméthylation events and the selective binding of activating proteins to the DNA (Gross 
and Garrad, 1988). Section 1.3.2.3.3 discusses regulation of CYPlAl in association with changes 
in chromatin structure Once a gene is activated by the unwinding of condensed, inactive chromatin, 
RNA polymerase is able to transcribe a pre-mRNA copy of the gene which includes both exons and 
introns. Nuclear-splicing removes the intron regions from the pre-mRNA and the exons are joined 
to form mature mRNA. The mRNA is then transported to the cytoplasm where it is translated by 
ribosomes to produce the polypeptide apoprotein (Goldfarb, 1990).
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L3.L1 DNase 1 Sensitivity
As described above changes in chromatin structure are often associated with activation of the 
expression of a gene. This is usually associated with an entire region near the active gene 
becoming selectively sensitive to nuclease, but there are hypersensitive sites or regions of only 
about 200 bp that are highly sensitive to nuclease digestion. These hypersensitive sites are thought 
to be nucleosome-ft-ee and hence accessible for binding of transcriptional regulatory proteins. Two 
DNase 1 hypersensitive sites have been found in the 5'-fIanking region of rat CYP2C12, which is 
predominantly expressed in the female liver (Zaphiropoulos et a l, 1990). However, there were no 
sex dependent differences in these regions. Other studies in the rat and mouse have found that the 
activation of CYPlAl results in general increased nuclease sensitivity and an increase in a DNase 1 
hypersensitive site in the proximal promoter region (Durrin and Whitlock, 1989). Hypersensitivity 
near the promoter of P450 genes and general sensitivity to nuclease correlates with gene expression 
(Kemper, 1993).
L3,L2 Méthylation of Genes
Actively expressed genes are usually hypomethylated, in some cases the méthylation of genes has 
been shown to correlate with gene expression (Cedar, 1988). In mammalian cells the dinucleotide 
CpG can be methylated. Déméthylation of rat CYP2E1 occurs shortly after birth in the neonate and 
has been correlated to CYP2E1 expression. CYP2E1 levels are virtually undetectable at birth and 
rise to high levels within a week (Song et a l, 1986; Umeno et a l, 1988). Hence CYP2E1 shows 
developmental stage-specific gene activation. It has also been shown that in the CYP2D genes, as 
in the CYP2E gene, déméthylation of sites near the RNA initiation site, but not in other regions of 
the genes, is associated with gene expression (Matsunaga and Gonzalez, 1990). It has not been 
demonstrated whether déméthylation is the result of active expression or if déméthylation is itself 
responsible for active expression.
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L3A3 Transcriptional Control
P450 gene expression is regulated at the level of mRNA synthesis via the interaction of trans-acting 
factors with cis-acting DNA elements adjacent to or within the gene. Cis-acting elements can be 
described as elements that act to regulate basal and tissue-specific expression and those that act to 
mediate induction of the gene by specific agents. These cis-acting regulatory elements have been 
defined in P450 genes by functional assays of the elements using in vitro transcription or 
transfection and expression of the genes in cultured cells (Kemper, 1993). Trans-acting factors, or 
DNA-binding proteins as they are also known, facilitate the entry of RNA polymerase molecules 
into the mRNA promoter site of the gene when they dock to their specific regulatory DNA 
sequences. DNA-binding proteins are present in the nucleus and the cytoplasm of mammalian cells 
and can be activated by ligand binding (drugs or hormones), by phosphorylation (second messenger 
signalling systems) or, less often, by metabolite-induced dimerisation/dissociation (Goldfarb,
1993).
1.3.1.3.1 Common Basal Elements
In mammalian genes, many basal and tissue-specific elements are found in the first 200 nucleotides 
from the RNA initiation site. All P450 genes, with the exception of rat CYP4A and GYP 17 which 
have other AT rich regions, share a common regulatory region referred to as the TATA sequence. 
This region has the concensus sequence TATAAA and lies about 20 to 25 nucleotides from the 
RNA initiation site. About 40% of P450 genes contain a form of the cis-acting CAAT sequence. 
Landschutz et al (1988) have described a protein that binds to this element which is important in 
liver-specific gene expression. The position of this motif is only conserved between members of 
the CYP2E subfamily.
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1.3.1.3.2 Functional Proximal Promoter Elements
In the adrenal P450 genes, the proximal promoter region is closely associated with induction by 
cyclic AMP. The functional activities of proximal promoter sequences has been studied in the 
CYPl A, CYP2A, CYP2C, and CYP2E genes (Kemper, 1993).
In the CYPlAl gene it has been shown that a proximal sequence other than the TATA sequence is 
required for both basal and induced expression. Xenobiotic response elements (XRE's) are also 
essential for the induced expression of CYPlAl. In 1990, Yanagida et a l reported that deletion 
analysis of the rat CYPlAl promoter showed that a region from -53 to -44 was required for basal 
expression in transfected cells, in the absence of multiple XRE's required for inducible expression. 
This element is known as the basic transcription element (BTE). Similar sequences are seen in the 
rat CYP2E1 gene.
1.3.1.3.3 Inducible Response Elements
Elements that mediate induction of gene expression often act at a large distance from the RNA 
initiation site and have the properties of enhancers, acting in an orientation independent manner 
(Kemper, 1993). A number of these inducible response elements have been described; sections 
1.3.2.2, 1.3.2.3 and 1.3.2.4 discuss some of these elements and their role in the induction of 
cytochrome P450 expression.
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P450 forms induced by xenobiotics have been classified into six groups according to their inducers 
(Soucek and Gut, 1992):
1. polycyclic aromatic hydrocarbons (3-methylcholanthrene, (l-napthoflavone, 2,3,7,8- 
tetrachlorodibenzo-p-dioxin);
2 . barbiturates (e.g. phénobarbital);
3. steroids (pregnenolone 16-a-carbonitrile, dexamethasone);
4. simple hydrocarbons with aliphatic chains (ethanol, acetone);
5. hypolipidemic drugs (clofibrate);
6 . macrolide antibiotics (triacetyloleandomycin).
P450 expression can also be induced by food components, smoking and physiological factors such 
as starvation (Conney, 1986; Okey, 1990).
1.3.1.3.4 Post-transcriptional Regulation
A variety of regulatory mechanisms are described as post-transcriptional, these include those which 
affect splicing, transport, stability and translatability of mRNA. Among the P450 genes the most 
frequently observed type of regulation at this level results in the stabilisation of mRNA, although 
the mechanism by which this occurs has not been elucidated (Goldfarb, 1990).
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1.3.1.3.5 Post-translational Control
Cytochrome P450 activity has been demonstrated to be regulated at the level of enzyme activity or 
stability. A good example is shown in CYP2E1 induction by small molecules such as ethanol, 
acetone or pyrazole, where there appears to be stabilisation of the active enzyme protein without a 
detectable change in CYP2E1 mRNA levels (Song et.a l, 1987). Experiments using cultured 
hepatocytes have shown that protection of the enzyme on binding of the inducer results in a major 
increase in the half-life of the protein (Eliasson et a l, 1988).
1,3.1,4 Regulation of Rat Liver P4S0 Genes
Table 1-2 summarises the mechanisms of regulation and the sequence homology to human 
homologues of the major rat liver cytochrome P450 genes.
Table 1-2. Rat Liver Cytochromes P450: Regulatory Mechanisms and Human Homologues
CYP Human
homolo­
gue
(a) Sequence 
homology (%)
Regulation of Gene Expression
Constitutive Inducible
Physiological
factors
Mechanism Inducers/
Physiological
factors
Mechanism
lA l lA l* 80 (78) MC, TCDD, 
ACER, ISF, 
BNF
transcriptional 
activation + 
mRNA 
stabilisation
1A2 1A2* 75 (70) transcriptional 
activation + 
mRNA 
stabilisation
2A1 age, sex,
growth
hormone,
diabetes,
hypertension
MC, PB, 
ACER, BNF, 
PCN, ISF
transcriptional
activation
2A2 age, sex 
(male), 
growth 
hormone
transcriptional
activation
2B1 2B6
2B7
78 (74) 
(76)
PB, AE,AC, 
ISF, PCN, 
starvation
transcriptional 
activation + 
mRNA 
stabilisation
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CYP Human
homolo­
gue
(a) Sequence 
homology (%)
Regulation of Gene Expression
Constitutive Inducible
Physiological
factors
Mechanism Inducers/
Physiological
factors
Mechanism
2C7 age, sex, 
diabetes
transcriptional
activation
2C11 2C9 80 (77) age, sex
(male),
growth
hormone,
diabetes
transcriptional
activation
2C12 age
sex(female),
growth
hormone,
diabetes
transcriptional
activation
2C13 2C8 age, sex 
(male), strain
transcriptional
activation
AE
2D1 2D6 (71) age, sex, 
strain
transcriptional
activation
MC, PB
2D2 age transcriptional
activation
2EI 2E1 75 (78) age, growth 
hormone, 
diabetes, 
starvation
transcriptional 
activation + 
mRNA 
stabilisation
ISN, AE, AC, 
B
protein
stabilisation
3A1 3A3 (78) PCN, DEX, 
PB,
hypertension
TAG
transcriptional 
activation + 
mRNA 
stabilisation
protein
stabilisation
3A2 3A5 (71) age, sex
(male),
growth
hormone,
diabetes,
starvation
transcriptional
activation
PB
TAG
transcriptional
activation
protein
stabilisation
4A1 4A9 transcriptional
activation
peroxisome
proliferators,
starvation
transcriptional
activation
Adapted from Soecek and Gut, 1992 and Nedelcheva and Gut, 1994.
* Rat P450 and human homologue share the same name but are not identical. Similarity of cDNA 
and amino acid (in parentheses) sequence stated. AC - acetone, ACLR - Acoclor 1254, AE - 
ethanol, B - benzene, BNF - p-Napthoflavone, DEX - dexamethasone, ISF - isofrole, ISN - 
isoniazide, MC - methylcholanthrene, PB - phénobarbital, PCN - pregnenolone-16a-carbonitrile, 
TAG - triacetyloleandomycin, TCDD - tetrachlorodibenzo-p-dioxin.
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1.3.2 Receptor Mediated P450 Gene Regulation
1,3.2.1 Steroid/Nuclear Hormone Receptor Superfamily
Steroids, retinoids, thyroid hormones, vitamin D 3 and eicosanoids have very different chemical 
structures, and yet bind to specific intracellular receptors that share a common structure. Within 
their target cells, these steroid/nuclear hormone receptors function as ligand-activated transcription 
factors. So far, not all o f  the identified steroid/nuclear hormone receptors have apparent ligands. 
These receptors are termed ‘orphan receptors’ (Calkhoven and Geert, 1996). The general structure 
o f  a steroid/nuclear hormone receptor is shown in Figure 1-2, together with the conserved regions 
and the functions o f  each domain (Dreyer e t  a l ,  1992; Calkhoven and Geert, 1996). A  m odel for 
the molecular pathway o f  steroid/nuclear hormone action is described by Figure 1-3.
Figure 1-2. Schematic Representation of Steroid/Nuclear Hormone Receptor
A/B
424-984 amino acids 
0
N-terminal
E/F
C-terminal
A/B C D E/F
sequence
similarity
exhibits little 
sequence 
similarity across 
the superfamily, 
variable in 
length
most conserved 
domain, contains 
two zinc-co­
ordinated modules 
(zinc fingers), that 
fold together to 
form a compact 
stmcture
large, hydrophobic, moderately 
conserved region
function/s ligand- 
independent 
/ra«5 -activation 
function with 
marked cell type 
and promoter 
specificity
DNA binding 
domain (DBD)
flexible hinge 
region
ligand binding domain (LBD), 
dimérisation, traw^-activation, in 
some cases heat shock protein 
binding
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Figure 1-3. Steroid/Nuclear Hormone Receptor Model
arach id o n ic  acid vitam in A ch o leste ro l ty ro sin e
(5,8,11,14-eicosatetraenoic acid)I H 1 HV
e ic o sa n o id s
V
re tino ids s te ro id
V
thyroid
ho rm o n es h o rm o n es
B io sy n th esis & vit. D
Diffusion
Hsp 90
m odified cell 
function
protein sy n th e s is
CY-rOPLASW
L, ligand; R, steroid/nuclear hormone receptor. Ligand passively diffuses into target cells where it 
binds intracellular receptor located either in the cytoplasm or the nucleus. Unliganded steroid  
hormone receptors are associated with a large multiprotein com plex o f  chaperones (H sp90 and 
other heat shock proteins). Non-steroid receptors do not bind heat-shock proteins and associate  
with D N A  in the presence and absence o f  ligand. Transcription is initiated on association o f  
activated receptor with a specific D N A  sequence, known as a response element. Cell function is 
m odified by the action o f  the new protein/s. The new protein itse lf may have an immediate effect 
or it may be involved in the transcriptional activation/repression o f  other genes. (Adapted from 
McDonnell et a/., 1993.)
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The members of the steroid/nuclear hormone receptor superfamily have been classified in a number 
of ways. Jiang et a l, (1995) have grouped the receptors according to dimérisation potential, DNA 
binding site specificity, and cellular location (Table 1-3). The steroid hormone receptors bind DNA 
and activate transcription as homodimers. They are present in the cytoplasm of cells complexed 
with heat shock proteins (HSP). Binding of ligand induces a conformational change of the LBD, 
causing dissociation of the multiprotein complex and exposure of the LBD/dimerisation interface. 
The dimeric receptor can then bind to its hormone response element. Non-steroid receptors, such 
as the retinoid X receptor (RXR), vitamin D receptor (VDR), the peroxisome proliferator-activated 
receptor (PPAR) and the thyroid receptor (TR), do not bind HSP and are primarily located in the 
nucleus (refer to Figure 1-3). Non-steroid receptors bind DNA not only as homodimers but also as 
heterodimers (Jiang et al, 1995; Calkhoven and Geert, 1996). RXRa is the most common 
heterodimerisation partner for non-steroid receptors. RXRa belongs to the RXR family, consisting 
of 3 isotypes: RXRa, RXRP and RXRy. These receptors are activated exclusively by 9-cis retinoic 
acid, see Figure 1-4 for chemical structure. A second family of retinoid receptors exist, the retinoic 
acid receptor (RAR) family, which also has a, p and y isoforms. Like RXRs, RARs are activated 
by 9-cis retinoic acid {9-cis RA), but unlike RXRs they are also activated by d\\-trans retinoic acid 
(all-/mw RA) (Chambon, 1996). Allosteric interactions among heterodimer partners creates 
complexes with unique properties. For example, the PPAR/RXR heterodimer shows synergistic 
activation by PPAR and RXR ligands (see section 1.3.2.2.2), whereas RXR activation by 9-cis RA 
is suppressed when RXR is complexed with VDR (Calkhoven and Geert, 1996). Additional levels 
of complexity in the regulation of gene transcription by the steroid/nuclear hormone receptors are 
being uncovered, with the identification and characterisation of coactivator and corepressor 
molecules (Wolffe, 1997; Perlmann and Vennstrom, 1995; Calkhoven and Geert, 1996, Chambon, 
1996,). The involvement of PPAR, RXR, GR and the recently identified pregnane X receptor 
(PXR), in the regulation of P450 gene transcription is discussed in sections 1.3.2.2.2 and 1.3.2.4.
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Table 1-3. Steroid/Nuclear Hormone Receptor Classification
Steroid/Nuclear Hormone Receptor Sub-Class
I II in IV
Cellular location 
of receptor
Bound to HSP in 
cytoplasm or 
nucleus in the 
absence o f ligand
Located in nucleus, 
tend to exist as 
monomers or 
heterodimers in 
solution
Located in 
cytoplasm and 
nucleus, exist as 
monomers in 
solution
Exclusive nuclear 
localisation, exist 
as stable 
homodimers in 
solution
Mode of action In presence o f  
ligand Hsp 
dissociates, 
receptors form 
homodimers and 
bind DNA
Depending on 
receptors and 
ligands present, 
bind DNA either as 
monomers, 
homodimers or 
heterodimers
Preference to form 
heterodimers, in 
particular with 
RXRa
Bind extended half­
sites as monomers
Bind DNA 
exclusively as 
homodimers
Binding site
indirect repeat with 
3 nucleotide spacer
->(0-5)->
direct repeat, 0 to 5 
nucleotide spacer 
(DROtoDRS)
—>(0)<— 
indirect repeat
->
extended half site
-» (l)->  
direct repeat (DRl)
Concensus half­
site
AGAACA
AGGTCA
AGGTCA (A,T)AAGGTCA AGGTCA
Receptors
(representative 
selection, not 
comprehensive list)
GR, ER, PR, MR, 
AR
RXR, RAR, TR, 
VDR, PPAR, 
COUP-TF
NGFI-B, SF-1 HNF-4
GR, glucocorticoid receptor; ER, estrogen receptor; PR, progesterone receptor; MR, mineralocorticoid 
receptor; AR, androgen receptor; RXR, retinoid X  receptor; RAR, retinoic acid receptor; TR, thyroid hormone 
receptor; VDR, vitamin D receptor; PPAR, peroxisome proliferator-activated receptor; COUP-TF, chicken 
ovalbumin upstream promoter transcription factor; NGFI-B, nerve growth factor-inducible gene B receptor; 
SF-1, steroidogenic factor 1 receptor; HNF-4, hepatocyte nuclear factor 4.
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Figure 1-4. RXR Ligand 9-cis Retinoic Acid and Synthetic Analogues
COOH
9- cîs  r e t i n o i c  acid
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LG 1069
COOH
LG 108754
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L3.2.2 CYP4A Induction
CYP4A1, involved in co- and ((û-l)hydroxylation of fatty acids and prostaglandins Ei and p2a, is 
expressed constitutively in rat liver and kidney (Simpson, 1997). Transcription of the CYP4A1 
gene is induced in the liver of rats and mice on exposure to a class of compounds that have been 
termed peroxisome proliferators (PPs) (Hardwick, Song, Huberman et a l, 1987). PPs are a diverse 
group of chemicals which include environmental contaminants such as herbicides, industrial 
plasticisers (e.g. phthalate esters) and fibrate hypolipidaemic drugs, see Table 1-4 (Moody et al, 
1991). Many PPs contain an acidic function, usually a carboxyl group, either present in the parent 
structure or a metabolite (Lake, 1995).
Administration of PPs to rats and mice rapidly results in the induction of CYP4A1, followed by 
liver hypertrophy and hyperplasia, and an increase in size and number of peroxisomes (peroxisome 
proliferation) (Reddy et a l, 1983). Co-ordinated with the induction of CYP4A1 is the transcription 
of genes encoding enzymes of the peroxisomal (3-oxidation pathway, including the trifunctional 
enzyme acyl CoA oxidase (AGO). AGO is the rate limiting enzyme in the p-oxidation of fatty acids 
and is often used as a marker for PP-mediated gene activation (Reddy et a l, 1986).
The peroxisome proliferation response to PPs has been found to be species specific. The mouse 
and rat are the most responsive species; the hamster shows an intermediate response; and the 
guinea-pig, marmoset, and primates (including man) are weakly or non-responsive (Moody et al, 
1991). Chronic exposure to PPs has been correlated with carcinogenesis in rodent models (Rao et 
<3/., 1991). Nutritional states, including high fat diets (Ishii et a l, 1980), vitamin E-deficient diets 
(Reddy et a l, 1981) and cold adaptation (Pollera et a l, 1983) have also been correlated with 
peroxisome proliferation.
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Table 1-4. Representative Peroxisome Proliferators
Fibric acids Non-Fibric
acids
Plasticizers Herbicides Environmental/
Physiological
Clofibrate Wy-14,643* Di-(2-
ethylhexyl)phthalate
(DEHP)
Lactofen Cold acclimation
Nafenopin* Tibric acid Di-(2-
ethylhexyl)adipate
(DEHA)
Formasafen High-fat diet
Methylclofenapate Niadenate Dibutyl phthalate Vitamin E- 
deficiency
Gemfibrozil Acetylsalicylic
acid
Triiodothyronine
(T3)
Bezafibrate* ' Obese vs lean mice
Ciprofibrate* High cholesterol
Fenofibrate Choline deficiency
Clofibric acid*
Adapted from Moody et a l, 1991 and Cattley and Preston, 1995. 
*Refer to Figure 1-5 for chemical structures.
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1.3.2.2.1 Peroxisome Proliferation
Peroxisomes are single membrane-limited cytoplasmic organelles and are found in the cells of 
animals, plants, fimgi and protozoa (Reddy and Lalwai, 1983; Lake, 1995). These organelles are 
found in large numbers in hepatocytes and in the proximal tubular epithelial cells of the kidney 
(Rao and Reddy, 1991). The hepatic peroxisomes in many species contain different types of 
crystalloid core or nucleoid. Usually this cystalloid core consists of urate oxidase (Reddy and 
Lalwai, 1983). Humans lack uricase and so human peroxisomes do not contain a crystalloid core. 
Peroxisomes usually contain one or more enzymes that use molecular oxygen to remove hydrogen 
atoms from specific organic substrates in an oxidative reaction that produces hydrogen peroxide, 
hence the name ‘peroxisome’ (Reddy and Lalwai, 1983). The hydrogen peroxide generated is 
utilised by catalase to oxidise a variety of other substrates, including alcohol and formaldehyde. 
The primary function of peroxisomal oxidative reactions is the breakdown of fatty acid molecules 
by the process of p-oxidation. The alkyl chains of fatty acids are shortened sequentially by blocks 
of two carbon atoms at a time that are converted to acetyl CoA and exported from the peroxisomes 
to the cytosol for reuse in biosynthetic reactions. In mammals p-oxidation also occurs in 
mitochondria (Reddy and Lalwai, 1983; Klewe, 1994; Alberts et al., 1994).
Peroxisomes occupy less than 2% of cytoplasmic volume in liver parenchymal cells. In rats and 
mice, PP exposure increases the volume of peroxisomes up to about 20% (Rao and Reddy, 1989). 
Hepatic mRNA for various peroxisomal p-oxidases is increased within several hours of 
administration of a PP to rats (Reddy et al, 1986). The activities of peroxisomal p-oxidases can 
increase 20- to 30-fold. Catalase, the enzyme responsible for degradation of hydrogen peroxide, is 
only induced by about 1.5- to 2-fold (Klewe, 1994). Hepatic CYP4A1 mRNA has been found to be 
significantly increased 6  hours after methylclofenapate treatment, rising to 15-fold above control 
levels at 30 hours post-treatment (Bell et al, 1991). It is thought that persistence of these
26
alterations in the levels of various enzymes contributes significantly to hepatocarcinogenesis. 
Increase in liver weight and size is apparent within a few days of PP administration, reaching steady 
state within 2 weeks. Hepatomegaly follows hyperplasia and hypertrophy of hepatocytes. The 
hyperplasia reaches a maximum at the end of the first week of PP administration and decreases 
thereafter. Chronic administration of PPs results in the appearance of liver lesions. Altered areas 
appear first, followed by neoplastic nodules and finally hepatocellular carcinomas develop (Rao and 
Reddy, 1991).
The molecular mechanism of carcinogenicity of PPs is not clearly understood. PPs have been 
found to give consistently negative results in mutagenicity and gentoxicity tests. There is also a 
long latency period involved in the development of tumours (Cattley and Preston, 1995). Several 
hypothesis have been proposed for the mechanism of PP-induced hepatocarcinogenesis (Klewe,
1994). Sustained oxidative stress has been proposed to produce hepatocarcinogenesis (Reddy and 
Lalwani, 1983; Rao and Reddy, 1989). A sustained level of oxidative stress may result from an 
imbalance in the production and degradation of peroxisomal hydrogen peroxide. Various studies 
have failed to find supportive evidence for PP-mediated DNA damage via increased peroxisomal 
hydrogen peroxide (Cattley and Preston, 1995). Currently, research is focusing on the possibility of 
a receptor-mediated mitogenic response to PPs, via the recently discovered peroxisome proliferator 
activated receptor, discussed in the following section.
1.3.2.2.2 The Peroxisome Proliferator Activated Receptor
Some of the pleiotropic actions of PPs are mediated by a novel member of the steroid/nuclear 
hormone receptor superfamily termed the 'peroxisome proliferator activated receptor' (PPAR). 
Evidence for the involvement of this receptor is supported by the absence of peroxisome 
proliferation responses in animals where the PPARa gene has been disabled by targeted disruption 
(Lee et al, 1995). PPAR was first described in the mouse and reported to be activated in transient
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transfection assays on exposure to peroxisome proliferators by Issemann and Green (1990). The 
mouse PPARa (mPPARa) is a 52.4 kDa protein consisting of a 70 amino acid DNA-binding 
domain (C domain) which possesses two zinc fingers, and a 200-250 amino acid ligand-binding 
domain (E/F domain) which has a hydrophobic pocket for ligand binding and is considered to be 
important in transcriptional activation of the target gene. Rat PPARa shows 98% cDNA sequence 
homology with mPPARa (Mukherjee et al., 1994).
Since the discovery of mPPARa a complex multigene family of PPARs has been uncovered, 
isolated from several species, see Table 1-5. The PPAR subtypes, PPARa, PPARp (or 5) and 
PPARy are selectively activated by a multitude of chemical compounds that include fatty acids, 
peroxisome proliferators, thiazolidinedione antidiabetic agents, and prostaglandins (Schoonjans et 
al, 1996; Auwerx et a l, 1996; Willson and Wahli, 1997). Table 1-6 lists compounds that have 
been shown to activate various PPAR isoforms from several species. The chemical structures for a 
selection of synthetic and natural PPAR activating compounds are shown in Figure 1-5 and Figure 
1-6 , respectively.
In the rat PPARa is principally expressed in tissues that have a high fatty acid catabolism, 
including the liver and the immune system. In the liver, PPARa is involved in the degradation of 
fatty acids and the detoxification of various xenobiotics, via the co- and p-oxidation pathways. Rat 
PPARp is abundantly and ubiquitously expressed (Kliewer et a l, 1994; Braissant et a l, 1996). Rat 
PPARy on the other hand is expressed in a more tissue specific fashion, in the retina, immune 
system and white adipose tissue. The tissue distribution of PPAR isoforms in the human is similar 
to that of the rat, the hPPARyl isoform corresponding to rPPARy. hPPARy2 is a minor isoform 
(Auboeuf e /ût/., 1997).
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Table 1-5, Isoforms of PPAR
Species Receptor Reference
Mouse mPPARa Issemann and Green, 1990
mPPARÔ Kliewer et al, 1994
mPPARyl Chen et a l ,1993; Zhu et a l ,1993; Kliewer et
mPPARy2 al,\994
Tontonoz et al, 1994; Zhu et al, 1995
Rat rPPARa Gottlicher et al, 1992
rPPARp Braissant e /<3/., 1996
rPPARy Braissant et al, 1996
Hamster haPPARy Aperlo et al, 1995
Guinea-pig gpPPARa B elle/(3/., 1998
Human hPPARa Sher et al\993
NUCl Schmidt e /û r / . 1992
(hPPARyl (Elbrecht et a l ,1996; Mukherjee et al,\991; Vidal-
hPPARy2) Puig e /<3/., 1997)
Xenopus laevis xPPARa Dreyer et al, 1992
xPPARp Dreyer e/ cz/., 1992
xPPARy Dreyer e/a/., 1992
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Table 1-6. PPAR Activators
PPAR Homologue Shown to be activated by: Reference
mPPARa Wy, Naf, MEHP, MCP, TCA Issemann and Green, 1990
C6 , C8 , CIO, C12, €14, €16,
€18:1, €18:2, €18:3, €20:4, €20:5, 
€22:8, TTA, Wy
Isseman et a/., 1993
LTB4 , iloprost 
ETYA, Wy 
GW2331
Devchand et ah, 1996 
Keller et a/., 1997 
Kliewer et a/., 1997
mPPARÔ
mPPARp
€18:3
iloprost
Kliewer et al, 1994 
Devchand et al., 1996
niPPARy €ip Zhu et al, 1993
Thiazolidinediones Lehmann et er/., 1995;
The prostaglandin: 15-deoxy- 
A*2>^ “-PJ2
Kliewer et al, 1995 ; Forman et al,  1995
LY-171883 Kliewer et a/, 1994
BRL49653 Devchand et al,  1996
GW2331 Kliewer et a/., 1997
rPPARa €fa, Wy, ETYA Mukherjee étal,  1994
gpPPARa Wy Bell éta l,  1998
xPPARa Wy Dreyereta/., 1992
LTB4, Wy Devchand et a/., 1996
GW2331, €16, €18:1, Pta, €18:2, 
€18:3, AA, 8 S-HETE
Kliewer et aA, 1997
Bezafibrate Kreyeta/., 1997
xPPARp Wy Dreyeretût/., 1992
Bezafibrate Kreyeta/., 1997
xPPARy Wy, Naf, €Io, Warf, T€A Dreyereta/., 1992
GW2331, €16, €18:1, Pta, €18:2, 
€18:3, AA, 8 R-HETE, PGJ2
Kliewer et a/., 1997
hPPARa Wy, €lo, Naf Shereta/, 1993
€fa, Wy, ETYA Mukherjee, 1994
GW2331 Kliewer et a/., 1997
hNUCI Wy, AA, OA, Dex Schmidt et a/,, 1992
hPPARy PGJ2 Kliewer et a/., 1995
GW2331 Kliewer et a/., 1997
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Table 1-6 Key:
Wy - Wy-14,643, MCP - methylclofenopate, LA - lauric acid, Dex - dexamethasone, Naf - 
nafenopin, 06 - caproic acid, C8  - capiylic acid, CIO - capric acid, C12 - Lauric acid, C14 - 
myristic acid, C16- palmitic acid. C l8:1 - oleic acid. C l8:2 - linoleic acid. C l8:3 - linolenic acid, 
C20:4 - arachadonic acid, C20:5 - eicosapentaenic acid, C22:8 - docosahexanoic acid, TTA - 
tetradecylthioacetic acid, Pta - petrosolenic acid, ETYA -5 ,8 ,1 1 , 14-eicosatetrayanoic acid, Cip - 
ciprofibrate, OA - oleic acid, TCA - trichloroacetic acid, Clo - clofibrate, Cfa - clofibric acid, Warf 
- warfarin, AA - arachadonic acid, MEHP - monoethylhexylphthalate, m - mouse, x - xenopus, h - 
human, r - rat, gp - guinea-pig, ha - hamster.
PPAR activators in bold text have been shown to bind PPAR directly by com petition binding 
assays.
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Figure 1-5. Synthetic Activators of PPAR
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Synthetic PPAR Activators (Figure 1-5 continued)
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Figure 1-6. Natural PPAR Activators
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Nuclear receptors control transcription of specific target genes by binding to specific DNA 
sequences in the 5 -flanking regions of these genes, see section 1.3.2.1. The response element for 
PPARa was identified in the 5-fianking region of the rat AGO gene (Tugwood et al., 1992). This 
peroxisome proliferator response element (PPRE), located between -573bp and -555bp, was shown 
to consist of an almost perfect direct repeat sequence spaced by a single-base pair: 
5' CGTGACCTTTGTCCTGG 3'. The transcriptional activation of the rat peroxisomal AGO gene 
has been shown to be directly regulated by mPPARa which binds to the PPRE. Rabbit CYP4A6 
and other PP-inducible genes have also been shown to possess PPREs which closely resemble that 
of AGO (Muerhoff et a l, 1992). The direct repeat of a hexanucleotide separated by a single 
nucleotide (DRl) seen in the PPRE is characteristic of other nuclear steroid hormone receptor 
response elements, for example hepatocyte nuclear factor 4 (see Table 1-3).
It has been shown that mPPARa and the retinoid X receptor alpha (RXRa) bind as a heterodimer to 
PPREs thereby enhancing PPAR-dependent gene expression (Mangelsdorf et a l, 1992; Bardot et 
al, 1993). In a similar manner RXRa also forms heterodimers with receptors for thyroid hormone, 
retinoic acid and vitamin D3 which bind to direct repeats with different spacings that make up their 
respective response elements (Hertz et al, 1995), refer to Table 1-3. Other nuclear receptors also 
bind the DRl motif recognised by PPARs, including ARP-1 (Palmer et a l, 1994) and GOUP-TF 
(Miyata et a l, 1993). These nuclear receptors have been shown to compete with PPAR for binding 
to PPREs and to suppress PPAR-mediated transcription of reporter genes. Recent studies have 
indicated that the DNA binding domain of PPARs, but not of RXRa, can bind as a monomer to a 
single core binding site with the 5' concensus flanking sequence (Johnson et al, 1996). A recently 
described human orphan nuclear receptor, LXRa, has been found to bind to PPARa and RXRa 
directly. However, LXRa did not form a DNA binding complex with PPARa on PPREs and in 
studies carried out in vitro, LXRa was found to inhibit binding of PPARa/RXRa heterodimers to
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PPREs. I n  v i v o  experiments also showed L X R a to be a negative regulator o f  PPAR-mediated 
activation o f  PP-responsive genes (M iyata e t  a i ,  1996). A  model for the activation o f  the various 
PPAR isoforms and transcriptional activation o f  target genes is illustrated in Figure 1-7.
Figure 1-7. Model for PPAR Activation
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Adapted from Auwerx e /a /., 1996.
LTB4 , leukotriene B4; PG J2, prostaglandin J2; AGO, acyl GoA oxidase, MGAD, medium chain 
acyl GoA dehydrogenase; apo I, apolipoprotein A-I; apo GUI, apolipo-protein G-III; LPL, 
lipoprotein lipase; ap2 , adipocyte fatty acid binding protein.
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The upstream region of the rat CYP4A1 gene has been examined for the existence of a PPRE, on 
the basis that the regulation of CYP4A1 is co-ordinated with transcription of AGO and may 
therefore be regulated in a similar manner. A PPRE was identified approximately 4300 nucleotides 
upstream of the rat CYP4A1 gene. This element consists of a pair of TGAGGT-like motifs 
separated by a single base-pair (DRl). PPARa and RXRa were found to bind as a heterodimer to 
this element. In reporter gene assays this PPRE was found to confer responsiveness to Wy-14,643. 
A second PPRE was identified 35 nucleotides further upstream, but when co-transfection assays 
were conducted this element did not bind PPARa/RXRa heterodimers and was unresponsive to 
Wy-14,643. This second element also resembles the preferred PPRE sequence, having one perfect 
and one divergent half-site separated by a single base-pair (Aldridge et al, 1995). Although both 
of these closely linked elements were found to be responsive to 9-cw-retinoic acid in the presence 
of RXRa, Aldridge et al propose that since RXRa does not bind to either element as a homodimer, 
then it may be that RXRa interacts with PPARa to regulate transcription via the more distal 
element. The DNA elements implicated in PP-mediated regulation of CYP4A1 are shown in Figure 
1- 8 .
In a recent review on the role PPAR in CYP4A regulation (Johnson et al, 1996) a second element 
overlapping the DRl motif already described has been found by alignment of PPREs from 
peroxisome proliferator responsive genes with that of the Z element of the CYP4A6 gene, see Table 
1-7. The DRl motif in the Z element is not sufficient for binding or function (Palmer et a l, 1995). 
This revealed a 5' extended consensus sequence similar to that seen for nuclear receptors such as 
Rev-Erb-A and RORa/RZRp which are thought to function as monomers. The binding sites for the 
Rev-Erb-A and RORa/RZRp receptors exhibit a single core binding site flanked by concensus 
upstream sequences similar to that seen flanking the DRl if PPREs. It is thought that this tripartite
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feature of PPREs together with imperfections in the core sites of DRl motif confers specificity for 
PPARa/RXRa binding to PPREs relative to other nuclear receptors.
Figure 1-8. DNA Elements Implicated in the Regulation of CYP4A1 Transcription
BamHI Bglll Smal Xbal SphI BamHI
6Kb -5Kb -4Kb -3Kb -2Kb -1Kb
Bglll
1 AGATCTAGGA GGAACTGGGA GCAGATGGAT ATAATCAAAA CATGTTGTAT
Xholl(2)
51 AAAATTCTCA AAAAACTCCA AAGAACAGTA ACTGACAAGC AGATGTAAAT
101
151
201
251
TCCAAAACTC TTTACAATGT GTTCCCTCAT TTTAGGGGTG AAAAATGGGG
Elem ent I
rGGGTAA AGAGGGAAAA TCCACAGTCT GAGTCCTAGG TCAGAGGGGA
Hinfl (182) TCC AGT TCC c cT 
Elem ent II
AGAGTACAAT GTAGATAGAA AAGGCAGGCA TGAAACTAGG GTAAAGTTCA
TCC c a t  TCaAGT
GTGAGATGGA GTGTAAATTG TTC 273
Element I (PPRE-like element) and element II (responsive PPRE) are marked in the diagram 
showing their positions in the CYP4A1 promoter. The nucleotide sequence shown corresponds to 
the first 273bp of the Bgll/Smal region. Nucleotide position 1 corresponds to the Bglll restriction 
enzyme site. The complementary nucleotide sequences for elements I and II are also shown, 
nucleotides shown in lower case letters represent divergence from the PPRE consensus TGACCT 
half-site. The shaded area of sequence corresponds to the (171/273) fragment inserted into the 
reporter plasmid p4Al(171/273)GCAT, see Figure 2-3.
(Aldridge et a l, 1995)
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Reporter gene studies using the rat acyl CoA oxidase gene (Osada et al., 1997), mutation studies 
using the malic enzyme gene (IJpenberg et ah, 1997) and DNA binding studies with a number of 
other natural PPRE elements (Juge-Aubery et ah, 1997) have confirmed the requirement for the 5' 
extended concensus sequence in binding of PPARa. These studies have also found that the binding 
polarity of PPARa/RXRa heterodimers is opposite to that of other heterodimers in which RXR is a 
partner. PPARa binds to the 5' extended half site of the response element. DNA binding studies 
have shown that PPARa/RXRy heterodimers bind to the CYP4A1 PPRE more strongly than 
PPARa/RXRa heterodimers (Juge-Aubry et al., 1997). These results show that the differential 
activation fi-om a given response element not only depends on the DNA sequence and PPAR 
subtype, but also on the RXR subtype present. RXRa is mostly expressed in liver, kidney, lung, 
muscle and spleen, RXRp is ubiquitously expressed, and RXRy is highly expressed in heart, muscle 
and liver (Mangelsdorf et al., 1992). The activation of a PPAR mediated response is further 
complicated by the interaction of PPAR with co-repressors and co-activators (Perlmann and 
Venstrom, 1995; Wolffe, 1997), as well as by signalling cross-talk (Juge-Aubery c/ al., 1995; 
Keller et al., 1995; Krey et ah, 1995).
13,23  Regulation of CYPlAl Expression
CYPlAl is transcriptionally activated by poly cyclic and halogenated aromatic hydrocarbons (PAHs 
and HAHs), compounds that serve as substrates for CYPlAl (Nebert and McKinnon, 1994). PAHs 
such as 3-methylcholanthrene (3-MC) and HAHs such as 2,3,7,8 -tetrachlorodibenzo-p-dioxin 
(TCDD) therefore enhance their own metabolism. CYPlAl induction in response to xenobiotic 
challenge is an adaptive cellular response, allowing rapid detoxification of compounds that would 
otherwise accumulate to toxic concentrations within the cell (Whitlock et al., 1996).
40
1.3.2.3.1 The AH receptor and ARNT
Some inbred strains of mice show an increase in CYPlAl associated aiyl hydrocarbon hydroxylase 
activity on exposure to 3-MC or TCDD and yet other inbred strains show no such increase. 
Inducibility was found to be an autosomal dominant Mendelian trait in cross-breeding experiments 
(Poland et a l, 1982). This inducibility trait led Poland to postulate the existence of a TCDD- 
binding protein, the aromatic hydrocarbon receptor (AH receptor). The AH receptor was detected 
in cytosol prepared from livers of responsive mice and was found in much lower concentrations 
with a reduced affinity for TCDD in non-responsive mice (Okey et a l, 1989). In AH receptor 
defective cell lines, CYPlAl transcription does not occur and therefore CYPlAl transcription is an 
AH receptor-dependent process (Landers and Bunce, 1991). Figure 1-9 shows the chemical 
structures for the AH receptor ligands TCDD, 3-MC, p-naphthoflavone and a-naphthofiavone.
The mouse AH receptor was cloned in 1992 (Ema et a l, 1992; Burbach et a l, 1992) and the human 
AH receptor was cloned a year later (Itoh, et a l, 1993; Dolwick et a l, 1993). The rat AH receptor 
has also been cloned and AH receptor mRNA has been found to be selectively expressed in the 
centrilobular cells of rat liver (Lindros c/ al, 1997). Analysis of the amino acid sequence of these 
clones has revealed that the aromatic hydrocarbon receptor is a member of the family of basic helix- 
loop-helix proteins (bHLH) (Hankinson, 1995). Helix-loop-helix proteins bind DNA either as 
homodimers or heterodimers, and they have a positively charged domain that recognises the DNA 
site. In the helix-loop-helix family are several proteins involved in control of cell growth and 
differentiation (Watson et a l, 1992a). Using mutant mouse Hepa 1 cells, defective in CYPlAl 
inducibility, it has been shown that another member of the bHLH family, the AH receptor nuclear 
translocator protein (ARNT) is required for AH receptor function (Reyes et a l, 1992). ARNT was 
originally thought to be a ‘nuclear translocator’ for the AH receptor, this was because the mutant 
Hepa 1 cells were defective in translocation of liganded AH receptor from the cytoplasm to the 
nucleus. It is now known that liganded AH receptor is unable to bind DNA in the absence of
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ARNT and ARNT is actually a heterodimerisation partner for the liganded AH receptor (Whitlock 
e ta l, 1996).
Figure 1-9. AHR Ligands
Cl ^  0 ^  Cl
2 ,3 ,7 ,8 , - te t rach lo rod ibenzo- /? -d iox in
p-naphthoflauone 
( 5 ,6-Bezoflauone)
3-Hethylcholanthrene
a-naphthoflauone 
(7,8-Benzoflauone)
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The ARNT and AH receptor proteins both contain bHLH motifs near their amino termini. Near 
their carboxy termini is contained a segment of homology, the PAS domain, that is also found in 
two regulatory proteins of Drosophila melanogaster, PER (neurogenic) and SIM (involved in 
circadian rhythm) (Josephy, 1997). The AH receptor, ARNT and SIM all contain glutamine-rich 
regions near their carboxy termini. The dependence of the AH receptor on binding of a ligand for 
activity makes this protein unique among the bHLH proteins. The PAS domain has only been 
found in the AH receptor, ARNT and SIM. (Hankinson, 1995) An unusual feature of the AH 
receptor-ARNT heterodimer is the specific DNA-binding sequence at which it binds. Nearly all 
bHLH proteins bind the E-box sequence (5' CANNTG 3') but the AH receptor-ARNT heterodimer 
interacts with the nucleotide sequence 5'TNGCGTG 3' (Whitlock et a l, 1996). This nucleotide 
sequence has been variously termed as the ‘xenobiotic-responsive element’ (XRE), the dioxin- 
responsive element and more specifically as the ‘AH-responsive element’ (AHRE) (Fujii- 
Kuriyama, 1992). Using mutational analysis it has been found that a core sequence, 5' CGTG 3' is 
essential for functional AH receptor-ARNT interaction with DNA (Shen et a l, 1992). Cytosolic 
AH receptor from a wide range of species has been shown to be able to transform and bind the 
AHRE, even though there are wide variations in species sensitivities to PAHs and HAHs (Bank et 
al, 1992).
In addition to CYPlAl induction, genetic and biochemical studies have implicated the AH receptor 
in numerous biological responses to TCDD (Hankinson, 1995; Josephy, 1997). Exposure to TCDD 
produces a broad range of adaptive and toxic response in experimental animals, including induction 
of other xenobiotic-metabolising enzymes, tumour-promotion, skin disorders, thymic involution 
and alterations in endocrine homeostasis (Safe, 1986). The AH receptor has also been implicated in 
normal liver development, immune function, cell cycle control and differentiation (Gonzalez et a l, 
1995; Ma and Whitlock, 1996). Recent studies have identified a protein that represses AH receptor 
activity, the AHR repressor, by competing for heterodimerisation with ARNT (Fujii-Kuriyama, 
1998).
43
Compounds formed by the UV irradiation of tryptophan have been found to be high affinity ligands 
of the AH receptor. For example, 6-formylinodolo[3,2-è]carbazole binds the AH receptor with 5 to 
10 times the affinity of TCDD and it has been postulated that this compound is a natural ligand for 
this receptor (Rannung, 1998).
1.3.2.3.2 cw-Acting Regulatory Elements
The rat (Yabusaki et a l, 1984; Hines et a l, 1985 and Sogawa et a l, 1986), mouse (Gonzalez et a l, 
1985a) and human (Kawajiri et a l, 1986) CYPlAl gene and 5'-flanking region have been isolated 
and sequenced. Figure 1-10 gives the nucleotide sequence for the upstream region of rat CYPlAl. 
Functional regulatory elements within these sequences have been isolated and characterised using 
reporter gene constructs transfected into cultured mammalian cells and by electrophoretic mobility 
shift assays (reviewed by Fujii-Kuriyama et a l, 1992; Gonzalez et al, 1993; Hankinson, 1995 and 
Whitlock era/., 1996).
DNA elements implicated in the regulation of rat CYPlAl transcription are summarised in Figure
1-11. AHREs were located by employing transient transfection of plasmids containing elements 
from the promoter of CYPlAl upstream of the bacterial chloramphenicol acetyltransferase gene. 
These AHREs were found, in a variety of mammalian hepatoma cell lines, to drive CAT expression 
on exposure of the cells to 3MC and TCDD. Six functional AHREs have been located at -537, -926, 
-1010, -1089, -1233 and -3586 bp upstream of rat CYPlAl (Sogawa et a l, 1986; Fujiisawa-Sehara 
et a l, 1987; Fujii-Kuriyama et a l, 1992 and Sogawa et a l, 1994). The distribution of AHREs has 
been found to be well conserved in the upstream region of rat, mouse and human CYPlAl (Kubota 
e ta l, 1991).
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Figure 1-10. Nucleotide Sequence of the First 4271bp of the Rat CYPlAl Promoter
-4271 TCGAGAAAGT GCAGTTTTCC ATTAGAGATG CTTG TTTATA CCTCACCATC ACGAAGCACT
-4211 GGTGGCAAAG CAGTCAACCA TCTCCTCCG G GAGTGGGTGG GCTGACGATC TGAGTTTAAT
-4151 GGGGAAGAGA GTGTGATGTA GGTTGGGTGG GGGGGAGAGT GGGTATGTAA TGAAAGATGA
-4091 GGTTGAAGTG TGAATAGTGG TTGGAGTGAA GGAGGTTGGA GTGAAGGAGG TGGTGGGGGG
-4031 TTATGTTTGT TTGGAGG TTT TTGGGGGATG GAAGGAAGAT GAGAGTGTGT TAGTGATTTG
-3971 GGTTGTTGTT GGTGTTTAGA GTATGATGGG TGGGAGGATG TGAGGAATAT GTTTGGGAAG
-3911 TTGGTGGGAT TATTGTAAGG TGTGGAGAAT GGGTATATGA TGTGGGTGAG GGTGGTTGGG
-3851 ATTGTGTAAG ATGTTTGGGG TGTGGTGTGG G TTTG TTTG G GGTGTGAGTG GTGTGTTGGT
-3791 GGTGGAGAAA G G G A TTTTTT TTTGG TAGGG TG TTG G TTG T TTGGTGGGTT GGAGTAGGTA
-3731 GGGGTGAGGA GTAGTAAGGA AAAGTGGAAA GGTATTGAGT GTGGAGGTTG AGTAGAAGGT
-3671 GTGTGGGTGG GTGGAGGGGG GAGGGGTGTG GGGTGGGAAT GTGTTGGTGG TATGAGTTAG
-3611 TAGGAAAGGG GAAGAGGTTG TGAGGGATAG GGTTATAAAG TTTGGGGTGA G TTG G G TG TT
-3551 TATGGGTGTG GGAAGGTGTG GAAAGGTTGT GGGGTTTAGG AAGGGATTAG TGAGGGGGAT
-3491 TG TTTGTATT GTGAGGGTTA GGAGAAAGAA GTGTTGGTGA TGATGAGTAT AAGGGGGATA
-3431 AGGGGAGTGG AGAGGGGGTG GGGAGATAGA GGGGTTTGGT TAGAGGGTGG GGGTGTTGGG
-3371 GAGGGGTTGG GGTTAGGAGG TAGAGGGATT GGGAGGAAGG AAGAGGTGAG GATGTTAGGG
-3311 TGAGATGTGA TGGGGGAGAG GTGAGTGGGT GTTTTGTTTG TGGGATGAAT GTGTGGAGGA
-3251 GAGAAGAAAG AGAGGAAGTG GTTTTATTAG CTAATAAAGT TTTTG GTAAG GAAGATGAGG
-3191 AAAAGAGGGG GGGTTGGTGG ATTGGTGTGT GGAAGGGTGG GAGGAGATTT GGTGAAGTGT
-3131 CGAGAGGTAA GGGATTGGTA GGGAGAATGG AAATAGGGAG AAGAGTGAGT GAGGGGAGGG
-3071 TGAGGGATGT AGAAGTGTGT TGGTTGGAGT GGGTGGGGAG GAGTTATTGG TAGAGGAGGT
-3011 GTTGGAGTTG TG TAGTTGTT GGTGGAATGT GGGTAGGAGG AAGGTTCTTA AGGTGAGTGG
-2951 AGAGGTGGAG TGAGTGGAAT GTGGGAGTGT AAAGATGGGG AGAGGAGGGA GGTTAGGTGG
-2891 TATG TGG GTT GGTTGGTGTG ATGGGGAATT TATTTGGGTA TT TTG TTTT T GTGTGTGGTT
-2831 GTGGTGGTGT TTGTTAAAAT TTTTA TTTTT TTATTTTTTG  GGAATTTGGG TATATGTGGT
-2771 GTGTAATGGT GGGTAGTGTA GTGTTAGTAT GTAGGGTAGG GTGAGGTTGA AGTGATGAAA
-2711 GTGGTGTTGG TTGAGGTTGG GAAGTATTAG AGATATAGGT ATGTGGGAGG GTGGGGAGGA
-2651 GTTGTGGGGT AATTTTATGA TTAGAGAGTT GGAGGTGAGT AGTAGGATGT TGGGGAGGTA
-2591 TAAGGGAGTT TGGGATTGAT TTGTAGGTGA GAGGGAGGGG TATATGTGAT TAATTTTGGA
-2531 GATGGATATT TTG TG TG TTG  GGGGATAGAG GAAGAAGAGG GAGATTGTGA GGGTGAGGTG
-2471 TGGTGAGAAT GGGTGGAAAG ATGGTGAGAA GGGGGGAGGT GAGGTGGTAT GGAGTTGGAG
-2411 TGGGGAGGAA GAGGGTTGTG GGAGTGTGTG GAGGTAAGGG AGTG AG TGG T AGGGAGATGG
-2351 AGATGAGAGG AAGAGTGATA TGGAGTGAAG TGTAAGTTGG TGTTGAGAAG ATGGAGGAAA
-2291 GGATAGAAGG GGGAAGGGAT GTTTTATTTA  GAGTGAGAAT GGAGAGTAGT AGAAGGGTAG
-2231 ATGGGGAGAG GTGGAGGATT GTGGAAGAGA GTGTGGTTGG TATGTGGAGA TAGGATTTGA
-2171 GGAAAGATGG TGGTGAGAGA AAGGATTTGA GATTGTGAGA GGGAGAGGGG GGAAGAAGTT
-2111 GAAAGAGTGA AAAGGGAAAG GGGAATGGAG TGTGTGGGGA TGAGTAGGGG TGTGGATGAG
-2051 AGTATGGAGA TGGGGGTTGA GGGATGTGAA AATGAAGAGA AGGATTGTTG GGGTGGAGTG
-1991 TAGGTGGAGG AGAGAAGGGT GAGTGATGTT GGTGAAGTTA GAGAGGGGGG AGAGTGGTGA
-1931 GTGTTATGTG GGTGGGTGGG ATAGTTGTTG GTGGGATAGG TATGGATGTG AGGAGAATGT
-1871 GAGGGGTTAG GAGAATGTGT ATAGATTTGG GTGTGTTGAG TGGTGTGGGA GAGAGGAGTG
-1811 GGGTGGGGAG GTGATTTGGA GGTGTAAAGT GTGGTGTGGT TATGGTTTAG GGATTGGGGG
-1751 GTTTGGAGTA TGTGTGTGTG TG TG TG TTG T TGGTTAGGAG GTGTGGGTAG CGTGGTGGGG
-1691 TGGGAGGAGA GGGTAAGGTG TGTGAAGGGA GGATTGTTAG GTGTTTTGAG GGGGATGGAT
-1631 GAGTAGTGTG GAGGGGATAG TAGGAGGTTG ATGAATATTT GGGGAATGTA TGAGGATGAG
-1571 ATGTGAGGAG AGTGGGAGGT GAGGGGGTGG ATGAGGTGGT TTTTG TG TTG  T T TTG TTTT T  
-1511 GTGGTGTTGG TGAGAGAGGA GATGGGAATG TTGTTTGTG G GGTGTGGAGG TGAGAGGGGA
-1451 GGGGAGGTGA GGATGTTAGT TAGGAAGAGG TTGAGTTAGA GAGGGAAGTT GAGGTGATGT
-1391 TGTTAGAGTA ATGTGAGTGT GGGAGGAGGG TTGAGGGGGA GAGAGGAGGT GGAAAAGAGG
-1331 GAGGTAGGGG TGGGGGGTGG TG G TG TG TG T GGTGGGAGTA AAAATGTGGA GAGAGGGTGT
-1271 GAGGGGTTTG GTGTGAGGGA GAAGGGGAGG ATTGGAGGGA AAGGGGGGGG TTTGGAGGGG
-1211 TGGGGGTGTG TAGTGGGGGG GTTGGAAAGG TTAAGAGTAT TTGTTGGTGT GAAAGGGGAG
-1151 GGGAAGGGGG GGGGAGAGGT GGGGGTTTAA GAGGGTGAGG GAGGGGTGGG GTGGGGGAGG
-1091 TAGGGTGAGA GGAGTGGGAG GGGGGGGGGG TAGTGAGTTG GGTAGGTGGG TGGGTGGGGA
-1031 GGGGTGGAGG GTGTTGTGAG GGAAGTGGGG GGGAGGTTGT GGGGAGGGAG GTGGGGGGGA
-971 GAGAGGGAAG GGGAGGTGTG GGGGGAGAGG ATGGAGGAGG GTGAGGGAGG GGAGGTGGAG
-911 GAAGGTGTGT GGAGGGGAAG TATAGGGGTT TGTGGGGGGA GAGGGGGTGG TGGTGTGTGG
-851 GGTGGATGGT GGGTGGAGTG TTTGGTGGAG GATAGGGTAG ATAGGTGTGG TGGGGGGGGG
-791 AGAGTTGTGT GTGTGGGGTG GTTGAGTATG GAAAAGAGTA GGAAGGGGTG GGAGGGTAGA
-731 GGGAGGGGGG AGAGGAATGT GGGAGGGTTG TAGGTTGGGT AAGGTGAGGG TTAGAGGTGG
-671 GATGTGGAAG GGAGGGTTAG ATGAAAGAGG GGGAAGTTGG GGGGGTAGGG AATTTGTGAG
-611 GGAGAGTGAG TGGAATGGGG GGAGTGGGGT TGGTGGGGTG TGAGGTGTGG GGTGGGGTCG
-551 CTGGAGTTGT GAGGGTAGGT TAGAGTGAGT AAGGGAGGGA AGGAAAGTGA GGAGTGAGGT
-491 TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGAG GAGTGATTGA GTTGTAGTGA
-431 GGAAGAGGAT GTTATAGAGG GAATGTGGGA ATGTGTTAGG AGGGGAAAAA TAGTGGAAAG
-371 GAAGTGGTAT GATGGGGGAT GGAGGGGGGG GGGGGGGGGG GGGAATAGAG GTTTTTAGGG
-311 TGGGGGAGAA TT TTT TTTT G  AAAGTGGTGG GTTAGTGGGA TTGTG TGG TG TGGATGGAGG
-251 GGGTTGAAAG TGAGGGTGAG GGGAGGGTTG AGAGTGTGTG TG TG TG TG TG  TG TG TG TG TG
-191 TG TG TG TG TG  TGTGTGGGTG GGTGTAGGTA GATGAGGTGT GGGGATTTGG GTTGTTGGGT
-131 ATGTGATGGA TGGGGGTGGT GGGTAGAGGA GTGGGTAAGG GTGTGGGTGG GTGAGTGGGA
-71 GGAGTGGGGT GAGAGAAGGA GGGGTGGGGA AGAGAGAGTG ATATAAAGGT GGTGGTGGGT
-11 TGAGGGTAAGG -1
(Sogawa et al, 1986)
45
Figure 1-11. DNA Elements Implicated in the Regulation of Rat CYPlAl Transcription
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Figure 1-11 also shows the TATA sequence located immediately upstream of the CYPlAl 
transcription start site (Fujii-Kuriyama et a l, 1992). The TATA sequence is the most common 
transcriptional control region found among eukaryotic genes (Watson et al, 1992b). Directly 5' of 
the TATA sequence lies a GC box sequence, the basal transcriptional enhancer or basic 
transcription element (BTE). Mutation or deletion of the BTE reduced both basal and TCDD- 
induced CAT activity in CYPlAl reporter gene experiments (Yanagida et al 1990). The BTE also 
contains a consensus Spl binding site (Hankinson, 1995). A novel protein, the basic transcription 
element binding-protein (BTEB), was found to bind the BTE (Imataka. et al, 1992).
46
PAH induction of both CYPlAl enzyme activity and mRNA levels have been found to be 
potentiated by glucocorticoids, by a factor of two to three times (Prough et al., 1996). Three 
glucocorticoid response element (GRE) half-sites have been found by sequence analysis of the first 
intron of CYPlAl. A CAT construct containing Ikb of the 5’ flanking region, exon I, intron I and a 
part of exon II of CYPlAl, demonstrated glucocorticoid potentiation of PAH induction. Deletion 
of the GREs abolished the response to the glucocorticoid dexamethasone. It has also been shown 
that the construct and native CYPlAl are non-responsive to glucocorticoids in the absence of PAH 
(Mathis et al., 1986; Prough et al, 1996). Prough et al. (1996) also report that there are no 
discernable GRE’s in the 5' flanking region of CYPlAl. Nucleotide sequence analysis reveals that 
there are four GRE half sites, TGTCCT, identical to those found in the first intron of CYPlAl. 
These are located at: -1298, -1777, -2468 and -2827 upstream of CYPlAl. A fifth GRE half site, of 
sequence TGTTCT, is found at -1478bp (sequence analysed using Vector NTI software).
A putative negative regulatory element (NRE), located between -746 and -882bp, in the 5' flanking 
region of rat CYPlAl is shown in Figure 1-11. CYPlAl expression is barely detectable in rat liver 
in the absence of inducer (Raval et al, 1991). Such a low level of basal expression lends support to 
the presence of cw-regulatory CYPlAl silencer elements.. Mouse (Gonzalez et a l, 1985a), human 
(Hines et al, 1988) and rat (Sterling et al, 1993) NRE directed suppression of CYPlAl expression 
has been demonstrated. Although the literature contains conflicting evidence regarding the ability 
of rodent NREs to down-regulate CYPlAl expression, Boucher and Hines (1995) report that in 
their transient expression assays that down-regulation of enhancer/promoter activity was not 
produced using either rat or mouse NRE fragments. This lack of suppressive activity was observed 
in rat, mouse and human cell lines. They also reported that down-regulation of CYPlAl via the 
human NRE only occurred using the human HepG2 hepatoma cell line. The human NRE failed to 
suppress CYPlAl expression in mouse and rat cell lines. More recently the rat NRE has been 
further characterised and the Oct-1 transcription factor has been reported to bind the rat CYPlAl 
promoter and to negatively regulate its expression (Bhat et al, 1996; Sterling and Bresnick, 1996).
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Sterling and Bresnick suggest that the NRE used by Boucher and Hines (1995) did not function as a 
silencer because it did not contain the same NRE as they had used in their work, because it lacked a 
region from -745 to -659bp. The complex negative regulation of rat CYPlAl requires further study 
to fully characterise the involvement of trans-diCÏmg factors and their action at cfj-acting DNA 
elements.
A retinoid responsive element, 5' CTTAGGTCACCACGGGGCA 3' (RARElAl), has been 
reported to be located at -454bp of the human CYPlAl promoter. Nucleotide sequence analysis 
(sequence analysed using Vector NTI software) of the rat CYPlAl 5' flanking region reveals 19 
possible retinoid responsive elements with 83% homology to the retinoic acid response element 
consensus sequence: direct repeat of A/GGG/TTCA separated by 1 to 5 bases (Mader et al, 1993). 
Elements similar to RARElAl, with a 4 base separation of the half sites, are found at -346, -357, - 
635, -2059 and -2417bp in the promoter of rat CYPlAl. RARElAl was shown to be 
transactivated, in vitro, by liganded RAR-al or TR-a (Vecchini et a l, 1994). Yet retinoic acid 
(RA) has been found to down-regulate basal CYPlAl expression and to antagonise coal tar 
(contains many PAHs) mediated CYPlAl induction (Li et a l, 1995). Some carotenoids 
(canthaxanthin, astaxanthin and (3-apo-8'-carotenal) are potent inducers of liver CYPlAl with no 
affinity for the TCDD binding site. Studies using AH receptor gene knockout mice, AH receptor- 
non-responsive mice and AH receptor-responsive mice have provided evidence that the induction 
by these carotinoids is Ah receptor dependent, p-carotene and P-apo-8 'carotenal are metabolised to 
yield retinal and retinoic acid. It would therefore be logical to suggest that it is the carotenoid 
metabolites that are involved in the induction response. But other carotenoids such as p-carotene, 
lutein and lycopene do not act as CYPlAl inducers (Gradelet et al, 1997). The effects of retinoids 
on CYPlAl expression and their involvement with the AH receptor requires further investigation. 
Benzimidazole compounds such as omeprazole, have also been shown to be CYPlAl inducers with 
no affinity for the AH receptor binding site, in human and rabbit hepatocytes (Curi-Pedrosa et a l,
1994). Mutation of the ligand binding domain of the AH receptor has shown that this site is
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required for omeprazole responsiveness and it has been suggested that omeprazole may be a 
proligand for the AH receptor (Daujat et a l, 1998).
1 .S.2.3.3 Mechanism of AH Receptor Mediated CYPlAl Transcriptional Activation
A model for the ligand-dependent activation of the AH receptor, leading to induction of CYPlAl 
transcription, is illustrated in Figure 1-12. Ligand-free AH receptor is believed to be localised in 
the cytoplasm, held in a receptive configuration for ligand binding by the heat shock protein, Hsp90 
(Whitlock et a l, 1996). It is now believed that cytosolic AH receptor is held in this configuration 
by two molecules of Hsp90 (Hankinson, 1995). Recently a novel 37 kDa cytoplasmic protein, an 
immunophilin homologue designated the AH receptor-interacting protein (AIP), has been cloned 
from a mouse hepalclc7 cDNA library (Ma and Whitlock, 1997). AIP has been shown to associate 
with unliganded AH. receptor and Hsp90. TCDD treatment disrupts the AHR-AIP-Hsp90 
interaction. Transcriptional activation of CYPlAl by TCDD is augmented by overexpression of the 
AIP protein. On ligand binding, the AH receptor translocates to the nucleus, where it forms a 
heterodimer with the ARNT protein Phosphorylation may play a role in the formation of the AH 
receptor-ARNT heterodimer and/or in AHRE binding (Pongratz et a l, 1991; Carrier et a l, 1992). 
The mechanism by which the liganded AH receptor localises to the nucleus and disassociates from 
Hsp90 and AIP is as yet undetermined (Hankinson, 1995; Whitlock et a l, 1996; Ma and Whitlock,
1997). AH receptor-ARNT heterodimers bind AHRE sites along with general transcription factors 
and an initiation complex is formed at the promoter. CYPlAl transcription follows (Hankinson,
1995).
The mechanism of CYPlAl induction described by this model (Figure 1-12) has been based on 
many in vitro experiments. Cw-elements have been isolated and characterised using transiently 
transfected reporter gene constructs and /ro«5-acting factors were examined using chimeras. 
However, in vivo, CYPlAl DNA is associated with histones and other chromosomal proteins in a 
chromatin complex and chromatin is structurally organised into nucleosomes. In vivo CYPlAl
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induction is associated with loss of a nucleosome positioned at the promoter, an increase in 
promoter accessibility, and general transcription factor binding. In the region of this nucleosome 
there are no AHRE enhancer elements. It is postulated that a system of communication must exist 
in order to transmit the induction signal from the liganded AH receptor-ARNT bound enhancer to 
the promoter (Whitlock et a l, 1996).
Figure 1-12. Model for Ligand-Dependent Activation of the AH Receptor
^Nuclear 
transiocatio
Ligand 
binding
H sp90
H sp90
O
 #
A rnt
Target Genes; “
. C Y P 1 A 1 ,C Y P 1 A 2  
s  N Q 01, G STYa,
" UGT1*06.
-  ALDHSc^J
AhRE f A Target Gene
Latent 
receptor
held in receptive 
configuration by 
Hsp90
Ahr, aromatic hydrocarbon receptor; Hsp90, 90kDa heat shock protein; AhRE, aromatic 
hydrocarbon response element; Arnt, Ahr nuclear translocator protein; NQOl, NADPH:quinone 
oxidoreductase; GSTYa, glutathione S-transferase; UGT1*06, UDP-glucuronosyltransferase; 
ALDH3c, tumour-associated aldehyde dehydrogenase.
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L3,2.4 CYP3A Induction
The function and regulation of the CYP3A family is fairly well conserved among mammalian 
species (Parkinson, 1996b). CYP3A enzymes are involved in the hydroxylation of steroid 
hormones, including corticosteroids, progestins, androgens, and DHEA-sulphate, as well as 
numerous xenobiotics (Juchau, 1990; Nebert and McKinnon, 1994).
In humans, a variety of non-invasive tests have shown that CYP3A activity levels vary more than 
ten-fold among individuals (Parkinson, 1996b). Recently, a genetic polymorphism in the promoter 
of the human CYP3A4 gene has been identified (Plant et a l, 1998). As yet, it has not been 
determined whether this polymorphism affects CYP3A4 expression. Polymorphisms may 
contribute to the variation of CYP3A activity seen in the human population. The polymorphic 
expression of CYP3A5 may also be a contributing factor (Cholerton et al, 1992).
Enzymes of the CYP3A family are induced or inhibited by many commonly used drugs. The 
induction of CYP3A enzymes and other P450s by phénobarbital is discussed in section 1.3.3. In 
association with the wide substrate specificity of these enzymes the potential for significant drug- 
drug interactions is high. Such drug-drug interactions have caused a number of fatalities in recent 
years. For example, the antibiotic erythromycin is a CYP3A inhibitor. When co-administered with 
the anti-histamine terfenadine, the plasma concentration of terfenadine is raised, which can lead to 
serious cardiac arrhythmias (Nebert and McKinnon, 1994). Terfenadine has since been withdrawn 
from over-the-counter sales in Britain for this reason.
CYP3A transcription is induced in response to glucocorticoids such as dexamethasone (DEX) and 
also by antiglucocorticoids such as pregnenolone 16a-carbonitrile (PCN) (Burger et a l, 1992; 
Quattrochi et a l, 1995; Huss et al, 1996). The ‘paradoxical’ induction of rat CYP3A1 by DEX 
and PCN led to postulation of a non-classical glucocorticoid pathway. It was also observed that 
induction of CYP3A1 required higher doses of glucocorticoids and showed a different rank order of
_
potency for glucocorticoid agonists (Burger et a l, 1992). Identification of response elements 
responsible for the DEX induction of CYP3A23 led to the suggestion of a role for a steroid/nuclear 
hormone receptor (Huss et al, 1996). It was postulated that such a receptor would explain the non- 
classical glucocorticoid response and the induction by the antiglucocorticoid PCN. Although the 
suppression of DEX induction by the antiglucocorticoid RU486 and the possible involvement of the 
GR would not be resolved (Burger et a l, 1992; 1995; Huss et al, 1996).
1.3.2.4.1 The Pregnane X Receptor
Recently a novel orphan nuclear receptor, the pregnane X receptor (PXR), has been cloned fi*om a 
mouse liver cDNA library (Kliewer et al, 1998). PXR is activated by a variety of compounds 
known to induce CYP3A gene expression including glucocorticoids, antiglucocorticoids, macrolide 
antibiotics and antimyotics. PXR binds as a heterodimer with RXR to previously isolated response 
elements (nuclear receptor DR3 elements) in rat and human CYP3A gene promoters (Kliewer et al,
1998). PXR and CYP3A also co-localise to the liver and tissues of the gastrointestinal tract 
(Kliewer et al, 1998 - abstract). Hence, PXR is strongly implicated in the regulation of CYP3A 
expression.
Rifampicin, a CYP3A inducer has been shown to bind the GR at the hormone binding site (Pascussi 
et a l, 1998). In CYP3A4 reporter gene studies using human hepatoma HepG2cells, DEX, 
rifampicin, carbamazepine, phenytoin and phenylbutazone induction was found to be enhanced by 
co-transfection of a GR expression plasmid. RU486 was shown to suppress CYP3A4 reporter gene 
induction (Ogg, 1998). The exact role of PXR and the possible role of the GR, if any, is yet to be 
determined.
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1.3.3 Phénobarbital Induction of P450s
P450s of the CYP2, CYP2B, CYP2C and CYP3A subfamilies are induced by phénobarbital (PB) 
(Gonzalez, 1993). CYP2B1 and CYP2B2, the two major rat PB-inducible P450 forms, are induced 
by a factor of 50-100 times in response to PB (Whitlock, 1986). PB inducible P450s are also 
expressed in Bacillus megabacterium, the original trivial names for these P450s: P 4 50b m -i and 
P450bm -3 are still used, although they are more correctly identified using Nelson’s (1993) 
nomenclature system as CYP106 and CYP102, respectively (Fulco, 1991).
The study of mammalian PB induced P450s has been hampered by the fact that cultured cell lines 
do not express these enzymes either constitutively or following exposure to phénobarbital as a 
result of phenotype instability. Thus, the induction of P450 by PB in Bacillus megabacterium has 
been studied as a model for the induction of mammalian P450. However, in the last ten years 
primary cultures of hepatocytes have been developed which continue to express CYP2B enzymes in 
a PB-dependent manner (Kocarek et a l , 1990).
CYP102 is fused to P450 reductase and is structurally more similar to microsomal P450 genes than 
bacterial or mitochondrial P450s (Fulco and Ruettlinger, 1987). Regulatory elements have been 
identified in studies where the 5’-flanking region of GYP 102 has been fused to a reporter gene. A 
region of sequence from -1 .1  kb to +0 . 2  kb was found to be required for both basal expression and 
PB-induced activity (Wen et al, 1989). The element involved in PB-inducibility was isolated to a 
region between -0.8 kb and -1.1 kb. This region also appeared to suppress endogenous GYP 102 
expression, perhaps by competing with a positive element for a /ra«5 -acting factor. 5'-flanking 
deletion studies showed that a region within a 300 bp fragment near the RNA initiation site was 
essential for this repression.
Some evidence for the involvement of nuclear factors in the regulation of mammalian PB-inducible 
P450s has been reported. In ffeeze-thawed nuclei from PB-treated rats the transcription of a
—
fragment (from -179 into the first exon) of the CYP2B2 gene was several times higher than that of 
the controls. An 85 kd protein was found by gel retardation analysis to bind this fragment and the 
protein-DNA complex formed was shown to have a different mobility on treatment with PB. 
Footprint analysis showed that a region from -57 to -89 of the fragment was protected from DNase 
digestion. These results present some evidence that in rats PB induction is regulated through the 
binding of this protein to the proximal promoter region (Rangarajan and Padmanaban, 1989; Rao et 
al, 1990). A pentadecamer resembling a glucocorticoid response element (GRE) located at -1357 
to -1343 has been described in the CYP2B2 gene. This pentadecamer has been found to confer 
dexamethasone inducibility on a chloramphenicol acetyltransferase (CAT) reporter gene driven by a 
thymidine kinase promoter (Jaiswal et al, 1990). Waxman and Azaroff (1992) give a detailed 
account of four different schemes describing the proposed mechanisms of CYP2B2 induction. 
These include two schemes for a PB receptor-dependent P450 induction mechanism and two 
schemes where PB induction involves the direct interaction of PB with cytochrome P450. The 
nucleotide sequence, including putative transcription factor binding sites, of the 5’ flanking region 
of the CYP2B1 gene (CYP2B1 shares 97% sequence identity with CYP2B2) has been presented in 
a paper on promoter region analysis of the rat CYP2B1 and CYP2B2 genes (Sommer et a l, 1996). 
Two liver-specific DNase I hypersensitive sites associated with CYP2B1 and CYP2B2 have been 
identified, located at -2.2 to -2.3 kb and at -0.05 to -0.15 kb. A foofr>rint region designated FT2 
found in the vicinity of the proximal hypersensitive site was found to bind bacterial expressed 
recombinant C/EBPa (CCAATT enhancer binding protein) and in vitro transcription assays found 
that the FT2 site contributed strongly to promoter activity. Mutation of the FT2 site reduced 
transcription by 80%. Transient transfection experiments showed, as expected, that C/EBPa could 
activate a 1.4 kb CYP2B promoter construct and that mutation of the FT2 site impaired both basal 
transcription and transactivation by exogenous C/EBPa (Luc et a l, 1996). Transient transfections 
were performed in the highly differentiated FGC4 hepatoma cell line. HepG2 cells were also 
transfected with the wild-type and the mutant CYP2B1 construct to show a more marked effect to
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the transcription factors C/EBPa and C/EBPp. The effect seen was greater in HepG2 cells because 
they do not express the CYP2B promoter construct at high levels. It was demonstrated that in vitro, 
the transcription factors C/EBPa and C/EBPp, play a role in modulating transcription of both 
CYP2B1 and CYP2B2. Phosphorylation/dephosphorylation events have been found to influence 
the ability of transcription factors to bind to various regions upstream of CYP2B1 and CYP2B2 
(Shephard, 1998).
In 1991, He and Fulco compared the 5'-flanking regions of the PB-inducible P450s in Bacillus 
megabacterium, CYP102 and CYP106, and in the rat, CYP2B1 and CYP2B2. A 17 bp region of 
sequence was found to be shared by these four genes with a high degree of sequence similarity. 
These "Barbie box" sequences, as they have been named, have been found in all of the eukaryotic 
genes with known 5'-flanking regions that encode barbiturate-inducible proteins (Shaw and Fulco, 
1993). The last 15 bp of the 17 bp sequences are highly homologous to the Barbie box sequence of 
the CYP102 gene and to a consensus sequence that strongly binds the barbiturate-regulated proteins 
of rat and Bacillus megabacterium. These sequences are shown in Table 1-8 which clearly shows a 
critical sequence AAAG for DNA-protein interaction that is present at the same relative location 
within the Barbie box sequences (Liang, He and Fulco, 1995). By gel retardation analysis, a 
protein was found in extracts of both Bacillus megabacterium and rat liver nuclei bound to the 
Barbie box sequences. Treatment with barbiturates had the opposite effects on the binding 
activities, the bacterial factor represses transcription whereas the analogous rat protein stimulates 
transcription. Liang, He and Fulco (1995) have presented a possible explanation as to how the 
barbiturate-regulated rat protein that bound to Barbie box sequences appeared to be a positive 
regulator, whilst the barbiturate-negatively regulated bacterial protein appeared to be a repressor. 
They have detected several proteins from Bacillus megabacterium which also bind the Barbie box 
and they suggest that they maybe analogous to the rat positive regulatory factor and could function 
by binding to the Barbie box and thereby displace the repressor. Their putative repressor appears to 
be identical to BmBRl, a helix-tum-helix DNA-binding protein, which has been shown previously
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to bind to a 20 bp palindromic operator sequence near the promoter region of CYP102 in the 
absence of barbiturates. In the presence of barbiturates BmSRl is inhibited from binding to its 
operator and induction is initiated. He and Fulco also present evidence for the induction of 
CYP106 by barbiturates involving competition between a positive DNA-binding protein and the 
BmSRl repressor (He and Fulco, 1995).
Together the data from gel retardation, footprinting, and deletion assays have established that 
Barbie box sequences are important cw-acting elements in regulating the basal level of expression 
and the barbiturate-mediated induction of P450s in Bacillus megabacterium. These and possibly 
other cw-acting elements, along with /raw^acting factors, mediate the increase in P450 expression in 
response to barbiturates.
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Table 1-8. Barbie Box Sequences in the 5'-flanking Regions of Barbiturate Inducible P450s
Gene 5* Location^ 15 bp sequence Identical bases to the 
concensus sequence
Concensus sequence ATCAAAAGCTGGAGG 15
CYP102 -227 ATCAAAAGCTGG t GG 14
(J5. megabacterium)
CYP106 -302 ATCaAAAGCTGGtGc 1 2
{B. megabacterium)
CYP2B1 (rat) -104 A g C t  AAAGC a GGAGG 1 2
CYP2B2 (rat) - 1 0 0 A g C c  AAAGC a GGAGG 1 2
CYP2C1 (rabbit) -228 t TCAAAAG a g GG c t t 9
CYP6A1 (house fly) -188 AaaAAAAGCTGaAtG 11
CYP3A2 (rat) -1166 AT a g AAAGC a t t c t G 8
CYP3A2 (rat) -1007 c a t t AAAGC c t G t GG 8
CYP3A2 (rat) -48 t cCcAAAGCTGt g t G 9
% o f sequences -
containing 
concensus base
67 44 56 44100100100100 89 4478 66 33 56 78
Adapted from Liang, He and Fulco, 1995. "Counting from the translation start site. Base changes 
from concensus sequence (capital letters) shown by case change from capital to lower case letters.
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1.4 Aims of Study
Investigation of the activities of a particular cytochrome P450 enzyme, following short term 
exposure to a xenobiotic, can provide a biochemical basis for the prediction of possible toxic 
effects. The objective of this project was to develop in vitro methodologies for the investigation of 
rat liver cytochrome P450 regulation. The advantages of such in vitro tools over in vivo studies for 
the toxicological assessment of new compounds are several-fold:
• smaller quantities of test compound are required
• very large numbers of compounds can be screened
• dose/response information can be obtained rapidly
• use of experimental animals is minimised
The initial aim was to develop reporter gene technology, using a peroxisome proliferator responsive 
element isolated from the rat CYP4A1 promoter, to produce and validate an in vitro assay that 
could detect whether a compound is potentially an inducer of rat CYP4A1. The assay was to be 
designed such that a large number of compounds could be rapidly screened using minimal 
quantities of test compound. Several factors were to be considered in the development of such an 
assay, these included:
• choice of cell line
• transfection method
• choice of reporter gene and expressed reporter gene product detection system
• exogenous factors required for inductive response
• assay sensitivity and format
Based on the established rat CYP4A1 reporter gene assay, a similar assay was to be developed for 
the detection of rat CYPlAl inducing compounds.
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2. Materials and Methods
2.1 Introduction
A detailed description of the materials, reagents and experimental procedures that were used for the 
work described in this thesis are presented in this chapter. It should be emphasised that the 
reagents used for transient transfections studies must be of the highest available purity in order to 
achieve reproducibly high transfection efficiencies. References are given in cases where 
procedures described are modifications of previously reported methods.
2.2 Materials
2.2.1 Chemicals and General Items
Chemicals and general items are listed in alphabetical order.
Chemical Supplier
3 MM paper
96-well plate covers (plastic self-adhesive) 
Acetic acid
Acrylamide stock solution 30% w/v 
Activated charcoal 
Ammonium persulphate 
Ampicillin
Anti-CAT-coated microtiter plates, black for 
chemiluminescence detection
Bacterialogical agar no.l
Whatman
Greiner
Fisher Scientific
BioRad
Sigma
Sigma
Sigma
Boehringer Mannheim 
Oxoid, UK
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Bezafibrate (2-[4"(2-[Chlorobenzamido]ethyl)- 
phenoxy]-2 -methylpropanoic acid)
BM Chemiluminescence ELISA reagent
Bovine serum albumin (BSA) protein standard
BRL49653 (5(2-[N-Methyl-N-2- 
pyridyl)amino)ethoxy]benzyl) thiazolidine-2,4- 
dione maleate)
Bromopalmitate (2-Bromohexadecanoic acid)
Calcium chloride (cell culture grade)
Ciprofibrate (2-[p-(2,2-Dichlorocyclopropyl)- 
phenoxy]-2 -methylpropanoic acid)
Clofibrate (2-(p-Chlorophenoxy)-2- 
methlypropanoic acid ethyl ester)
Clofibric acid (2-(p-Chlorophenoxy)-2- 
methylpropanoic acid)
Cupric sulphate (CUSO4)
D-glucose (cell culture grade)
Dexamethasone (9a-Fluoro-16a-methyl- 
11 P,17a,21-trihydroxy-l,4-pregnadiene-3,20-dione)
Dextran T70
Dicumarol (3,3 '-Methylene-bis-(4- 
hydroxycoumarin)
Dimethylformamide (DMF)
Disodium hydrogen phosphate (Na2HP0 4 .H2 0 ) 
Eicosatetrayanoic acid (ETYA)
Epidermal Growth Factor (human, >98%)
ICN
Boehringer Mannheim 
Sigma
SmithKline Beecham R & D
Aldrich
Sigma
Sigma
Sigma and Biomol Research Laboratories 
ICN
British Drug Houses
Sigma
Sigma
Pharmacia
Sigma
Dimethyl sulphoxide (DMSG), endotoxin tested. Sigma 
sterile filtered
Sigma
Sigma
Sigma and Biomol Research Laboratories, Inc. 
Sigma
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Ethanol
Ethoxyresorufîn (7-Ethoxy-3H-phenoxazin-3 - 
one)
Ethylenediaminetetraacetic acid (EDTA)
Folin & Ciocalteu’s Phenol reagent
Glycerol
Glycine
HEPES (cell culture grade)
Hybond PVDF membrane 
Hydrochloric acid
Isoniazid (Isonicotinic acid ethyl ester)
Isopropanol
Kanamycin
Linoleic acid (c/5'-9 -cw-1 2 -Octadecanoic acid) 
MEKl Inhibitor (PD98059)
2-P-Mercaptoethanol 
Methanol
Milk powder (fat-free)
N,N,N,N-Tetramethylethylenediamine
(TEMED)
NADPH (Nicotinamide adenine dinucleotide 
phosphate, reduced form)
a-napthoflavone (7,8-Benzoflavone)
p-napthoflavone (5,6-Benzoflavone)
o-nitrophenyl-p-D-galactopyranoside (ONPG)
Optiplate-96, white
Hayman
Sigma
British Drug Houses Ltd.
Sigma
Sigma
Bio-Rad Laboratories Ltd
Sigma
Amersham
Fisher Scientific
Sigma
Fisher Scientific
Sigma
Sigma
New England Biolabs, Inc. 
Sigma
Fisher Scientific.
Tesco own brand 
Sigma
Sigma
Sigma
Sigma
Sigma
Packard
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Phénobarbital (5-Ethyl-5-phenyl-2,4,6- 
trioxohexahydropyrimidine)
Photographie films: Polaroid type 667 
(positive), type 339 (colour)
Poly-D-Lysine
Ponceau-S
Potassium chloride
Potassium sodium tartrate
Pregnenolone 16a-carbonitrile (PCN)
Pyronin Y
Resorufin (7-Hydroxy-3 H-phenoxazin-3-one)
Sodium acetate
Sodium chloride
Sodium dodecyl sulphate (SDS)
Sodium hydrogen carbonate 
Sodium hydroxide
Solution 555 (mild detergent for cleaning plastic 
ware used in maxi-preps)
Streptavidin horseradish peroxidase conjugate
Tris base
Tris-EDTA (cell culture grade)
Tiyptone
Tween-20 (Polyoxyethelenesorbitan laurate) 
Ultrapure agarose
Wy-14,643 ([4-Chloro-6-(2,3-xylidino)-2- 
pyrimidinylthio] acetic acid)
Yeast extract
Sigma
GRI
Boehringer Mannheim 
Sigma
British Drug Houses Ltd..
British Drug Houses Ltd.
Sigma
Sigma
Sigma
Fisher Scientific International Co.
British Drug Houses Ltd.
Bio-Rad Laboratories Ltd 
British Drug Houses Ltd.
Fisher Scientific International Co.
Beckman
Amersham
British Drug Houses Ltd.
Sigma 
Oxoid, UK
British Drug Houses Ltd.
Boehringer Mannheim Ltd
Chemsyn Science Laboratories and Campro 
Scientific
Oxoid, UK
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2.2.2 Enzymes
Restriction endonucleases, DNA polymerases, DNA ligases and their appropriate buffers were all 
supplied by Promega. p-galactosidase for use as a positive control in the colorimetric p- 
galactosidase assay was supplied by Sigma. Positive control enzymes for CAT ELISA, P-Gal 
ELISA and AP chemiluminescent assays were supplied as kit components, see section 2.2.7.
2.2.3 Vectors
Maps for the cloning, reporter and expression vectors used during the course of this project are 
given in this section. Vector constructs that were produced for this work are described in Chapter 
3. The company or person from which each vector was obtained is also given. Examples of typical 
restriction digests for conformation of vector identity are shown in Figure 2-10, Figure 2-11 and 
Figure 2-12.
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Figure 2-1. pBluescript (Stratagene)
Nae1131
Ssp I 2850
Xmn I 2645 Ssp I 442 
Pvu I 500 
> Pvu II 529
Sca I 2526
Pvu I 2416
BssHII619 
—  Kpn I 657pBluescript® Il SK (-)
2961 bp
Sac I 759 
BssH II 792
Pvu II 977
AfI III 1153
The Bluescript II SK(-) phagemid is derived from pUC19. pBluescript was used as carrier DNA for 
some transient transfections.
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Figure 2-2, Eukaryotic Expression Vectors pSG5 (Stratagene), pSGSPPAR and pSGSRXR
Sai
pSGS
A- L/EcoR I (RXRa) 
BamH I (PPARa) 
7  \Bglll
Sal l/Xba
pSG5 was constructed by combining pKCR2 and Stratagene’s pBS vector (Green, S. et a l, 1988). 
T7 bacteriophage promoter facilitates in vitro transcription of cloned inserts. Intron II of rabbit (3- 
globin gene facilitates splicing of expressed transcript. Polyadenylation signal increases level of 
expression. The mPPARa expression vector pSGSPPAR (gift of Stephen Green, Zeneca, 
Macclesfield, U.K.) contains a 1.8kb sequence that codes for mouse PPARa inserted at the BamHI 
site. The mRXRa expression vector (gift of Prof. P. Chambon, Strasbourg) contains a 2.1 kb 
sequence that codes for mouse RXRa inserted at the EcoRI site.
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Figure 2-3. CYP4A1 Reporter Gene Construct p4Al(171/273)GCAT
Bam HI
Hind III
.+10
p4A1(171/273)GCAT
eooobp
pEMBL8+
Bglll
p4Al(171/273)GCAT (Aldridge et al., 1995) was a gift of Jonathan Tugwood (Zeneca, 
Macclesfield, U.K.). This construct contains a 102bp response element from the promoter of 
CYP4A1, inserted into pGCAT (Isseman and Green, 1990). pGCAT was constructed using 
pEMBL8+ (Klein-Hitpass et al, 1986), a member of the EMBL family of vectors (Dente et al., 
1983).
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Figure 2-4. CYP4A1 Reporter Construct p4AlBam+20CAT
Bam HI
Bam HI
Bam HI/
fusion
p4A1Bam+20CAT
11kb
pEMBL8+
p4AlBam+20CAT contains a genomic fragment (approximately 5.5kb) of the promoter of CYP4A1 
and 20bp of the gene itself (Aldridge et al., 1995). The construct is based on the pGCAT vector 
(Isseman and Green, 1990), the rabbit p-globin promoter has been deleted.
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Figure 2-5. CYPIAI Reporter Construct pMClcat
CYP1A1
+2545
pMCIcat
10kb
-3200
pMClcat was a gift of J. Weaver (U.S.A.). This reporter construct contains -3200 to +2545 of the 
rat CYPlAl promoter and structural gene (Hines, R.N. et «/., 1985; Sogawa,K. et al., 1986), linked 
to a CAT reporter gene.
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Figure 2-6. Eukaryotic p-galactosidase Expression Vector pSV-P-Galactosidase (Promega)
Hind III 414
SV40 Promoter 
and Enhancer
EcoR 16815^^
pSV-p-Galactosidase
6821 bp
EcoR I 3701
^  BamH I 4151 
^Sall4163 
Pstl4173
The p-SV-p-galactosidase control vector (Promega) was designed as a positive control vector for 
monitoring transfection efficiencies in mammalian cells. The vector is a modification of pRSV- 
pGAL with SV40 and pUC18 sequences substituted for RSV and pBR322 sequences.
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Figure 2-7. Eukaryotic p-galactosidase Expression Vector pCHllO (Pharmacia Biotech)
Hind 111(1) ATG Kpn I (204)
1
SV40 ori/ 
Early Promoter
40
codons
gpt
28
codons
trpS
Pvu il (372)'
Hpa I (706)'
Pvu il (6782) 
pBR322
SV40
pCH110
7128bp
Hpa I (1330)* 
Ava I (1620)'
Pst 1(5239)
^Pvu II (2929)'
EcoR I(«87)-' > --------
Pdt I (3736) BamH I (3736) Pvu II (3292)*
* Site not unique
The plasmid pCHl 10 (Pharmacia Biotech) contains a functional lacZ gene which is expressed from 
the SV40 early promoter in eukaryotes. Like the pSV-p-galactosidase vector, pCHl 10 can be used 
for monitoring transfection efficiencies in mammalian cells.
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Figure 2-8. TOPO TA Cloning® Vector pCR®2.1-TOPO (Invitrogen)
Mtfl Reversa Primer H!nd III I
Kiprti Sflçl BspnHI Sjjel
I I
CAO GAA ACA GCT & IS ACC ATG ATT ACG CCA AÔC TTG GTA CÇC AGC TCO GAT CCA CTA 
GTC CTT TOT CGA TAC TGG TAC TAA TGC GGT TCO AAC CAT CGC TCO AOC CTA GOT CAT
BsKI £cani
GTA ACO GCC CCC AGT GTg ' c TG OAA TTC CCC 
CAT TGC CGC CGC TCA CAO GAC CTT AAG CCG G-
EcpRI
AG GGC OAA TTC TOC 
TTC CCG CTT AAG . ACO
E cc fW  B$fK\ Noi\ Xho[ N siiXbaX  ApalI 1 1 1  11 1
AGA TAT CCA TCA CAO TOO COO CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG 
TCT ATA GOT AOT OTO ACC OCC OGC GAG CTC GTA COT AGA TCT CCC GGG TTA AGC
CCC TAT 
GGG ATA
T7 Promoter M13 Forwand {•»>} PMmer MIS Forward [-40) Primer
AOr GAG TCG TAT Ti>C AAT TCA CTO GCC GTC GTT TTA OAA CGT COT GAC TGG OAA AAC 
TCA CTC AGC ATA ATG TTA AGT GAC CGG CAO CAA AAT GTT CCA GCA CTO ACC CTT TTC
lacZa
pCR ©2.1-TOPO
3908bp
pCR®2.1-T0P0 was supplied by Invitrogen as part of the TOPO TA Cloning Kit. The vector 
pCR®2.1-T0P0 has been designed for rapid cloning of Taq polymerase generated PCR products 
and produces higher cloning efficiencies than its predecessor pCR™II (approximately 80% as
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compared to 60%). Incorporated into the vector are priming sites for T7, M l3 forward and M l3 
reverse, for sequencing clones. The vector also has a large multiple cloning site, providing a wide 
range of strategies for subcloning of PCR inserts. In vitro transcription can be carried out from the 
T7 promoter. Screening for positive clones is simplified by the presence of the LacZ gene for 
blue/white colour screening. This vector also has both ampicillin and kanamycin resistance genes 
for bacterial selection and maintenence. The fl origin can be used for single-strand rescue.
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Figure 2-9. Eukaryotic Reporter Vector pSEAP2-Promoter (Clontech)
1 40
GGTACCGAGCTCTTACGCGTGCTAGCCCGGGCTCGAGATCT PSV40,
Asp718l 
Kpn I
Mlul Nhel
250 270 • —
AAGCTTCGAATCGCGAATTCGCCCACCATGCTG
Srfl Xho I Bgl II 
>
Hindlll BstBI NruI EcoRI
MCSA
J-41 /
MCSB
245-264
Not!
4833
BamH!
481SV40 ori
Ql pSEAP2-Promoter
4870bp
Asel
3377
SV40 
poly A
pUCori ^Xbal
1794
BamH!
2056Sali
2062
TB=transcription blocker
pSEAP2-Promoter contains the SV40 early promoter inserted upstream of the SEA? gene in 
pSEAP2-Basic (Clontech). A sequence of interest (e.g. a putative enhancer) can be inserted into 
the multiple cloning site upstream of the SEA? gene. Proper and efficient processing of the
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inserted transcript is ensured by the SV40 late polyadenylation signal downstream of the SEAP 
gene. Background transcription is reduced by the synthetic transcription blocker (TB), composed 
of adjacent polyadenylation and transcription pause sites (Eggermont and Proudfoot, 1993).
Figure 2-10. Restriction Digest Analysis of p4AlBam+20CAT, p4Al(171/273)GCAT and 
pGCAT, 0.9% Agarose Gel Electrophoresis
10000 bp>  
8000 bp > 
6000bp >
SOOObp > 
4000bp > 
3000bp > 
2500bp > 
2000bp >
1500bp >
lOOObp > 
750b>
1 p4AlBam+20CAT digested with BamHI, as expected 2 fragments produced of sizes: 
6000bp and 5000bp
2 p4Al(171/273)GCAT digested with BamHI, as expected 1 fragment produced of 
approximate size: 6000bp
3 pGCAT digested with EcoRI, as expected 2 fragments produced of approximate sizes: 
4000bp and 1500bp
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Figure 2-11. Restriction Digest Analysis of pMClcat, 0.9% Agarose Gel Electrophoresis
IKb Mkr
lOOOObp 
8000 bp-
6000bp> 
5000bp >
3000 ^P-
2500 bp — ----------
2000 bp >
1500 bp >
1000bp> 
750 bp > 
500 bp >
250 bp
1 pMClcat digested with BamHI,as expected 2 fragments produced of approximate sizes: 
5500bp and 4500bp
2 pMClcat digested with EcoRI, as expected 3 fragments produced of approximate sizes: 
7000bp, 1750bp and 1250bp
Figure 2-12. Restriction Digest Analysis of pSG5, pSGSRXR and pCHllO
IKb High Mass
Mkr 1 2 3 4 5 6 MkrlOOOObp
8000bp
6000bp
5000bp
4000bp
3000bp
2500bp
2000bp
1500bp
lOOObp
pSG5 digested with EcoRI, fragment size corresponds to plasmid size of 4076bp as
expected
Uncut pSG5
pSGSRXR digested with EcoRI, fragments produced correspond to plasmid size 4076bp 
and insert size 2100bp
Uncut pSGSRXR
pCHl 10 digested with EcoRI, fragment sizes correspond to those expected: 6377bp 
and 1201 bp
Uncut pCHllO
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2.2.4 Bacterial Strains
Plasmid vectors were propagated in a variety of E. coli strains. Table 2-1 lists the vectors 
propagated by each strain and the genotypes.
Table 2-1. Bacterial Strains and Genotypes of Propagated Plasmids
E. coli. 
Strain
Genotype Plasmids propagated
DH5-a® (j)80/acZAM15 r e c A l  e n d A l  g y r A 9 6  t h i - \  h s d R l l  
(rK mK^ s u p  EAA r e l A l  d e o R  A { la c Z Y A -a r g F ) lJ \6 9
pSV-p-galactosidase
pcDNA3hPPARy
HBlOl t h i - l  h s d S20 (rg' mg') su pE A A  r e c A \ 3  a r a - \ 4  le u  B6  
p r o  A 2  l a c Y l  r p s  L 2Q  (Str^) x y l - 5  m tI-1
pMClcat
JM109 r e c A l  e n d A l  g y r A 9 6  th i  h s d R l l  (fk‘ r e l A l  s u p  
EAA (le iC -proA B ) [F' t r a  D36 /ac/^’ZAMlS]
pGCAT2
TOPIO F' mcrAA(mrr-foi/RMS-wcrBC) (j)80/acZAMl 5 
A/acX74 r e c A l  araD139 A { a r a - le u ) 1 6 9 1  ga/U g a l R  
r p s L  (Str^) e n d A l  n u p G
pCR®2.1-T0P01Al(-1171/-l)
TOPlOF' F  {lad" TNIO (Tet^)} mcrAA(mrr-fei/RMS-/wcrBC) 
(j)80/acZAM15 A la c X lA  r e c A l  a r d D l 3 9  A ( a r a -  
I e u )7 6 9 7  g a l U  g a l K  r p s L  e n d A l  n u p G
pCR®2.1-T0P04Al(171/273) 
pCR®2. l-T0P04Alrev
p4Al(171/273)seap
plAl(-1171/-l)seap
XL-2 Blue 
MRF'
r e c A l  e n d A l  g y r A 9 6  t h i - l  h s d R l l  su pE A A  r e l A l  la c  
{ F 'p r o A B  /ac7"ZAM15 T n lO  (Tet^)]
pBluescript II SK- 
pSG5PPARa 
pSGSRXRa 
pCHllO
p4Al(171/273)GCAT
p4Alrevseap
p4AlBam+20CAT
pSEAP2-promoter
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The important features of the bacterial strains used are:
endAl Endonuclease mutation that gives rise to improved quality of plasmid DNA 
isolations.
lacZ AMI 5 Partial deletion of (3-D-gaIactosidase gene that allows blue/white colour 
selection for recombinant colonies when plated on X-gal.
recAl, recAlS Mutation in recombination that prevents recombination of introduced DNA 
with host DNA, ensuring stability of inserts. Inserts are more stable in 
recAl than recAlS.
2.2.5 Media and Materials for Mammalian Cell Culture
Australian Foetal Bovine Serum (FBS), Dulbecco’s Modified Eagles Medium (DMEM), Minimum 
Essential Medium (MEM), Ham’s FIO Medium (FIO), trypsin-EDTA, non-essential amino acids 
(NEAA), L-glutamine and gentamycin were supplied by GibcoBRL for the culture of mammalian 
cell lines. Vented flasks and 6-well dishes were supplied by Nunc. 24-well cell culture plates were 
obtained fi*om GibcoBRL and 96-well cell culture plates were purchased Jfrom Sigma.
2.2.6 Antibodies 
2.2.6J  Antibodies for ELISA
The following antibodies were supplied as components of the CAT ELISA and p-Gal ELISA kits 
produced by Boehringer Mannheim: anti-p-Gal -digoxigenin (mouse monoclonal antibody to p-Gal 
that is conjugated to digoxigenin), anti-DIG-peroxidase (sheep polyclonal antibody to digoxigenin 
that is conjugated to peroxidase), anti-CAT-digoxigenin (sheep polyclonal antibody to CAT that is
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conjugated to digoxigenin) and anti-DIG-peroxidase (sheep polyclonal antibody to digoxigenin 
that is conjugated to peroxidase).
2.2.6.2 Antibodies for Western Blotting
Primary antibodies: PPARa, PPARp and PPARy were supplied by Autogen Bioclear UK Ltd. 
Secondary antibodies: anti-goat IgG-HRP and anti-mouse IgG-HRP were supplied by Santa Cruz 
Biotechnology Inc. The specificity of PPARa, PPARp and PPARy, as stated in the manufacturers 
data sheet, can be found in the following paragraphs.
PPARa (N-19) reacts with PPARa of mouse, rat and human origin by Western blotting and 
immunohistochemistry. PPARa (N-19) does not cross-react with PPARp and PPARy. PPARa (N- 
19) is an affinity-purified goat polyclonal antibody raised against a peptide corresponding to amino 
acids 2-21 mapping at the amino terminus of PPARa of human origin (differs from corresponding 
mouse sequence by two amino acids).
PPARp (N-20) reacts with PPARp of human origin by Western blotting and 
immunohistochemistry. This antibody does not cross react with either PPARa or PPARy. PPARp 
(N-20) is an affinity-purified goat polyclonal antibody that maps to an amino acid sequence of 
human PPARp.
PPARy (E-8) reacts with PPARyi and PPARyz of mouse, rat and human origin by Western blotting 
and immunohistochemistry. PPARy (E-8) does not cross-react with PPARa or PPARp. This 
antibody is a mouse monoclonal IgG antibody that was raised against a peptide corresponding to 
amino acids 456-475 that map to the carboxy terminus of PPARy of human origin (identical to 
corresponding mouse sequence).
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2.2.7 Solutions and Kit Components
General solutions, buffers, media, and kit contents, along with their storage requirements, are 
described in alphabetical order in Table 2-2.
Table 2-2. Solutions, Buffers, Media and Kit Components
Solution/Buffer/Media/Kit Preparation Storage conditions
P-Gal ELISA Kit (Boehringer 
Mannheim)
Kit Components:
p-Gal enzyme: stabilised 
lyophilizate, recombinant protein 
from E. coli, purity >99% (SDS- 
PAGE)
Anti-P-Gal -digoxigenin (Anti-p- 
Gal-DIG): stabilised 
lyophilizate, monoclonal antibody 
to P-Gal (from mouse) that is 
conjugated to digoxigenin
Anti-DIG-peroxidase (Anti-DIG- 
POD): stabilised lyophilizate, 
polyclonal antibody to 
digoxigenin (from sheep) that is 
conjugated to peroxidase
POD substrate, ABTS®: ready to 
use solution, stabilised
Substrate enhancer: powder, prior 
to use diluted in ABTS® 
substrate solution, stir SOmins, 
only stable for 4 hours
10 x Washing Buffer: PBS 
containing Tween® 20
Prior to opening 4°C. 
Reconstituted P-Gal 
enzyme and anti-p-Gal - 
DIG must be stored at - 
20°C in aliquots. 
Reconstituted anti-DIG- 
POD is stored at 4°C. 
Working dilutions of all 
solutions must be 
prepared fresh for use.
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P-Gal ELISA Kit (Boehringer
Mannheim), continued;
Sample buffer: PBS containing 
blocking reagents, ready to use 
solution
5 X Lysis buffer: hypotonic cell 
lysis buffer, pH 6.5 (MOPS- 
buffered saline containing 
Triton® X-100)
Microtiter plate: strip frame with 
12 modules of 8 wells precoated 
with a monoclonal antibody to p- 
Gal (from mouse) and postcoated 
with blocking agent, shrink-
wrapped with a dessicant capsule 
Self-adhesive plate cover oil: 
used to prevent evaporative loss 
during the incubation steps
Agarose gel (x)% (x)g of agarose was dissolved in 
100ml 1 X TAB, heated gently in 
a microwave, 2pl ethidium 
bromide was swirled into the 
molten gel, the gel was cooled 
until hand hot and poured into a 
casting mould.
Cast gels can be 
wrapped in Saran wrap 
and stored o/n at 4°C
Ampicillin Stock Solution 
(lOOmg/ml)
lOOmg/ml in milliQ water, 
sterilize by filtration
Store in aliquots at - 
20°C
Aurora Alkaline Phosphatase 
Chemiluminescent Reporter Gene 
Assay (ICN)
Kit components:
Starlight™ Chemiluminescent 
substrate
Aurora™ AP assay buffer: contains 
alkaline phosphatase inhibitor L- 
homoarginine
Store in dark at 4°C
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Aurora Alkaline Phosphatase 
Chemiluminescent Reporter Gene 
Assay (ICN), continued:
Aurora '^  ^AP reaction buffer: 
contains chemiluminescence 
enhancer
5 X d ilu tio n  b u ffer
Positive control placental alkaline 
phosphatase in 50% (v/v) 
glycerol, 200mM Na2HP0 4  pH7.2
Calcium Chloride, 2M CaCli for 
transfection
10.8g of cell culture grade 
CaCl2.6H20 in 20ml of milliQ 
water, sterilize by passage 
through a 0.22-micron filter
Store the sterile solution 
in aliquots at -20°C
ECL Plus^ "^  Western Blotting 
Detection System (Amersham™)
Kit components:
Solution A: ECL Plus substrate 
solution containing tris buffer
Solution B: Stock Acridan 
solution in dioxane and ethanol
4°C
CAT ELISA Kit (Boehringer 
Mannheim)
Kit Components:
CAT enzyme: stabilised 
lyophilizate, type I, recombinant 
protein from E. coli, purity >98% 
(SDS-PAGE)
Anti-CAT-digoxigenin (Anti- 
CAT-POD): stabilised 
lyophilizate, polyclonal antibody 
to CAT (from sheep) that is 
conjugated to digoxigenin
Anti-DIG-peroxidase (Anti-DIG- 
POD): stabilised lyophilizate, 
polyclonal antibody to 
digoxigenin (from sheep) that is 
conjugated to peroxidase
Prior to opening 4°C. 
Reconstituted CAT 
enzyme and anti-CAT- 
DIG must be stored at - 
20°C in aliquots. 
Reconstituted anti-DIG- 
POD is stored at 4°C. 
Working dilutions of all 
solutions must be 
prepared fresh for use.
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CAT ELISA Kit (Boehringer
Mannheim), continued:
POD substrate, ABTS®: ready to 
use solution, stabilised
Substrate enhancer: powder, only 
required when CAT concentration 
is low, prepared by addition of 
Img per ml ABTS®, stirred 30 
mins.
10 X Washing Buffer: PBS 
containing Tween® 20
Sample buffer: PBS containing 
blocking reagents, ready to use 
solution
5 X Lysis buffer: hypotonic cell 
lysis buffer, pH 6.5 (MOPS- 
buffered saline containing 
Triton® X-100)
Microtiter plate: strip frame with 
12 modules of 8 wells precoated 
with a polyclonal antibody to 
CAT (from sheep) and postcoated 
with blocking agent, shrink- 
wrapped with a dessicant capsule
Self-adhesive plate cover oil: 
used to prevent evaporative loss 
during the incubation steps
Dicumarol for EROD Prepare O.OIM solution in O.IM 
sodium phosphate buffer (pH7.6). 
For dicumarol to dissolve in the 
assay buffer it is necessary to add 
0.5M sodium hydroxide dropwise.
Prepare fresh
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DNA Loading Dye (Promega’s 6 x 
Blue/Orange)
Contains orange G (migrates at 
approx. 50bp), xylene cyanol FF 
(migrates at approx. 4kb) and 
bromophenol blue (migrates at 
approximately 300bp)
-20°C
DOTAP transfection reagent 
(Boehringer Mannheim)
Aqueous dispersion ofN-[l-(2,3- 
Dioleoyloxy)propyl]-N,N,N- 
trimethylammonium 
methylsulfate (DOTAP) in MBS 
(MES-buffered saline, pH6.2) 
bottled under argon, 1 mg/ml, 
sterile
4°C
EDTA stock solution (0.5M) 186.1 g EDTA, 20g NaOH pellets, 
add 800ml of milliQ water, adjust 
to pH 8.0, make up to 11 with 
milliQ water and sterilize by 
autoclaving
RT
EndoFree Plasmid Maxi Kit 
(Qiagen)
Kit components
Qiagen-tip 500
QIAfilter Maxi Cartridges
RNase A (beef pancreas)
Buffer PI : 50mM Tris-HCl, 
10mMEDTApH8
Buffer P2: 200mMNaOH, 
1%SDS
Buffer P3: 3M Potassium acetate 
pH5.5
Buffer QBT: 750mMNaCl, 
50mM MOPS pH7, 15% 
isopropanol, 0.15% Triton X-100
Buffer QC: IMNaCl, 50mM 
MOPS pH 7,15% isopropanol
RT. After addition of 
RNaseA to Buffer PI 
sore at 4°C. Pre-chill 
buffer P3 to 4°C.
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EndoFree Plasmid Maxi Kit 
(Qiagen), continued:
Buffer QN: 1.6MNaCl, 50mM 
MOPS pH 7,15% isopropanol
Buffer TE: lOmMTris, ImM 
EDTApHS
Buffer ER: Proprietary 
formulation
Endotoxin-ffee water
Ethidium Bromide Solution Stock solution of lOmg/ml in 1 x 
TAE
RT
Ethoxyresorufin for EROD 25mM stock in ethanol -20°C
Galacto-Light Plus Kit 
Chemiluminescent Reporter Gene 
Assay System for the Detection of 
(3-galactosidase (Tropix)
Kit components:
Chemiluminescent substrate: 100 
X Galacton-Plus® which is 
diluted in reaction buffer diluent 
prior to use
Reaction Buffer Diluent: lOOmM 
sodium phosphate buffer pH8, 
ImM magnesium chloride
Light Emission Accelerator-II: 
Ready to use luminescence 
accelerator reagent
4°C
Hepes Buffer for Transfection 20mM HEPES (cell culture 
grade), adjust to pH 7.4, sterilize 
by passage through a 0.22-micron 
filter
Store the sterile solution 
in aliquots at -20°C
Hepes-Buffered Saline, 2 x HBS 1.6gNaCl, 0.074gKCl, 0.0027g 
Na2HP0 4 . 2  H2O, 0.2g dextrose,
1 g HEPES add 90ml milliQ 
water, adjust pH to 7.05 with 
0.5M NaOH, make up to 100ml
Store the sterile solution 
in aliquots at -20°C
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IPTG lOOmM stock solution Dissolve 238mg of IPTG in 10ml 
milliQ water, sterilize by passage 
through a 0.22-micron filter. 
Spread 40pl per agar plate, 
incubate at 37°C for 30mins, plate 
is now ready for use.
Store in aliquots at - 
20°C
LB (Luria-Bertaini) Medium lOg tryptone, lOg NaCl, 5g yeast 
extract, make up to 11 with milliQ 
water and sterilize by autoclaving
RT
Lysis Buffer (5x) Supplied by Boehringer 
Mannheim as part of CAT ELISA 
Kit, contains: Triton® X-100 in 
MOPS-buffered saline
4°C
NADPH for EROD Prepare NADPH as a IM solution 
in P/oNaHCOs
Do not store, make up 
fresh
PAGE Running Buffer (5x) 15.15g Tris base, 72g glycine, 5g 
SDS, make up to 11 with milliQ 
water
4°C
Phosphate Buffered Saline (PBS) 
for Transfection (Ca^\ Mg^ "^  free)
Add 5 PBS tablets (Dulbecco ‘A’ 
tablets, Oxoid) to 500ml of milliQ 
water, sterilize by autoclaving
4°C
Wizard^^ PCR Preps DNA 
Purification System
Kit components:
PCR Preps DNA Purification 
Resin: contains guanidine 
thiocyanate
Wizard""^ "^  PCR Preps 
Minicolumns
Wizard^ *^  PCR Preps Direct 
Purification Buffer: 50mM KCl, 
10mMTris-HCLpH8.8,1.5mM 
MgCh,, 0.1% Triton® X-100
Syringe Barrel, 3c.c.
RT
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Protein Sample Loading Buffer 4ml milliQ water, 1ml (pH 6.8), 
0.8ml glycerol, 1.6ml 10% (w/v) 
SDS, 0.4ml p-mercaptoethanol, 
0.5ml 0.05% (w/v) Pyronin Y
RT, store in dark for 
maximum of 2 weeks
Protein Transfer Buffer 3.03g Tris base, 2g SDS in 650ml 
milliQ water, add 200ml methanol 
and make up to 11
4°C
QIAquick Gel Extraction Kit Kit components:
QIAquick Spin Columns
Buffer QG: Proprietary 
formulation containing chaotropic 
salts, very denaturing
Buffer PE: Proprietary 
formulation, low salt buffer 
containing tris and ethanol
Collection tubes: 2ml
RT
Resolving Gel 12% for PAGE 7.5ml acrylamide stock solution 
(30%(w/v)), 9ml resolving gel 
buffer, 2ml distilled water, 180pl 
ammonium persulphate stock 
solution (10%(w/v) prepare 
fresh), 18plTEMED
Can be stored wrapped 
in buffer soaked tissues 
and Saran wrap, o/n at 
4°C
Resolving Gel Buffer (2x) 181.6g Tris base, 4g SDS in 
900ml milliQ water, adjust to 
pH8.8 with HCl and make up to 
11
4°C
Resorufin standards for EROD Prepare standards of resorufin in 
ethanol
-20°C
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Stacking Gel 4% for PAGE 1.8ml acrylamide stock solution 
(30%(w/v)), 5ml resolving gel 
buffer, 4ml distilled water, 50|il 
ammonium persulphate stock 
solution (10%(w/v) prepare 
fresh), lOpl TEMED
Can be stored wrapped 
in buffer soaked tissues 
and Saran wrap, o/n at 
4°C
Stacking Gel Buffer(2x) 60.6g Tris base, 4g SDS in 900ml 
milliQ water, adjust to pH6.8 and 
make up to 11
4°C
TAE (Ix) 40mM Tris-acetate, ImM EDTA. 
10 X stock solutions can be made 
up for convenience
RT
TBS-Tween 0.1%(v/v) (TBS-T) Dilute 5ml Tween 20 in 51 TBS to 
give a 0.1 %(v/v) solution
4°C
Topo TA Cloning® Kit Version B 
(Invitrogen)
Kit components:
21 X 50pl TOPIO one Shot™ 
competent cells
pUC18 control DNA
0.5M p-mercaptoethanol
SOC medium: 2% tryptone, 0.5% 
yeast extract, lOmM NaCl, 
2.5mM KCl, lOmM MgCh, 
lOmM MgS0 4 , 20mM glucose
pCR®2.1-TOPO: lOng/pl 
plasmid DNA in 50% glycerol, 
50mM Tris-HCl pH7.4, 
ImMEDTA, ImMDTT, 0.1% 
Triton X-100, lOOpg/ml BSA, 
phenol red
10 X PCR Buffer: lOOmM Tris- 
HCl pH8.3, 500mM KCl, 25mM 
MgCh, 0.01% gelatin
Competent cells are 
stored at -80°C and all 
other kit components at 
20°C
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Topo TA Cloning® Kit Version B 
(Invitrogen), continued:
50mM dNTPs: 12.5mM dATP, 
12.5mMdCTP, 12.5mMdGTP, 
12.5mM dTTP, neutralised at pH8 
in water
Ml 3 Forward (-20) Primer: 
O.lpg/ml in TE buffer
M13 Reverse Primer: O.lpg/ml in 
TE buffer
Control template: O.lpg/ml in TE 
buffer
Amplification Primer 1: O.lpg/ml 
in TE buffer
Amplification Primer 2: O.lpg/ml 
in TE buffer
Sterile Water
Tris Buffered Saline (TBS) 12.1 g Tris base, 40g sodium 
chloride, add 4500ml milliQ 
water adjust to pH7.6 and make 
up to 51
4°C
Tris-EDTA(TE) 1.21g Tris-HCl, 2ml 0.5M EDTA 
pH8, add 800ml milliQ water, 
adjust to pH8, make up to 11 and 
sterilize by autoclaving
RT
Tris-HCl IM stock solution 121.Ig Tris-HCl in 800ml milliQ 
water, adjust to desired pH with 
concentrated HCl, sterilize by 
autoclaving
RT
Wizard® Plus Maxipreps DNA 
Purification System (Promega)
Kit components:
Wizard™ Maxicolumns with 
Reservoirs
Cell Resuspension Solution: 
50mM Tris-HCl pH7.5, lOmM 
EDTA, lOOpg/ml RNase A
Cell Lysis Solution: 0.2mM 
NaOH, 1%SDS
Neutralization Solution: 1.32M 
potassium acetate pH 4.8
Wizard® Plus SV Column Wash: 
80mM potassium acetate, 8.3mM 
Tris-HCl pH7.5,40pM EDTA, 
55% ethanol
Wizard™ Maxipreps DNA 
Purification Resin: 40% 
isopropanol/4.2M guanidine 
hydrochloride
RT, protect resin from 
light.
Wizard® Plus SV Minipreps DNA 
Purification System (Promega)
Kit components:
Wizard® P/W5SV Cell 
Resuspension Solution: 50mM 
Tris-HCl pH7.5, lOmMEDTA, 
lOpg/ml RNaseA
Wizard® Plus SV Cell Lysis 
Solution: 0.2mM NaOH, 1%SDS
Wizard® P/W5SV Cell 
Neutralization Solution: 4.09M 
guanidine hydrochloride, 0.759M 
potassium acetate, 2.12M glacial 
acetic acid
Wizard® Plus SV Minipreps Spin 
Columns
RT
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Wizard® Plus SV Minipreps DNA 
Purification System (Promega) 
continued:
2ml Collection Tubes
Alkaline Protease Solution
Nuclease-Free Water
Wizard® Plus SV Column Wash: 
60mM potassium acetate, lOmM 
Tris-HCl pH7.5, 60% ethanol
X-Gal (5-bromo-4-chloro-3- 
indolyl-p-D-galactopyranoside) 
Stock Solution
Supplied by Promega as 50mg/ml 
in dimethylformamide. To add to 
agar plates: pre-warm plate to 
37°C, spread 40pl of stock 
solution and dry plate.
Protect from light by 
storing in brown bottle 
at-20°C. Protect plates 
spread with X-gal from 
light.
Z Buffer for colorimetric p- 
galactosidase assay
0.06MNa2HP047H20, 0.04M 
NaH2P0 4 .H2 0 , O.OIM KCl, ImM 
MgS047H20
4°C
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2.2.8 Protein and DNA molecular Weight Markers
GibcoBRL High DNA Mass Ladder
8jil, 1% agarose
Fragment sizes (ng DNA per fragment for 8pl loading): 10000 (400), 
6000 (240), 4000 (160), 3000 (120), 2000 (80), lOOObp (40)
1 0 0 0 0  bp 
6000 bp 
4000 bp 
3000 bp
2 0 0 0  bp
1 0 0 0  bp
Amersham ECL Protein Molecular Weight Markers
Protein MW: 97400, 68000, 46000, 31000, 20100, 14400 Da
Due to the sensitivity of ECL detection, further feint bands may be 
observed at 55000, 43000 and 16700
97000 Da 
68000 Da
46000 Da
31000 Da
21100 Da 
14400 Da
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Pharmacia Biotech 100 Base Pair Ladder
1.5|ul, 1.5% agarose gel
Smallest fragment size is lOObp, fragment size increases in increments 
o f  lOObp
N ote that the 800 bp fragment produces a brighter band
800 bp
400 bp 
300 bp
200 bp
100 bp
Promega Ikb D N A  Ladder
5pil lOOpg/ml, 1% agarose gel
Fragment sizes: 10000, 8000, 6000, 5000, 4000, 3000, 2500, 2000, 
1500, 1000, 750, 500, 250bp
10000 bp 
8000 bp 
6000 bp 
5000 bp 
4000 bp 
3000 bp 
2500 bp 
2000 bp
1500 bp
1000 bp 
750 bp
500 bp
250 bp
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2.3 Methods
2.4 Sterilization Procedures
Solutions, plasticware and glassware for cell culture and nucleic acid procedures were sterilised in 
an RSI series 32 automatic autoclave at 121°C for 20 minutes at a pressure of 151b/in .^ Solutions 
that are degraded by the autoclaving process were sterilised by passage through a 0.22-micron 
filter.
2.5 Plasmid DNA Purification Procedures
Glassware, plasticware and solutions for use in the preparation of DNA were autoclaved to destroy 
nucleases.
2.5.1 Retrieval o f Plasmids from Paper Stocks
Reporter constructs p4Al(171/273)GCAT and p4AlBam+20CAT were received contained as 
transformation-competent plasmids in Whatman 5MM paper. The labelled circle of paper 
containing each plasmid was firstly cut out and each paper circle was put into a separate eppendorf 
tube. 50pl of lOmM Tris, pH7.6 was added to each tube and vortexed. The paper circles were 
rehydrated for 5 minutes and briefly centrifuged. The supernatant containing the plasmids was then 
used to transform competent bacteria.
2.5.2 Preparation of Competent Cells
1ml of an overnight culture of host E. coli cells was diluted into 60ml of LB medium and grown at 
37°C in a shaking incubator for 2 hours (optical density of culture should be 0.5-0.6 at 650nm). 
The cells were put on ice for 20 minutes and then collected by centrifugation at 80 x g for 5 
minutes. The cells were resuspended in 20ml ice-cold CaCl] and centrifuged for a further 5 minutes
_
at 80 X g. The competent cells were resuspended in 2ml of ice-cold C&Ch and stored on ice ready 
for use for up to 3 hours.
2.5.3 Transformation of Host Bacteria with Recombinant Plasmids
The general method used for the transformation of host bacteria with recombinant plasmids is the 
method given in this section, although in cases where the TOPO TA Cloning® Kit was used the 
manual protocol was followed (see section 2.6.9).
For each transformation, 200pl of competent cells were aliquotted into a sterilin tube. 3pi of 
DMSO was added to each tube and mixed in gently. 10-20ng plasmid DNA was added very gently 
to each tube and the cells were incubated on ice for thirty minutes. A control transformation was 
set up using sterile water in place of DNA. The cells were heat shocked by incubation at 42°C for 
90 seconds and immediately replaced onto ice. 2ml of LB medium was added to each 
transformation and the cells were allowed to recover at 37°C with gentle shaking.
2.5.4 Selection of Transformed Cells
Depending on the recombinant plasmid that had been transformed into the host, cells were selected 
by spreading 50-200pl of transformation reaction mixture onto agar plates containing one of the 
following:
• 50-100ug/ml ampicillin
• 50pg/ml kanamycin
• X-gal, IPTG (for blue/white colour screening) and either 50pg/ml ampicillin or 50pg/ml 
kanamycin
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2.5.5 Preparation of Bacterial Glycerol Stocks
To 0.85ml of bacterial culture was added 0.15ml of sterile glycerol in a sterile ciyotube. The tube 
was briefly vortexed, snap frozen in liquid nitrogen and stored at -80°C.
2.5.6 Selective Bacterial Culture
The frozen surface of a glycerol stock was scraped with a sterile innoculating needle and used to 
streak either a 50-100pg/ml ampicillin or a 50pg/ml kanamycin LB agar plate. The plate was 
incubated for 14 hours at 37°C. A single colony was picked from the selective agar plate and used 
to innoculate 5ml of LB medium containing either lOOpg/ml ampicillin or 50pg/ml kanamycin. 
This 5ml culture was incubated with shaking for 8-16 hours. Larger cultures were produced by 
innoculation of 500ml LB medium (containing either lOOpg/ml ampicillin or 50pg/ml kanamycin) 
with 0.5-1ml bacterial culture. Large cultures were incubated with shaking for 12-16 hours at 
37°C.
2.5.7 Purification of Plasmid DNA from Bacterial Cultures
Plasmid DNA was purified from bacterial cultures using three different methods, the chosen 
method being dependent on the end application of the DNA and the time, within the duration of this 
project, at which the preparation was carried out. Small scale DNA preparations for cloning and 
sequencing purposes were carried out using Promega’s Wizard™ Plus SV Minipreps DNA 
Purification System. Initially, at the beginning of the project, Promega’s Wizard"'^ '^  Plus Maxipreps 
DNA Purification System was used for the preparation of larger quantities of plasmid DNA for 
mammalian transient transfections. During the project it was found that the Qiagen EndoFree Maxi 
Kit DNA Purification System produced plasmid DNA that reliably gave higher transfection 
efficiencies as compared to the Promega Kit (see Chapter 4).
95
2.5.7.i Promega*s Wizard™Plus Maxipreps DNA Purification System
Promega’s Wizard™ Plus Maxipreps DNA Purification system was used for rapid large-scale 
plasmid preparation from 500ml bacterial cultures. This technique exploits an SDS-alkaline lysis 
method for the removal of chromosomal DNA, followed by binding of the plasmid DNA from the 
cleared lysate to a silica-based resin. The selective adsorption in the presence of high 
concentrations of chaotropic salts of the plasmid DNA to a silica-based resin allows contaminants 
to be washed away and the DNA can then be eluted with a low ionic strength solution such as TE 
buffer.
Production of a Cleared Lysate:
500ml of cells were pelleted by centrifugation at 4000 x g for 20 minutes at room temperature in a 
Beckman J6 rotor. A pasteur pipette was used to completely resuspend the cell pellet in Cell 
Resuspension Solution. 15ml of Cell Lysis Solution was added and the solution was mixed by 
gentle stirring. Under these alkaline conditions both plasmid DNA and chromosomal DNA are 
efficiently denatured. Once the solution had become clear and viscous, 15ml of Neutralization 
Solution was added. The addition of this high salt buffer in the presence of the sodium salt of SDS 
causes the chromosomal DNA to base-pair in an intrastrand manner forming an insoluble aggregate 
that falls out of solution and the covalently closed nature of the plasmid DNA promotes intrastrand 
rehybridization allowing the plasmid to remain in solution. The insoluble potassium salt of SDS 
causes the precipitation and aggregation of proteins which assist in the capture of the high 
molecular weight chromosomal DNA. The neutralised solution was centrifuged at 15,000 x g for 
20 minutes in a room temperature Beckman JA-17 rotor and the cleared supernatant was filtered 
through Whatman® GFA filter paper. 0.5 volume of isopropanol was added to the filtered 
supernatant and the precipitate was centrifuged at 15,000 x g for 20 minutes in a room temperature 
Beckman JA-17 rotor. The DNA pellet was resuspended in 2ml of TE buffer.
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Plasmid Purification:
10ml of Wizard™ Plus Maxipreps DNA Purification Resin was added to the cleared lysate and 
swirled to mix. The resin/DNA mix was pulled through a Wizard™ Maxicolumn with a vacuum. 
25ml of Colunm Wash Solution was then drawn through the maxicolumn with a vacuum. The resin 
was rinsed with 5ml of 80% ethanol and the vacuum was drawn through the column for an 
additional minute. The maxicolumn was put into a 50ml Falcon tube and centrifuged at 2500rpm 
for 5 minutes in a bench top centrifuge with a swinging bucket rotor. The column was dried for an 
additional 5 minutes with the re-application of a vacuum. The maxicolumn was put into a clean 
50ml Falcon tube. To elute the DNA 1.5ml of preheated (65°C) 0.1 x TE was applied to the column 
for a period of one minute and the maxicolumn was centrifuged at 2500rpm for 5 minutes in a 
bench top centrifuge with a swinging bucket rotor. To remove any resin fines that may be present in 
the eluate, the solution was put through a 0.22pm filter into a microfuge tube. The plasmid DNA 
was stored at -20°C.
Ethanol Precipitation:
To improve the DNA quality for the purpose of transfection the Wizard maxiprep plasmid DNA 
was ethanol precipitated. To the DNA solution was added 0.1 volume of sodium acetate (3M, 
pH5.2) and the solution mixed. 2 volumes of ice-cold ethanol were then added with mixing and the 
ethanolic solution was stored at -20°C for 2 hours. The precipitated DNA was recovered by 
centrifugation at 13,000rpm for 10 minutes at 4°C in a microfuge. The DNA pellet was washed 
with 70% ethanol and recentrifuged at 13,000rpm for 2 minutes at 4°C in a microfiige. The 
supernatant was carefully removed and the pellet was allowed to air dry. The DNA pellet was 
resuspended in 0.1 x TE and stored at -20°C.
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2,5.7,2 Qiagen EndoFree Maxi Kit DNA Purification System
The Qiagen EndoFree Maxi Kit DNA Purification System yields ultrapure, endotoxin-free plasmid 
DNA, that according to the manufacturer is suitable for demanding applications such as transfection 
and gene therapy. The system is based on a modified alkaline lysis procedure, followed by binding 
of plasmid DNA to QIAGEN Anion-Exchange Resin under appropriate low-salt and pH conditions. 
A medium low-salt wash is used to remove RNA, proteins, dyes and low-molecular-weight 
impurities. Plasmid DNA is eluted in a high-salt buffer and then concentrated and desalted by an 
isopropanol precipitation step. QIAGEN-tips are packed with QIAGEN Resin and operate by 
gravity flow, making multiple sample preparation easier than protocols requiring the use of a 
vacuum manifold.
Routinely, 100-200ml of bacterial culture were harvested by centrifugation at 4000 x g for 
20minutes at 4°C, in a Beckman polypropylene bottle. The bacterial pellet was completely 
resuspended in 10ml ice-cold Buffer PI. 10ml Buffer P2 was added and the bottle was inverted 5 
times. Lysis was allowed to proceed for no more than 5 minutes. 10ml of ice-cold buffer P3 was 
added and the bottle was again inverted 5 times to ensure gentle but thorough mixing. The lysate 
was directly poured into the barrel of a stoppered QIAfilter cartridge and incubated for 10 minutes. 
The stopper was removed from the QIAfilter outlet nozzle and a plunger was gently inserted into 
the QIAfilter Maxi Cartridge. The filtered cell lysate was collected into a 50ml sterilin tube and 
2.5ml of Buffer ER added. The sterilin tube was inverted 10 times and then incubated on ice for 30 
minutes. During this incubation period a QIAGEN-tip 500 was equilibrated by application of 10ml 
Buffer QBT, the column was allowed to empty by gravity flow. After 30 minutes incubation with 
Buffer ER, the cleared lysate was applied to the prepared QIAGEN-tip and allowed to enter the 
resin by gravity flow. The QIAGEN-tip was washed twice with 30ml Buffer QC. and the DNA 
eluted with 15ml Buffer QN into a 50ml polypropylene tube. DNA was precipitated using 10.5ml 
room-temperature isopropanol and immediately centrifuged at 15,000 x g for 30 minutes at 4°C.
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The DNA pellet was washed with 2.5ml endotoxin-free water and centrifuged at 15,000 x g for 10 
minutes at 4°C. The pellet was air dried and redissolved in 400|il endotoxin-free Buffer TE. DNA 
was stored at -20°C.
2.5.7.5 Promega *s Wizard ™ Plus SV Minipreps DNA Purification System
As with the Promega and Qiagen maxipreps described previously (see sections 2.5.7.1 and 2.5.7.2), 
the miniprep process involves the production of a cleared lysate and plasmid DNA purification 
using a column. An additional step in the miniprep process is the addition of alkaline protease to 
the lysate, this enzyme inactivates endonucleases and other proteins that are released during the 
lysis of the bacterial cells.
Routinely, 1.5ml of bacterial culture was harvested by centrifugation for 5 minutes at 10,000 x g in 
a tabletop centrifuge. The supernatant was carefully removed and the pellet resuspended in 250pl 
Wizard® Plus SV Cell Resuspension Solution. 250p,l Wizard® Plus SV Cell Lysis Solution was 
added and the tube inverted 4 times to mix. The cell suspension was incubated until it had cleared, 
but for no longer than 5 minutes. lOpl Alkaline Protease Solution was then added and the tube 
again inverted 4 times to mix. 350pl Wizard® Plus SV Neutralization Solution was added and 
mixed in by inversion of the tube 4 times. The bacterial lysate was centrifuged at 14,000 x g for 10 
minutes at room temperature. The cleared bacterial lysate was applied to a Wizard® Plus SV 
Minipreps Spin Column on a vacuum manifold. A vacuum was applied to draw the lysate throu^ 
the column. 750pl of Wizard® Plus SV Column Wash Solution was then drawn through the 
column under vacuum. A second wash was carried out using 250pl of wash solution. The column 
was transferred to a 2ml collection tube and centrifuged at 14,000 x g for 2 minutes to remove any 
residual column wash. Plasmid DNA was eluted with lOOpl Nuclease-Free Water with a 1 minute 
centrifugation at 14,000 x g. Miniprep DNA was stored at -20°C.
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2.5.8 Purification of DNA from Agarose Gels
2.5,8,1 QIAquick Gel Extraction Kit
For the extraction of pure DNA from agarose gel slices, in particular for the purification of small 
fragments, the QIAquick Gel Extraction Kit was used according to the manufacturers instructions. 
Using this kit, fragments from 70bp to lOkb can be purified from agarose, with yields of 80% for 
lOObp fragments and a maximum recovery rate of 80% for SOObp to Ikb fragments (Qiagen Product 
Guide, 1998). Fragments isolated using this method were found to perform very well in ligation 
reactions. The QIAquick system is based on a simple bind-wash-elute system utilising silica gel 
membranes that are capable of adsorbing up to lOpg of DNA.
DNA fragments were separated using a standard TAE agarose gel containing ethidium bromide and 
were visualized using medium wavelength UV light. The band of interest was excised from the gel 
quickly, so as to minimize exposure of the DNA to UV light, using a clean scalpel. The gel slice 
was weighed and 3 volumes of buffer QG was added to 1 volume of gel. A maximum of 400mg 
agarose was applied to any one column. The gel slice was heated in buffer QG at 50°C until the 
agarose had melted, approximately 10 minutes with vortexing every couple of minutes. Buffer QG 
contains a pH indicator so that the pH can be optimized for optimal adsorption of the DNA to the 
QIAquick membrane. The desired colour (indicating a of pH7.5) of the heated mixture is yellow, if 
the mixture was orange or violet the pH was lowered with the addition of 3M sodium acetate, pH5. 
One gel volume of isopropanol was mixed in to the yellow mixture and applied to a QIAquick 
column. The column was centrifuged for 1 minute to allow the DNA to bind. The column was 
washed with 750pl of buffer PE and centrifuged for a further minute. DNA was eluted with 30pl of 
sterile water, pH7, applied to the centre of the QIAquick membrane and 1 minute centrifiigation.
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2,5.8,2 Wizard ™PCR Preps DNA Purification System
The Wizard™ PCR Preps DNA Purification System was used for the rapid purification of double­
stranded PCR amplified DNA from PCR reactions and from agarose gels. Using this kit in 
accordance with the manufacturers instructions up to 90% of a SOObp fragment can be retrieved 
from agarose and up to 99% of a SOObp fragment can be retrieved by direct purification from a PCR 
reaction (Promega Technical Bulletin No. 118). The recovery of smaller fragments >200bp is less 
efficient at >69%, as compared to the 80% recovery that can be obtained with the QIAquick gel 
extraction system. The purified DNA is of suitable quality for use in ligation/transformation 
reactions.
DNA products were purified using agarose gel electrophoresis and isolated in a gel slice (300mg or 
less) as described in section 2.5.8.1. 1ml of DNA Purification Resin was added to the gel slice and 
heated at 65°C until melted, approximately 5 minutes. For direct purification from a PCR reaction, 
lOOpl of Direct Purification Buffer was added to 30-300pl PCR reaction and the mixture was 
briefly vortexed. To the PCR reaction/resin mixture, 1ml of resin was added and the mixture 
vortexed briefly over a 1 minute period. The melted agarose/resin mixture or PCR reaction/resin 
mixture was added directly to a prepared minicolumn and a vacuum applied to draw the mixture 
through. Under vacuum, the column was washed with 2ml 80% isopropanol and the column was 
dried for a maximum of 30 seconds with the vacuum. The minicolumn was centrifuged for 2 
minutes at 10,000 x g to remove residual isopropanol. 50pl of water was applied to the column and 
the DNA was eluted by centrifugation at 10,000 x g for 20 seconds.
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2.6 Analysis, Modification and Cloning of Plasmid DNA
2.6.1 Agarose Gel Electrophoresis
Agarose gel electrophoresis is an invaluable tool for the separation, identification and purification 
of DNA fi'agments (Sambrook et al, 1989). Estimations of DNA quantity can easily be made using 
agarose gel electrophoresis in conjunction with an appropriate DNA mass marker. The quality of a 
plasmid DNA preparation can also be assessed using this technique; chromosomal contamination of 
plasmid DNA and prolonged alkaline lysis produce tell-tale smearing or resistance to digestion on 
restriction endonuclease treatment (see QIAGEN Plasmid Purification Handbook).
Agarose gels were cast by melting agarose in 1 x TAE buffer until a clear, transparent solution was 
achieved. Typically a 1% agarose gel was cast. The melted solution was cooled to 50-60°C and 
poured into a mould with a comb in place to form loading wells. The gel was allowed to set for a 
minimum of 25 minutes and if not used immediately was wrapped in Saran wrap and stored at 4°C. 
Once the gel has set, a matrix forms, the density of which is determined by the agarose 
concentration. Gels were placed into the chamber of a mini-electrophoresis tank and run in 1 x 
TAE buffer. Loading dye was added to the DNA sample prior to loading into the wells. Loading 
dye increases the density of the sample and also provides a visible marker to monitor the progress 
of the DNA fragments through the gel matrix. DNA is negatively charged at a neutral pH and 
hence moves towards the anode when an electric field is applied across the gel. The rate of 
migration of the DNA is determined by numerous parameters, including: the molecular size of the 
DNA, agarose concentration, DNA conformation, applied voltage, direction of the electric field, 
base composition and temperature, presence of ethidium bromide and the composition of the 
electrophoresis buffer. Routinely gels were run at 80 volts.
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The nucleic acids were visualized in the gels using the fluorescent dye ethidium bromide. Ethidium 
bromide intercalculates nucleic acid molecules and on exposure to UV light emits light in the 
red/orange region of the visible spectrum. Hence, nucleic acids are seen as bright pink/orange 
bands on the gel when illuminated from underneath by a UV transilluminator. Full UV face shields 
were worn in the presence of UV light. Gels were stained using one of two methods: either (1) by 
the addition of 2pl ethidium bromide (lOmg/ml) per 100ml agarose, or (2) by immersion of the gel 
in a solution of ethidium bromide (3pg/ml in 1 x TAE) for 10 minutes with shaking and a 10 
minutes destain in 1 x TAE with shaking. Addition of ethidium bromide to the gel reduces the 
mobility of the DNA by about 15%.
Ethidium bromide stained agarose gels were photographed on a UV transilluminator using a 
Polaroid Land Speed MP-4 camera with an orange filter. Polaroid film Type 667 was used.
2.6.2 Spectrophotometric Determination of DNA Concentration and Purity
Spectrophotometric measurements were carried out using quartz cuvettes and samples were blanked 
against milliQ water. The concentration and purity of a high quality DNA preparation may be 
determined by spectrophotometric measurement using the following equations (Sambrook et al, 
1989):
Equation 2-1 Calculation of DNA Concentration in pmol/pl
DNA concentration (pmol/pl) = A260 x dilution factor / number of nucleotides x 330 
where the average molecular weight of a nucleotide = 330
Equation 2-2 Calculation of DNA Concentration in pg/pl
DNA concentration (pg/pl) = A260 x dilution factor x 1 absorbance unit (pg/ml) / 1000 
For dsDNA, 1 absorbance unit = 50pg/ml
_
Equation 2-3 Determination of DNA Purity
For pure DNA: A260/A280 = 1-8
Contamination of the DNA preparation with either protein or phenol will reduce the A260/A280 ratio.
2.6.3 Restriction Enzyme Digestion of Plasmid DNA
Restriction enzymes bind to and cleave dsDNA at specific recognition sites (Sambrook et al, 1989). 
Type II restriction enzymes are commonly used in molecular cloning, they consist of a restriction 
endonuclease that cleaves a specific sequence of nucleotides and a separate methylase that modifies 
that sequence. A typical type II restriction enzyme recognition site is an exact palindrome of 4, 5, 
6, 7 or 8bp with an axis of rotational symmetry. Cleavage by a restriction enzyme will generate one 
of a number of different ends which will either be overhang (sticky), or blunt ends, usually with a 
5’-phosphate and 3’-hydroxyl group. For example EcoRI recognises the sequence: GvAATTC and 
leaves overhang ends; whereas PvuII recognises the sequence CAGvCTG and leaves blunt ends. 
The ends that a restriction enzyme leaves after cleavage of the DNA is a major consideration during 
the process of cloning and determines how a subsequent ligation reaction can be carried out. When 
constructing a cloning strategy it is important to carefully think about the choice of restriction 
enzyme, and to consider using isoschizomers (isoschizomers share the same recognition and cut 
sequence) or neoschiomers (neoschiomers share same recognition sequence but cut at different 
site). Some restriction enzymes produce compatible ends even if their recognition sequences are 
not identical.
Purified plasmid DNA was examined by restriction digest and agarose gel electrophoresis. Plasmid 
identity was confirmed by checking fragment sizes and cleavage patterns produced. Restriction 
enzyme digestion was also performed during the process of DNA cloning to isolate DNA fragments
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for ligation into plasmids that had also been prepared by restriction digestion. Routine restriction 
digests were set up, in the stated order, as follows:
Nuclease-ffee water make reaction volume up to 20pl
Restriction enzyme lOx buffer 2pl
BSA, acetylated (1 mg/ml) 2pl
DNA sample (in water or TE) 0.2-1 pg
Restriction enzyme 2-1 OU
Restriction enzyme digests were usually incubated for 1-4 hours at 37°C. The optimum conditions 
for a restriction digest depend on the particular enzyme or enzymes used for the digest, the quantity 
of DNA to be digested and also on the buffer composition.
2.6.4 Filling 5 -Protruding Ends Using Klenow
Klenow (DNA Polymerase I Large) Fragment was used to fill 5'-protruding ends with dNTPs. The 
Klenow fragment consists of a single polypeptide chain which lacks the 5' to 3' exonuclease 
activity of intact E. coli DNA Polymerase I, but retains its 5' to 3' polymerase, 3' to 5' exonuclease 
and strand displacement activities (Promega Technical Bulletin No. TB525).
5' overhang fill in reactions were set up with: 6pl 10 x Klenow Buffer, 40pM each dNTP, SOOng 
purified DNA fragment, 20pg/ml acetylated BSA, and 0.5u Klenow enzyme, made up to 60pl with 
nuclease free water. The reaction was incubated at room temperature for 10 minutes and stopped 
by incubation at 75°C for 10 minutes.
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2.6.5 Ligation Reactions
A typical ligation reaction was set up using: 50-200ng of vector DNA, Ipl Ligase 10 x Buffer, lu 
T4 DNA Ligase and was made upto a final volume of lOpl with nuclease-free water. In cases 
where an insert was being ligated into a plasmid vector, vector to insert ratios of 1:1 and 1:3 were 
set up. Usually several ligation reactions were set-up and performed using a range of conditions, 
within the following parameters:
blunt end ligation 22°C for 4-16 hours
protruding ends 22°C for 3 hours or 4°C for 16 hours
2.6.6 Oligonucleotide Primers
Oligonucleotide primers were synthesized commercially using GibcoBRL Custom Primer Service, 
with the exceptions of the pUC/M13 Forward(-40) and pUC/M13 Reverse Primers, which were 
purchased from Promega. Oligonucleotides were received from Gibco BRL as lyophilizates and 
were rehydrated for two minutes in a suitable volume of TE buffer, vortexed and stored in small 
aliquots at -20°C. Table 2-3 lists the sequences of these oligonucleotide primers.
When designing the primers for PCR reactions, several factors were taken into consideration: PGR 
primers should contain 40-60% G + C, the 3'-ends of the primers should not be complementary, 
runs of three or more G or C nucleotides near the 3'-end of the primer were avoided and primer 
pairs were designed if possible with similar annealing temperatures (Tm).
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Table 2-3. Oligonucleotide Primer Sequences
Primer Sequence (5' to 3') % GC
lAl-3200 AAC ATG AGC AAA ACA GCG GG 50
lAl-2729 GAC CTT GAA CTC ATG AAA GT 40
lAl-1171 TTC TTC CTC TCA AAC CCC AC 50
lAl-820 ATA CGG TAG ATA GCT CTG CT 45
lAl-530 AGA CTC AGT AAC CCA GGG AAG CAA 50
lAl-1 GGT TAG GGT GAA GGC ACC AC 60
lAl+2545 CTA GGT GGC TGC TGA GAA GT 55
4A1171 . TCC ACA GTC TGA GTC CTA GG 55
4A1.273 GAA CAA TTT ACA CTC CAT CT 35
pUC/M13 Forward (-40) GTT TTC CCA GTC ACG AC 53
pUC/M13 Reverse CAG GAA ACA GCT ATG AC 47
-40 Primer GTT TTC CCA GTT CAC GAC GTT 48
2.6.7 Automated Sequencing
Automated fluorescence sequencing was carried out on a Perkin Elmer Applied BioSystem 
Instrument (operated by Mr. Steven Dyer, Molecular Microbiology Group, School of Biological 
Sciences) using the dye termination cycle sequencing procedure. For the sequencing reaction: 
SOOng of DNA template and 3.2 pmol primer were made up to 20pl in dye/enzyme mix.
2.6.8 PCR Amplification of DNA
In order to clone specific elements of DNA firom the upstream regions of the CYP4A1 and 
CYPlAl genes, the polymerase chain reaction (PCR) was used. PCR products were then inserted
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into the pCR®2.1-T0P0 vector, which does not require enzyme modification of the PCR product 
(see section 2.6.9).
A typical PCR reaction would contain:
DNA template
PCR buffer lOx
dNTPs (50mM)
Primers
Sterile water
Taq DNA Polymerase
lO-lOOng 
5ul 
0.5 pi
IpM ofeach
made up to 50pl total reaction volume 
1.25 units
Routinely, PCR reactions were set up on ice. The DNA template was dispensed into autoclaved 
Perkin-Elmer thin walled PCR tubes, to which the PCR master mix was added (containing the 
remaining PCR reaction components). A negative control would be set up alongside and would 
contain sterile water in place of the DNA template. For some PCR reactions the magnesium 
concentration of the reaction required optimisation, this was done empirically. PCR products were 
synthesised using modifications of the following cycling parameters:
dénaturation 
annealing 
extension 
(25 cycles) 
final extension
1 minute, 94®C
1 minute, (lowest Tm of primer pair)°C 
1 minutes, 72°C
10 minutes, 72°C
A final extension step at 72°C was included in the cycling parameters to ensure that all PCR 
products were full length and 3' adenylated. Modifications were made to the cycling parameters
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according to the size of the amplicon and the Tm of the primers. For the extension step 
approximately 1 minute for every Ikb of amplicon was used. The annealing temperature of the 
reaction was set according to the temperature of the lowest primer Tm (see Equation 2-4).
Equation 2-4 Calculation of Primer Melting Temperature (Tm)
Tm = 81.5 + 16.6 • (logio[Na+]) + 0.41 • (%G+C) - 675/n
Where [Na+] is the molar salt concentration; [K+]= [Na+] and n = number of bases in the 
oligonucleotide (Promega Protocols and Application Guide, 1996).
2.6.9 Subcloning of PCR Products using the TOPO TA Cloning® System
Taq polymerase-amplified PCR products were subcloned into the TOPO TA Cloning® System 
plasmid vector pCR®2.1-T0P0. The PCR product was inserted in either orientation into the 
middle of the multiple cloning site of pCR®2.1-T0P0 (see section 2.2.3), facilitating sub-cloning 
into the vector of choice. pCR®2.1-T0P0 is supplied linearized with single 3' thymidine (T) 
overhangs and topoisomerase. Ligation of a PCR product, containing 3' A overhangs, into the 
prepared vector takes only five minutes.
Using this kit, cloning and transformation were carried out according to the manufacturer’s 
instructions. Briefly, 0.5-2pl of fresh PCR product and Ipl pCR®2.1-T0P0 vector were made up 
to 5pi with sterile water, mixed gently and incubated for 5 minutes at room temperature. The 
TOPO-Cloning™ reaction was briefly centrifuged and put on ice prior to dierctly transforming into 
One Shot™ cells. 2pi 0.5M (3-mercaptoethanol was gently stirred into one vial of One Shot™ cells 
with 2pl of the TOPO-Cloning™ reaction and incubated on ice for 30 minutes. The cells were heat 
shocked for 30 seconds at 42°C and immediately transferred back onto ice for 2 minutes. 250pl of 
SOC medium was added to the tube of cells, which were then incubated at 37°C with shaking for
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30 minutes (ampicillin selection) or 1 hour (kanamycin selection). During this incubation period the 
tube was positioned horizontally in the incubator. After the incubation the tube was placed onto ice 
and 50-1 OOpl of transformation was spread onto a selective prewarmed agar plate. The plates were 
incubated overnight at 37°C. White or light blue colonies were then picked for analysis.
2.7 Protein Determination
The protein concentration of cell lysates and cell homogenates was determined using the method of 
Miller, G. L. (1959). 25pi of sample was diluted with milliQ water to a final volume of 1ml. 0, 
20,40,60,80 and lOOpg BSA standards were also made upto 1ml in milliQ water. Samples and 
standards were set up in triplicate. To each sample and standard tube was added 1ml of Solution A 
(1ml 5%(w/v) CUSO4.5 H2O, 10ml 1% (w/v) Potassium Sodium (+) Tartrate, 100ml 10% (w/v) 
sodium carbonate anhydrous). Tubes were incubated for exactly 10 minutes at room temperature. 
3ml of solution B (1 x Folin & Ciocalteu’s Phenol reagent) were then added to each tube and 
incubated at 50°C for 10 minutes to allow colour development. Tubes were cooled with cold 
running water and the absorbance of the standards and samples were read at 650nm.
2.8 SDS-FAGE and Western Blotting
Western blotting is a very useful technique for the identification and quantification of specific 
proteins in complex protein mixtures such as cell extracts. Proteins are separated by SDS-PAGE 
using denaturing conditions, hence eliminating problems of solubilisation, aggregation and co­
precipitation of target protein with other proteins (Sambrook et al, 1989). These proteins are then 
transferred to a solid support by the process of electroblotting and the target protein detected by 
immunoblotting. An outline of the SDS-PAGE western blotting techniques that were employed is 
given in Figure 2-13.
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Figure 2-13. General Scheme for SDS-PAGE Western Blotting
SDS-PAGE 
separation of sample proteins 
and biotinylated marker proteins
Electroblotting of proteins 
onto Hybond-PVDF Membrane
Block non-specific sites
Primary antibody incubation 
(mouse or goat anti-PPAR subtype IgG antibody)
Incubation with strepavidin- 
HRP conjugate
Incubation with secondary 
antibody 
(anti-mouse/goat-HRP 
conjugated antibody)
ECL-Plus chemiluminescence detection
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2.8.1 Sample Preparation
2,8,L1 Preparation of HepG2 Cell Lysates and Cell Homogenates
12 X 75cm^ vented culture flasks were seeded with HepG2 cells (3 x 10'^  cells/cm^). 24 hours later 
4 flasks were transfected with pSGSPPARa (160pg pSGSPPARa per flask) and 4 flasks were 
transfected with pcDNA3PPARy (160pg pcDNA3PPARy, gift of J. Owens, University of Surrey) 
using calcium phosphate-mediated DNA transfection method 2 (see 2.12.2.4). The remaining 4 
flasks had fi*esh media put on. After 18 hours the transfection media was removed and replaced 
with fi*esh growth media. Cells were harvested 48 hours later. Half of the flasks were lysed; 1ml of 
lysis buffer was put on per flask, incubated at room temperature 30 minutes, microftiged at 13,000 
rpm for 5 minutes and the supernatant frozen on dry ice. The remaining flasks were used for the 
preparation of homogenates: cells were scraped into O.IM sodium phosphate buffer, pH7.6, using a 
rubber policeman and homogenized with a Teflon-glass Potter Elvehjeim type homogeniser. 
Homogenates were firozen on dry ice. Lysates and homogenates were stored at -80°C.
2.8d,2 Preparation o f Protein Samples for Gel Loading
10-50pg of cell lysate or cell homogenate were resuspended in protein sample loading buffer and 
incubated at 100°C for 4 minutes. Samples were transferred to ice and stored temporarily ready for 
gel loading. l}xl of protein molecular weight marker in 9pl of protein sample loading buffer was 
prepared in the same manner.
2.8.2 SDS-PAGE Polyacrylamide Gel Electrophoresis
SDS-PAGE was used to separate proteins by molecular weight and was first described by Laemmli 
(1970). Proteins were denatured under reducing conditions by the presence of an excess of SDS. 
SDS binds the amino acid chain resulting in the protein having a negative charge that is 
proportional to the molecular w e i^ t of the protein.
SDS-PAGE gels were run using a Bio-Rad Mini-PROTEAN II dual slab cell system. The 
components of the resolving gel (12%) were added in the order stated (see Table 2-2) and mixed 
thoroughly. Polymerization begins as soon as the TEMED is added and hence the gel must be 
poured immediately between the assembled glass plates. A 5mm layer of ethanol was applied to the 
top of the liquid gel to prevent oxygen from diffusing into the gel, thereby inhibiting 
polymerization. The ethanol layer also to produces a flat interface between the resolving and 
stacking gels. Once the gel had polymerized, approximately 30 minutes, the layer of ethanol was 
removed, the top of the gel washed with milliQ water and residual water removed with blotting 
paper. The components of the stacking gel (4%) were then mixed and poured onto the top of the 
resolving gel. A plastic comb was inserted into the liquid stacking gel, taking care not to trap any 
air bubbles. After one hour the comb was removed and the wells were immediately washed with 
milliQ water to remove any unpolymerised acrylamide. The gel was mounted in the electrophoresis 
apparatus and the tank was filled with 1 x running buffer. The marker and protein samples were 
loaded onto the gel. The gel was run at a constant 120 volts for about one and a half hours, until 
the loading dye had reached the very bottom of the gel.
2.8.3 Transfer of Proteins onto PVDF Membrane
Proteins were transferred by electroblotting onto PVDF (polyvinylidine difluoride) membrane. 
PVDF membrane has a higher protein binding capacity than nitrocellulose and also gives lower 
backgrounds.
The gel was removed from the electrophoresis apparatus, trimmed and soaked for a minimum of 15 
minutes in protein transfer buffer. Methanol was included in the protein transfer buffer in order to 
minimize gel swelling during the blotting process. A piece of PVDF membrane and four pieces of 
Whatman 3MM paper were cut to the same size as the gel. The membrane was wet in methanol for 
10 seconds, water for 5 minutes and then soaked in transfer buffer for a minimum of 15 minutes. 
The 3MM paper and two fibre pads were thoroughly wet in transfer buffer prior to use. The blot
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was assembled in the transfer cassette in the following order: 1 fibre pad, 2 pieces 3MM paper, 
equilibrated gel, PVDF membrane, 2 pieces 3MM paper and lastly 1 fibre pad. Care was taken to 
eliminate trapped bubbles of air and the whole assembly was maintained soaked in transfer buffer. 
The transfer cassette was put into the transfer tank with the gel side towards the cathode and the 
membrane on the side of the anode. A cooling block was inserted into the transfer tank and the 
tank topped-up with chilled transfer buffer. The blot was run at a constant 100mA overnight, 
approximately 16 hours.
2,83.1 Staining of Immobilized Proteins Using Ponceau S
Ponceau S staining was used to provide visual evidence that the proteins had been succesfully 
transferred from the gel to the membrane. The membrane was removed from the protein transfer 
apparatus, rinsed in milliQ water and the protein side of the membrane marked with pencil. The 
membrane was then transferred to a tray containing a working solution of Ponceau S stain and 
incubated for 10 minutes with gentle agitation. The membrane was then washed in several changes 
of milliQ water. The proteins were stained a pink-purple colour. Prior to immunoblotting the 
membrane was washed in 0.1% (v/v) TBS-Tween for 5 minutes.
2.8.4 Immunoblotting
The immunoblotting procedure was optimized for each particular protein that was being detected. 
Modifications of the following method were used: the wet membrane was blocked at room 
temperature for 1 hour with 10%(w/v) dried skimmed milk in 0.1% (v/v) TBS-Tween. The 
membrane was briefly rinsed and washed 1 x 5  minutes in 0.1% (v/v) TBS-Tween prior to a 1 hour 
incubation with primary antibody (diluted in 0.1% (v/v) TBS-Tween). The membrane was washed 
again: 2 x 10 minutes in 0.1% (v/v) TBS-Tween. The secondary antibody (diluted in 0.1% (v/v) 
TBS-Tween) was incubated with the membrane for 1 hour and for detection of the protein markers 
a 15 minute incubation in streptavidin-HRP conjugate was carried out (diluted in 0.1% (v/v) TBS-
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Tween). Before chemiluminescent detection, the membrane was washed 3 x 10 minutes in 0.1% 
(v/v) TBS-Tween.
2.8.4.1 ECL Plus Chemiluminescent detection
HRP was detected with the ECL Plus kit, which is a luminol based product. The detection reagents 
were mixed according to the manufacturers instructions immediately prior to use. lOOpl of the 
prepared detection reagent per cm  ^ of membrane was incubated on the protein side of the 
membrane for 5 minutes. The membrane was then exposed to type 667 Polaroid film in a mini­
camera. The length of exposure was dependent on the signal intensity, usually between 30 seconds 
and 3 minutes,
2.9 EROD Assay
Ethoxyresorufin O-deethylation activities were measured in p-napthoflavone treated and untreated 
HepG2 cells. 7-ethoxyresorufin is a relatively specific substrate for CYPlAl (Burke, M.D. et al, 
1985). Ethoxyresorufin O-deethylation activity is considered therefore to be a marker for CYPlAl. 
The method used is principally based on those described previously by Burke and Mayer (1974) 
and Grant et al. (1988).
2.9.1 Sample Preparation
10 X 75cm  ^vented culture flasks were seeded with HepG2 cells (3 x  10"^  cells/cm^). The cells were 
allowed to settle for 48 hours prior to daily dosing for 3 days. 2 flasks were not dosed, 2 flasks 
were dosed with solvent alone (0.1% DMSO), 2 flasks with 2pM BNF, 2 flasks with lOpM BNF 
and the remaining 2 flasks with 50pM BNF (BNF was prepared as 1000 x stocks in DMSO). 
HepG2 cell lysates and homogenates were prepared on day 6. Half of the flasks were lysed and half
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were used for the preparation of homogenates. Lysis and homogenisation procedures for HepG2 
cells is given in section 2.8.1.1.
2.9.2 Ethoxyresorufin-O-deethylation Measurement
EROD activities were determined by following the generation of resorufin fluorimetrically using a 
Perkin Elmer LS5 luminescence spectrophotometer. The spectrophotometer was set at excitation 
wavelength 510nm, excitation slit width lOnm, emission wavelength 586nm and emission slit width 
2.5nm. The following reagents were added to a 3ml quartz fluorimeter curette: 1.8ml O.IM sodium 
phosphate buffer pH7.6, 200pl sample, lOpl ethoxyresorufin and dicumarol at a final concentration 
of lOpM. Dicumarol was added to inhibit cytosolic DT-diaphorase. A baseline was recorded. The 
reaction was followed on addition of lOpl 50pM NADPH (in 1% NaHCOs). The increase in 
fluorescence was monitored and the initial rate of resorufin generation was calculated from the 
slope. Calibration was carried out by adding aliquots of resorufin to an incubation mixture 
comprising of all the reaction components except the substrate.
2.10 Cell Culture
2.10.1 Routine Cell Subculture
The cell lines used for this study grew as monolayer cultures and were therefore all subcultured in a 
similar manner. After washing the cell sheet (75cm^) in 5ml of PBS, cells were detached from the 
bottom of the flask by incubation at room temperature with 1ml trypsin-EDTA. Routinely cells 
would detach from the flask after a 3 minute incubation with the trypsin-EDTA and a few sharp 
taps to the side of the flask. 11ml of pre-warmed media was added to the flask and the cells seeded 
into vented Nunc flasks. Pre-warmed media was added to each flask to make up to 20ml. Cells 
were incubated at 37°C in 5% CO2.
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2.10.2 HepG2 Human Hepatoma Cell Line
Passage 92 HepG2 cells were obtained from the European Collection of Cell Cultures (ECACC) 
and were maintained in MEM supplemented with 10% (v/v) FBS, 1% gentamycin, 2mM L- 
glutamine and 1% (v/v) non-essential amino acids (NEAA). Confluent cultures were split 1:3 to 
1:6 i.e. seeded at 2-4 x 10'*cells/cm .^
2.10.3 H4HEC3 Rat Reuber Hepatoma Cell Line
H4IIEC3 cells (unknown passage number) were obtained from ECACC and were maintained in 
DMEM supplemented with 10% (v/v) FBS and 1% (v/v) gentamycin. Confluent cultures were split 
1:3 i.e. seeded at 4 x 10'* cells/cm^.
2.10.4 HepalclcT Mouse Hepatoma Cell Line
Hepalclc? cells (unknown passage number) were a gift of Joanna Owens, University of Surrey. 
These cells were maintained in DMEM supplemented with 10% (v/v) FBS, 1% (v/v) gentamycin 
and 2mM L-glutamine. Hepalclc? cells have a cell doubling time of about four hours, which 
requires cells to be split 1:6 every couple of days i.e. seeded at 2 x 10'* cells/cm^.
2.10.5 CHO Chinese Hamster Ovary Cell Line
CHO cells (supplied by Prof. P. Goldfarb, University of Surrey) were maintained in Ham’s FIO 
medium supplemented with 10% (v/v) FBS and 0.2% (v/v) gentamycin. Confluent cultures were 
split 1:3 to 1:6 i.e. at 2-4 x 10'* cells/cm^
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2.11 Storage of Cell Lines in Liquid Nitrogen
Aliquots of cells low passage number cells were stored in liquid nitrogen. Transfection efficiency 
decreases in some cell lines such as HepG2 if the cells have been passaged for many generations 
(see Chapter 4).
2.11.1 Procedure for Freezing Cells
Cells were harvested by trypsin-EDTA in the same manner used for routine culture and counted 
using a haemocytometer. The counted cells were then sedimented by centrifugation at 70-100g for 
5 minutes. The cell pellet was gently resuspended in freeze medium (91% (v/v) FBS + 9% (v/v) 
DMSO) to give a final cell concentration of 4 x 10^  cells/ml. 1ml of cells in freeze medium was 
aliquotted into each ciyovial. Cryovials were wrapped in cotton wool in sealed polystyrene boxes 
and frozen to -80°C overnight before transferring to liquid nitrogen storage.
2.11.2 Creation of HepG2 Cell Bank
A HepG2 bank of 100 cryovials each containing 4 x 10^  cells at passage number 98 (6 passages 
since receipt from ECACC) was created to provide a stock of HepG2 cells at the same passage 
number suitable for reproducible transient transfection work.
2.11.3 Resuscitation of Cells from Liquid Nitrogen Storage
Cryovials were removed from liquid nitrogen and put into a polystyrene float in a 37°C waterbath 
for 1-2 minutes until defrosted. Cryovials were wiped with a tissue soaked in 70% ethanol prior to 
opening. The contents of the cryovial were pipetted into 10ml of prewarmed media and the cells 
collected by centrifugation at 70-100g for 5 minutes. The cell pellet was resuspended in 20ml of 
prewarmed media and transferred to a vented 75 cm  ^ flask. The flask was incubated overnight at
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37°C, 5% CO2. After an incubation of 16-24 hours the media was aspirated off and replaced with 
fresh media.
2,12 Reporter Gene Assays
A simplified scheme of the reporter gene assays developed during this project is presented in Figure 
2-14.
Figure 2-14. General Scheme for Reporter Gene Assays
d o sin g
calcium phosphate-DNA 
co-precipitate I  liposomal mediated 
transient transfection
CAT/SEAP
reporter
construct
p-gal
expression
plasmid
receptor
expression
plasmid
Nucteus
Response
Element
eponer , 
îizyin a
6-galactosldase
HepG2 / H epalclc? / 
H4IIEC3 Cell C ulture
0A7ISEÂP sisssjy
P-galactosidase
assay
2.12.1 Stripping of Foetal Bovine Serum using Dextran Coated Charcoal (DCC)
Foetal bovine serum (FBS) naturally contains substances such as steroids and fatty acids that can 
interfere with the P450 fold-induction response seen in P450 reporter gene assays. In order to 
remove some of these activating substances FBS was stripped using dextran coated charcoal 
(Fenske, 1991; Nakama et ai, 1995). 500mg activated charcoal and 50mg dextran T70 was added 
to 500ml FBS and the mixture stirred for 30 minutes. Solids were removed by centrifugation for 15
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minutes at 1,500 x g. The supernatant was passaged through a 0.45-micron filter to remove any 
remaining solids and then sterilized by passage through a 0.22-micron filter.
2.12.2 Transient Transfection Techniques
A large number of methods have been used to transfer DNA into eukaryotic cells for the study of 
gene regulation and expression. These methods include the use of calcium phosphate or other 
divalent cations, polycations, liposomes, retroviruses, microinjection and electroporation 
(Sambrook et a l, 1989; Promega Protocols and Applications Guide, 1996). The choice of 
transfection method depends to a large extent on the cell type that is to be transfected and the 
conditions under which the particular cell type can be cultured. For each cell type, under a given 
set of conditions, the transfection method must be fully optimized. Optimization of transfection 
efficiency is discussed further in Chapter 4.
2.12.2.1 Seeding Cells for Transfection
Cells were seeded into wells in 6-well plates, 24-well plates or 96-well plates, 24 hours prior to 
transfection. At the time of transfection cells were 60-80% confluent . The media used for 
transfection was phenol-red free and contained DCC-treated FBS. Phenol red was omitted from 
transfection media because it has been found that phenol red (phenolsulphonphthalein) can imitate 
an oestrogen effect and also can interfere in fluorescence tests and chemiluminescence readings 
(Points of View No.2, PAA Laboratories Limited, 1997). The number of cells seeded per well and 
the transfection medium components are given in Table 2-4. The conditions given in this table are 
optimal for transfection using the methods described in this chapter. Details of transfection 
efficiency optimization can be found in Chapter 4. As part of the process of transfection efficiency 
optimization, HepG2 cells were also seeded into poly-D-lysine coated 6-well plates for transfection.
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Table 2-4. Typical Cell Seeding Conditions for Transfection
Transfection Number of Cells Seeded per Well
Cell Type Media 6-well plate 24-well plate 96-well plate
HepG2 MEM without phenol red, 
supplemented with DCC-FBS, 
1% gentamycin, 2mM L- 
glutamine and 1% NEAA
6x10^ 1x10^ 2.4 X 10^
Hepalclc? DMEM without phenol red, 
supplemented with 10% DCC- 
FBS and 1% gentamycin
5x10^ Ix lO ’
H4IIEC3 DMEM without phenol red, 
supplemented with 10% DCC- 
FBS and 1% gentamycin
1x10^
CHO Ham’s FIO medium, 
supplemented with DCC-FBS 
and 0.2% gentamycin
2.5x10^
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2.12.2.2 Poly-D4ysine Coating of Cell Culture Plates
500pl of poly-D-lysine (0.1 mg/ml) was added per well of a 6-well plate and distributed to cover the 
entire well surface. After 5 minutes the poly-D-lysine was aspirated off and each well was washed 
with 1ml sterile PBS. The plates were allowed to dry overnight and then packaged to maintain 
sterility for storage at room temperature.
2.12.2.3 Liposome-mediated DNA Transfection
Cationic liposome-mediated transfections were carried out using DOTAP reagent. DOTAP forms 
unilamellar vesicles (liposomes) in aqueous solution after sonicating; these then interact 
spontaneously with negatively charged DNA to form stable complexes. These complexes adhere to 
the cell surface, fuse with the cell membrane and release the DNA into the cytoplasm. 
Transfections using DOTAP were performed and optimised in accordance with the manufacturers 
instructions.
One hour prior to transfection cells were washed three times in PBS and media was replaced with 
firesh serum-free medium (without phenol red). DNA was diluted to O.lpg/pl in Hepes buffer in a 
sterile glass or polystyrene tube. In a separate glass/polystyrene tube the lipofection reagent 
DOTAP (N-[l-{2,3-Dioleoyoxy}propyl]-N,N,N-trimethylammonium methylsulfate, Boehringer 
Mannheim) was added with Hepes buffer. The optimal ratio of DNA to DOTAP for the particular 
cell line was used (see Chapter 4). The solution of DNA was added to the DOTAP in Hepes buffer 
and carefully mixed by pipetting up and down several times. The transfection mixture was 
incubated for 15 minutes. After incubation the mixture was added to serum-free DMEM culture 
medium at a final concentration not exceeding 30pg DOTAP per ml of culture medium. Culture 
medium was aspirated off the cell monolayer and was replaced with the medium containing the 
transfection mixture. The cells were incubated with the transfection mixture for 4-24 hours, 
depending on the cell type. 24 hours post-transfection the cell monolayer was washed once with
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PBS and fresh media (containing DCC treated FBS, phenol red-free) was added. Cell extracts and 
media samples were collected 24-48 hours after transfection.
2,12.2.4 Calcium Phosphate-mediated DNA Transfection into Mammalian Cells 
Method (1)
Essentially this method follows that described by Sambrook, Fritsch and Maniatis in Molecular 
Cloning: A Laboratory Manual, 1989.
One hour prior to transfection cells were washed three times in PBS and fresh media (containing 
DCC-treated FBS, phenol red-free) was put onto the cell monolayer. For each 25cm^ area to be 
transfected: 220pl of DNA (40pg/ml in 0.1 x TE (pH 8.0)) and 250pl of 2 x HBS was added to a 
sterile 5ml plastic tube and 31 pi of 2M CaCb was added dropwise with gentle mixing. The mixture 
was incubated for 20 minutes at room temperature or until a fine precipitate had formed. At the end 
of the incubation the precipitate was resuspended by pipetting the mixture up and down once. 500pl 
of the precipitate was added to 5ml of media (containing DCC-treated FBS, phenol red-free). The 
media on the cell monolayer was aspirated off and replaced with the transfection medium. Cells 
were incubated for 16-24 hours before putting on fresh media (containing DCC-treated FBS, phenol 
red-free). Cell extracts and media samples were collected 48 hours post-transfection.
Method (2)
A calcium phosphate-mediated method of DNA transfection was developed, during the course of 
this work, based on the method described by M. Jordan et al in their paper- “Transfecting 
mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitation 
formation” (1996).
123
One hour prior to transfection, cells were washed once in PBS and fresh media (containing DCC- 
treated FBS, phenol red-free). The reagents for transfection were incubated on ice prior to 
preparation of the precipitate. lOOpl of 2.5M CaClz and the desired amount of plasmid DNA was 
diluted with 1/10 TE buffer to a final volume of 1ml. One volume of this 2 x Ca/DNA solution was 
added to an equal volume of 2 x Hepes solution and the two solutions were immediately mixed 
once by pipetting up and down. The transfection mixture was incubated for 1 minute on ice. lOOpl 
of precipitate was added per ml of medium (containing DCC-treated FBS, phenol red-free) to the 
cell monolayer. The media on the cell monolayer was aspirated off and replaced with the 
transfection medium: 5ml per 25cm^ flask, 2ml per well of a 6-well plate, 400pl per well of 24-well 
plate or 120pl per well of 96-well plate. The cells were incubated with the precipitate for 16-18 
hours before putting on fresh media (containing DCC-treated FBS, phenol red-free). Cell extracts 
and media samples were collected 48 hours post-transfection.
2.12.3 Dosing of Transiently Transfected Cells
Dosing compounds were made up as either x2000 or xlOOO stocks in DMSO. Cells were dosed 
immediately post transfection. Controls were dosed with an equal concentration of DMSO alone.
2.12.4 Measurement of p-galactosidase and Reporter Gene Product Levels
The p-galactosidase activity of cell lysates was initially measured by a colorimetric P-galactosidase 
assay using 2-nitrophenyl-p-D-galactopyraniside as a substrate. Although this assay was simple and 
inexpensive it was not sensitive enough to detect small amounts of enzyme. This assay was subsequently 
replaced with an ELISA method. The p-galactosidase ELISA has the advantage that it specifically 
detects the bacterial enzyme and not the analogous lysosmal p-galactosidase. During the course of this 
project a Packard LumiCount^"  ^ was purchased. This facility allowed p-galactosidase levels to be 
measured using a rapid and sensitive 96-well plate format chemiluminescent assay.
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Determination of CAT levels in cell lysates was performed by an ELISA method. The ELISA 
method had the disadvantage that a relatively large volume of lysate was required for measuring the 
level of the enzyme. To produce the required volume of lysate for the CAT ELISA, transfections 
had to be performed in a minimum well size of a 6-well plate.
During the project it was decided that the secretory alkaline phosphatase (SEAP) reporter gene 
would allow transfection throughput to be increased. The response elements of interest were 
subsequently cloned into SEAP reporter vectors. This meant that transfections could be performed 
in 96-well plates. A 96-well plate format provided enough lysate for chemiluminescent assay of p- 
galactosidase levels and ample media for chemiluminescent SEAP assay.
For each method of measurement of reporter gene products, samples were routinely assayed in 
duplicates or triplicates and relevant standards or positive controls were assayed alongside samples. 
Negative controls, usually mock transfected cell lysate or media, were also assayed to determine 
background signals. Care was taken to stay within the linear range of each assay.
2.12,4.1 Cell Lysate Preparation
Cell lysates were collected for analysis of p-galactosidase and CAT enzyme levels. Culture 
medium was aspirated off and the cell monolayer was washed three times in pre-cooled PBS (4°C). 
The last wash was carefully removed and replaced with lysis buffer: 1ml per 25cm^ flask, 500pl 
lysis buffer per well of a 6-well plate, lOOpl per well of a 24-well plate or 25pl per well of a 96- 
well plate. The cells were incubated with lysis buffer for 30 minutes at room temperature and 
collected in eppendorf tubes or 96-well plates. Cell extracts were frozen on diy ice and stored at - 
70°C.
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2.12.4.2 Collection of media samples
Media samples were collected into 96-well plates and stored at -20°C prior to analysis for secretory 
alkaline phosphatase activity.
2.12.4.3 Colorimetric f-galactosidase Assay
To lOOpl of cell lysate, 700pl of Z Buffer was added in disposable cuvettes. The cuvettes were 
incubated at 37°C for 5 minutes. To each cuvette was added 140pl of 2mg/ml 2-nitrophenyl-p-D- 
galactopyraniside (ONPG, Sigma) in Z Buffer. Cuvettes were incubated for about 4 to 5 hours until 
sufficient yellow colour had developed to measure spectrophotometrically at 420nm. Cuvettes set 
up with cell lysate from cells mock-transfected were used as controls for endogenous p- 
galactosidase production, p-galactosidase activity was calculated using the following equation. 
Equation 2-5.
Equation 2-5 Determination of p-Galactosidase Activity
p-galactosidase activity (unit/pl.hr) = 1000 x (OD420 / pi cytosol x no. of hours in cuvette)
2.12.4.4 P-galactosidase ELISA
The principle of the p-galactosidase ELISA is illustrated in Figure 2-15. The ELISA assay was 
carried out according to the manufacturers instructions. Briefly: 200pl of P-galactosidase standard 
or cell lysate was dispensed into each well of the anti-CAT coated plate. The plate was covered 
and incubated at 37°C for 1 hour. The solution was removed and the plate was washed 3 times with 
250pl washing buffer per well. 200pi of anti-p-gal-DIG was dispensed into each well and 
incubated in the covered plate for 1 hour at 37°C. The plate was washed as before and then 
incubated for a further hour with 200pl anti-DIG-POD. The plate was washed as before and 200pl
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of POD substrate with enhancer was incubated in each well at room temperature. When colour 
development was sufficient for photometric detection, approximately 15-40 minutes, the 
absorbance of the samples was read at 405 nm (reference wavelength 490 nm) using a microtiter 
plate reader.
Figure 2-15. ELISA Principle
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p-gal, p-galactosidase; MTP, microtitre plate; DIG, digoxigenin; POD, peroxidase.
2.12.4.5 Chemiluminescent P-galactosidase Assay
The Galacto-Light Plus™ chemiluminescent p-galactosidase assay has several advantages over the 
ELISA method: it is simple to perform, a large number of samples can be processed at one time, the 
assay can be completed within a couple of hours and it is less expensive. The substrate for the 
assay (Galacton-Plus™) has a half-life of approximately 180 minutes after the addition of Light 
Emission Accelerator-II. With such a long half-life it was possible to use this assay with a manual 
injection plate reader. This assay has a wide dynamic range and is capable of detecting 2fg to 20ng 
p-galactosidase (Jain and Magrath, 1991).
Samples were assayed according to the Galacto-Light Plus™ Kit instructions: sufficient Reaction 
Buffer (Galacton-Plus™ diluted 100-fold with Galacto-Light™ Reaction Buffer Diluent) and Light 
Emission Accelerator for the assay were equilibrated to room temperature. 10-20pl of cell lysate 
was aliquotted into a white 96-well plate and the volume per well was made upto 20pl with lysis 
buffer. 70pl of Reaction Buffer was added per well and mixed. The samples were incubated with
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the Reaction Buffer for 1 hour at room temperature. lOOpl of Light Emission Accelerator was then 
added per well, in the same consistent time frame as the Reaction Buffer had been added. The plate 
was read immediately using a Packard LumiCount™.
2.12.4.6 CATELISA
The principle of the CAT ELISA is the same as for the p-galactosidase assay, see Figure 2-15. The 
CAT sandwich ELISA does not require the use of radioactive material (unlike the CAT TLC assay) 
and allows for a large number of samples to be analyzed within a relatively short period of time. 
Briefly: 200pl of CAT standard or cell lysate was dispensed into each well of the anti-CAT coated 
plate. The plate was covered and incubated at 37°C for 1 hour. The solution was removed and the 
plate was washed 5 times with 250pl washing buffer per well. 200pl of anti-CAT-DIG was 
dispensed into each well and incubated in the covered plate for 1 hour at 37°C. The plate was 
washed as before and then incubated for a further hour with 200pl anti-DIG-POD. The plate was 
washed as before and 200pl of POD substrate (with substrate enhancer if CAT levels low) was 
incubated in each well at room temperature. When colour development was sufficient for 
photometric detection, approximately 10-40 minutes, the absorbance of the samples was read at 
405nm (reference wavelength 490 nm) using a microtiter plate reader.
Modification of CAT ELISA for Chemiluminescence Detection
The sensitivity of an ELISA is often dependent on the detection limit of the colorimetric substrate. 
The dynamic range of a colorimetric assay is restricted to a maximum of two orders of magnitude 
due to the physico-chemical limitations of absorbance measurement (Beer-Lambert Law). It was 
possible with the availability of the LumiCount^^ to use a chemiluminescence detection system. 
Chemiluminescent detection is more sensitive, has a larger dynamic range and produces a more 
rapid and constant signal than the standard colorimetric detection system. The signal (photons) are
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generated in an enzyme-catalysed light emitting reaction (luminescence). Horseradish peroxidase 
(POD, HRP) in the presence of hydrogen peroxide catalyses the oxidation of diacylhydrazides like 
lumino. The reaction product emits light as it decays from the excited to the ground state. The 
light emission is strongly enhanced by the agent 4-iodophenol (a constituent of substrate reagent 
A), which acts as a radical transmitter between the formed oxygen radical and luminol. Reagent B 
contains stabilized hydrogen peroxide. For use with the chemiluminescence detection reagents the 
standard CAT ELISA kit transparent coated microtiter plate had to be replaced with black anti-CAT 
coated microtiter plates. The standard CAT ELISA protocol was followed up to the incubation 
with anti-DIG-POD. The plate was then washed 3 times and lOOpl of BM chemiluminescence 
reagent (100 parts of solution A to 1 part solution B, mixed 15 minutes) was added to each well. 
Samples were read after 3 minutes using the Packard LumiCount™.
2.12.4,7 Chemiluminescent SEAP Assay
For the rapid and sensitive detection of secreted placental alkaline phosphatase in cell lysates, the 
Aurora™ AP Chemiluminescent Reporter Gene Assay Kit was used. Using this system as little as 
lO'^^g of SEAP protein can be detected and the assay is linear over a 10^ -^fold range of enzyme 
concentrations. Levels of SEAP activity have been shown to be directly proportional to changes in 
intracellular concentrations of SEAP mRNA and protein (Berger et a l, 1988; Cullen and Malim, 
1992). SEAP is extremely heat stable and resistant to the inhibitor L-homoarginine (Cullen and 
Malim, 1992). These unusual properties allow endogenous alkaline phosphatase activity to be 
eliminated by pre-treatment of media samples at 65 °C with L-homoarginine.
SEAP detection was carried out in accordance with the manufacturers instructions but the assay 
was scaled down for use with a plate reader instead of a luminometer. Sufficient Assay Buffer, 
Dilution Buffer (diluted 5 x in milliQ water) and Reaction Buffer Diluent for the experiment were 
allowed to equilibrate to room temperature. Reaction buffer was prepared by 20-fold dilution of
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Starlight™ substrate with Reaction Buffer Diluent. 15jil of sample medium was added per well of a 
white 96-well plate. 45pl of 1 x Dilution Buffer was added per well and the plate was mixed. The 
96-well plate was carefully covered with a plastic plate sealer, to prevent sample evaporation 
during incubation. The samples were incubated at 65°C for 40 minutes. Samples were then cooled 
on ice for 3 minutes and equilibrated to room temperature. 60pl of Assay Buffer was added per 
well and incubated for 5 minutes prior to the addition of 60pl Reaction Buffer. Samples were 
measured every 5 minutes after the addition of the Reaction Buffer until the maximum light 
emission was reached, usually between 20 and 60 minutes. The maximum sensitivity of the assay is 
obtained by reading at the point of optimum light emission.
2.12.5 Histochemical Analysis for Transfection Efficiency
48 hours after transfection the cell monolayer was washed once with PBS and 2ml of fixative (2% 
formaldehyde, 0.2% glutaraldehyde in PBS) was added per well of a 6-well plate. The cells were 
incubated for 15 minutes at room temperature. The fixative was aspirated off and the cell 
monolayer was washed three times in PBS. To each culture well was added 1ml of staining 
solution (1 part X-gal solution (in DMSO} to 19 parts Iron Buffer {potassium ferrocyanide and 
potassium ferricyanide in PBS, stabilized}, Boehringer Mannheim (3-Gal Staining Set) and was 
incubated for 0.5-3 hours until cells could be seen to be stained blue under a light microscope 
(without phase contrast). Cell counts of stained versus non-stained cells were made in order to 
determine transfection efficiency.
2.13 Statistical Analyses and Molecular Biology Software
Statistical analysis was carried out using the SuperANOVA Software package (Apple Computer, 
Inc., U.S.A.). Vector NTI (InforMax, Inc., U.S.A.) was used as a database to store sequence data 
and as a tool in the design of cloning stratagies.
130
3. Reporter Plasmid Constructions
3.1 Introduction
The construction of the reporter vectors pGCAT2, p4Al(171/273)seap, p4Alrevseap and plAl(-lA 
1171)seap is fully described in this chapter. pGCAT2 was produced to provide a negative control 
for transfection studies with p4Al(171/273)GCAT (Figure 2-3). pGCAT2 was created by deleting 
the CYP4A1 element 4Al(171/273) from p4Al(171/273)GCAT and so this control vector still 
contains the CAT reporter gene and rabbit p-globin promoter but not the 4Al(171/273) element. In 
reporter gene studies this control vector can therefore be used to prove that a response to a 
xenobiotic is due to the presence of the 4A1(171/273) element.
The reporter vector p4Al(171/273)seap (Figure 3-1) contains the same CYP4A1 element as 
p4A1(171/273)GCAT. p4Al(171/273)seap has an SV40 early promoter upstream of the CYP4A1 
element in place of the rabbit p-globin promoter in p4A1(171/273)GCAT. p4Al(171/273)seap was 
produced to change the reporter gene from one encoding chloramphenicol acetyltransferase (CAT) 
to one encoding secretory alkaline phosphatase (SEAP). The advantages of using the SEAP 
reporter gene over the CAT reporter gene are discussed in Chapter 7. p4Alrevseap only differs 
from p4A1(171/273)seap in that it has has the 4Al(171/273) element inserted in the reverse 
orientation.
plAl(-l/-1171)seap contains the first 1171bp from the promoter of rat CYPlAl upstream of the 
SV40 early promoter linked to the SEAP reporter gene, see Figure 3-2. This vector was 
constructed for use in CYPlAl reporter gene activation studies. The 1A1(-1/-1171) element 
contains four AHREs from the rat CYPlAl promoter (see section 1.3.2.3).
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Figure 3-1. Diagrammatic Representation of p4Al(17I/273)seap Containing 102bp of the 
Promoter From Approximately 4.3Kb Upstream of the CYP4A1 Gene
SEAPSV40 early promoter
PPRE-llke
element PPRE
►102bp
PPRE, peroxisom e proliferator response element; SEAP, secretory alkaline phosphatase gene. 
Refer to section 1.3.2,2 for nucleotide sequence.
Figure 3-2. Diagrammatic Representation of plAl(-l/-1171)seap containing the first I171bp 
of the rat CYPlAl Promoter
-1171
CYPIAljItrorhpter
1 f  f  V
R7# B asic  tran sc rip tio n  e lem e n tM. '
SV40 early 
promoter SEAP
TATA
TATA TATA box
A rom atic  h y d ro ca rb o n  re s p o n s e  e lem e n t
Refer to section 1.3.2.3 for nucleotide sequence.
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3.2 Deletion of CYP4A1 Insert from p4Al(171/273)GCAT to produce 
pGCAT2
3.2.1 Summary o f pGCAT2 Construction
To produce the control reporter vector pGCAT2, the 102bp CYP4A1 promoter fragment was 
deleted from p4Al(171/273)GCAT. Figure 3-3 outlines the strategy employed to perform this 
deletion. The CYP4A1 promoter fragment is flanked by Hindlll and BamHI sites in 
p4Al(171/273)GCAT which allowed simple excision of the fragment by a Hind III/BamHI double 
restriction digest (section 2.6.3). The non-compatible ends produced by Hindlll/BamHI digestion 
were filled-in using Klenow to produce blunt-ends. The vector was re-circularised by blunt-end 
ligation to produce pGCAT2.
3.2.2 Deletion of 4Al(171/273) Element
p4A1(171/273)GCAT was double digested with Hind III and BamHI. The digests were analysed 
by 1% agarose gel electrophoresis, see Figure 3-4. The 6000bp fragments were excised from the 
gel and purified using Wizard™ PCR Preps DNA Purification Kit (section 2.5.8.2). The 
purification products were examined by electrophoresis on a 1% agarose gel, see Figure 3-5.
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Figure 3-3. Cloning Strategy for the Deletion of the CYP4A1 Insert from 
p4Al(171/273)GCAT
Hind III Bam HI
EMBL8+ CYP4A1 I P-giobin* ?  I promoter CAT
G|!---------^c c t a g I
Bam HI /Hind III double digest 
and agarose gel purification 
of large fragment
Fill-in 5 ' overhangs 
using Klenow [%
Blunt-end ligation 
using T4 DNA Ligase
Transform into competent cells
Miniprep plasmid DNA from selected clones 
and analyse by restriction digest and sequencing
EM BL8 +, plasmid vector (Klein-Hitpass e t  a/., 1986); CYP4A1, 4 A l(1 7 1 /2 7 3 ) elem ent from  
CYP4A1 promoter; p-globin promoter, rabbit p-globin promoter; CAT, chloramphenicol 
aeteyltransferase reporter gene.
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Figure 3-4. Results of Double Digest of p4Al(171/273)GCAT with BamHI and Hindlll; 1% 
Agarose Gel Electrophoresis
Ikb
Mkr 1 3 4 5 6
6000bp >
250bp >
< 102bp 4A1 insert 
(faint)
1-6 20pl per lane o f  Bam HI/Hindlll digested p4A l(171/273)G C A T
20pl Uncut p4A l(171/273)G C A T
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Figure 3-5. 1% Agarose Gel Electrophoresis of 6000bp Fragment Purified From
p4Al(171/273)GCAT Digest
High
mass
Ikb Mkr 1 2 3 4 5 6 Mkr
6000bp > 6000bp (120ng)
1-6 5pi per lane of purified 6000bp fragment from double digest of p4Al(171/273)GCAT
High Mass Marker 4pl loading
3.2.3 5 -Protruding Ends Klenow Filling Reaction and Blunt-End Ligation
The fragment ends generated by the double digest with BamHI/Hindlll are not compatible, as 
illustrated in Figure 3-3. In order to re-eirularise the plasmid it was necessary to use Klenow (DNA 
Polymerase I Large Fragment) to fill in the 5'-protruding ends with dNTPs. A Klenow filling 5'- 
protruding ends reaction was performed (section 2.6.4) and 8.5pi of this Klenow reaction was then 
incubated at room temperature for 3 hours with T4 DNA Ligase (section 2.6.5). 2pi of the blunt- 
ended ligation was then transformed into competent cells (section 2.5.3). This transformation did 
not produce any colonies when spread onto selective ampicillin agar plates. It was possible that the 
Klenow Reaction Buffer could possibly have inhibited the blunt-ended ligation reaction. To 
overcome any possible inhibition effects of the Klenow reaction components on the subsequent
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ligation, the Klenow reaction was run on a 1% agarose gel and purified using Wizard™ PCR Preps 
DNA Purification Kit. A second attempt was then made to re-circularise the plasmid, using several 
different reaction conditions. Four blunt-end ligation reaction mixtures (8pl purified Klenow 
reaction, Ipl 10 x Ligase Buffer, Ipl Klenow) were set up and incubated using the following 
conditions:
1. 3 hours at room temperature
2. 16 hours at 4°C
3. 16 hours at 15°C
4. 16 hours at 20°C
3.2.4 Transformation and Analysis of Clones
2pl of each ligation was transformed into competent JM109 cells. Transformations were spread 
onto ampicillin selective agar plates and incubated. Transformation results are shown in Table 3-1.
Table 3-1. Blunt-end Ligation Transformation Results For pGCAT2
Ligation Conditions Transformation Results
1. 3 hours, room temperature no colonies produced
2. 16 hours, 4°C no colonies produced
3. 16 hours, 15°C single colony produced
4. 16 hours, 20°C no colonies produced
5. no DNA control no colonies produced
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The colony produced from transformation number 3 was streaked onto an ampicillin agar plate and 
incubated. 5 colonies were picked and cultured in LB with ampicillin. Plasmid DNA was purified 
from these cultures using Wizard® Plus SV Minipreps DNA Purification System (section 2.5.7.3). 
The plasmid DNA was then analysed by restriction digest and 1.2% agarose gel electrophoresis, to 
see if the CYP4Al(171/273) insert had been successfiilly deleted from p4Al(171/273)GCAT to 
produce pGCAT2. Restriction digest analysis showed that the CYP4A1(171/273) insert had been 
successfully deleted from p4A1(171/273)GCAT, see Figure 3-7. The blunt-end ligation product 
was named pGCAT2 and differs from pGCAT by less than 30bp. The oligonucleotide -40 Primer 
(refer to Table 2-3) was used to sequence across the boundary of the blunt-ended ligation at the 
point where p4A l(l71/273) had been deleted. The sequence, see Appendix (a), confirmed the 
identity of pGCAT.
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Figure 3-6. Restriction Digest Analysis of Blunt-End Ligation Product; 1.2% Agarose Gel
Electrophoresis
1Kb
Mkr la lb 2a 2b 3a 3b
6000bp >
2000bp >
ISOObp >
lOOObp > 
750bp >
*;'v5 «
15pi loading per lane:
la Uneut p4Al(171/273)GCAT: supercoiled, open circle and linear plasmid forms ean be 
seen
lb As expeeted uncut blunt-end ligation product: plasmid has run further than uncut
p4A 1 ( 171/273)GCAT (la) because the insert deletion has resulted in a smaller sized 
plasmid
2a p4Al(171/273)GCAT EcoRI digest
2b blunt-end ligation produet EcoRI digest
3a p4Al(171/273)GCAT BamHI/Hindlll double digest: as expected a band for the plasmid
ean be seen at 6000bp, the 102bp band for the insert is not visible on this gel
3b blunt-end ligation product BamHI/Hindlll double digest: as expeeted the blunt-end ligation
product has not been cut by either BamHI or Hindlll since deletion of the insert has 
removed these restriction sites
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3.3 CYP4A1 Reporter Plasmid Constructions
3.3.1 Summary of p4Al(171/273)seap and p4Alrevseap Construction
Two CYP4A1 SEAP reporter plasmids were constructed, both containing the 4A1 (171/273) 
element (see section 1.3.2.2) from the promoter region of the rat CYP4A1 gene, but inserted in 
opposite orientations. This 102bp element was generated by PCR using p4A1(171/273)GCAT 
(Aldridge et al, 1995) as a template. The PCR generated element was inserted into pCR®2.1- 
TOPO (Figure 2-8) by TOPO TA cloning (section 2.6.9) as illustrated in Figure 3-7. This cloning 
method is not directional and hence the CYP4A1 promoter element was inserted into pCR®2.1- 
TOPO in either orientation. The site at which PCR generated fragments are inserted into pCR®2.1- 
TOPO is flanked by a large number of unique restriction sites, which facilitated subcloning into the 
reporter construct pSEAP2-Promoter (Figure 2-9). The 4Al(171/273) elements were isolated from 
the TOPO cloning vector by Kpnl and Xhol double restriction digest. pSEAP2-Promoter was 
prepared for ligation with the 4Al(171/273) inserts by Kpnl and Xhol double restriction digests. 
The vector and inserts were ligated to produce p4Al(171/273)seap and p4Alrevseap as illustrated 
in Figure 3-8.
3.3.2 Generation of 4Al(171/273) Element By PCR
PCR reactions for the generation of the 4Al(171/273) element were set up as described (section 
2.6.8) alongside negative controls. Negative controls were set up in parallel with the PCR reaction 
tubes using the same reaction mixture but replacing template with nuclease-free water. 
p4Al(171/273)GCAT was used as a template and reactions carried out with an annealing 
temperature of 41°C. Oligonucleotide primers 4A1.171 and 4A1.273 (Table 2-3) were used for the 
PCR reactions and controls. PCR products and negative controls were examined by 2% agarose gel 
electrophoresis (Figure 3-9).
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Figure 3-7. TOPO TA Cloning of CYP4Al(171/273) Element
c = iO ’
EMBL8+ CYP4A1 P-globinpromoter CAT
p4A1(171/273)GCAT tem pla te
<53CE5S3
Generate 4Al(171/273) element by PCR
4Al(171/273) Element A
TOPO TA
Cloning
H in d lll S acl Spel EcoRI 
K pnl Bam H I B stX l
 ...... .....J_________ J_. J ___L
Amp’^
Insert PCR generated element into 
pCR ® 2.1-T 0P0 multiple cloning site
E coR I BstX I X h o l A pal 
E coR V  N otl N s il  X bal
L _ J  î L J  U _ 1
pCR ©2.1-TOPO
Transform into competent cells
Blue/white colour screening on kanamycin selective plates
Analyse transformants by EcoRI restriction digest 
to determine presence/absence and size of insert. 
Sequence to determine orientation of insert.
Subclone insert into pSEAP2-Promoter
EM BL8 +, plasmid vector (Klein-Hitpass e t  a l ,  1986); CYP4A1, 4 A l(1 7 1 /2 7 3 ) elem ent from  
CYP4A1 promoter; (3-globin promoter, rabbit |3-globin promoter; CAT, chloramphenicol 
aeteyltransferase reporter gene; Amp% ampicillin resistance gene; Kan^ kanamycin resistance gene.
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Figure 3-8. Sub-cloning CYP4Al(171/273) fragment into pSEAP2-Promoter in Both the 
Sense and Anti-sense Orientation
H indlll Sacl Spel EcoRI 
Kpnl BamHI BstX l
I I I I I I
EcoRI BstXI X hol Apal 
EcoR V  N otl N s il X bal
. .  L  J .  ..L. !.. j.. L .I..
Amp^ T 4A1(171/273) X
pCR®2.l-T0P04A1 (171/273) I 
pC R®2.1-T0P04A1 rev
KpnI/XhoI double digest 
and gel purify fragment
S a d  Spel EcoRI 
BamHI BstXI
EcoRI BstXI 
EcoR V  N otl
T '4 A 1  
(171/273) X
Kaif
Ligate with gel purified fragment o f  
KpnI/XhoI digested pSEAP2-Promoter 
and transform into competent cells
S a d  Spel EcoRI 
BamHI BstXI
EcoRI BstXI 
EcoR V  N otl
Amp' T 4A1(171/273) X ÏSV401 SEAP
X hol B g lll
p4A1(171/273)seap I 
p4A1 revseap
Analyse by restriction digest. 
Confirm identity by sequencing.
EM BL 8 +, plasmid vector (Klein-Hitpass e t  a L ,  1986); CYP4A1, 4A1 (171/273) elem ent from  
CYP4A1 promoter; P-globin promoter, rabbit p-globin promoter; CAT, chloramphenicol 
aeteyltransferase reporter gene; A m p\ ampicillin resistance gene; Kan% kanamycin resistance gene.
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Figure 3-9. Visualization of PCR Generated 4Al(171/273) Element on a 2% Agarose Gel
100 bp
Ladder P C R l PCR2 control 1 control 2
< template
800bp >
100bp> < 102 bp element
< primer dimers
lOpl loading per lane:
PCR 1 a clear discrete band can be seen, corresponding to a specific PCR product of
approximately lOObp, a weak band can be seen at the top of the gel corresponding 
to the plasmid template p4Al(171/273)GCAT, primer dimers are also visible at the 
bottom of the gel
PCR 2 as for PCR 1 ,a replicate PCR product
control 1 no band corresponding to template (not added to reaction mix), primer dimers are
visible, no PCR product indicating PCR reactions were not contaminated
control 2 as for control 1, no contamination of PCR reaction
3.3.3 TOPO TA Cloning of PCR Generated 4Al(171/273) Element
1 pi of fresh PCR product was used in a TOPO Cloning™ reaction (section 2.6.9) and 2pl of this 
reaction was used to transform competent TOPI OF' cells. Transformants were blue/white colour 
screened on kanamycin selective plates (section 2.5.3). Kanamycin agar plates were used because 
only transformants containing the TOPO vector would grow and not transformants containing the 
template vector. The template vector, p4A 1(171 /273)GCAT, does not contain a kanamycin 
resistance gene. 50pl of transformation reaction produced approximately 200 white colonies and 
200 blue colonies. It was expected that 95% of colonies produced from the TOPO transformation
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would be white and that 90% of these would contain insert. Only about 50% of the colonies 
produced from this transformation were white. This was probably because the insert was small in 
size (<500bp) and therefore did not necessarily disrupt the reading frame of the lacZ gene. 10 
white and 10 light blue colonies were picked and cultured in LB with ampicllin. Wizard® Plus SV 
Minipreps DNA Purification System was used to prepare plasmid DNA from these mini-cultures. 
Plasmid DNA was digested with EcoRI and analysed by 2% agarose gel electrophoresis in order to 
determine whether the insert had been successfully cloned into pCR®2.1-T0P0. Successful 
incoiporation of the insert into pCR®2.1-T0P0 was indicated by a two band fragment pattern of 
sizes 3908bp and 120bp in all 20 clones. Due to the small size of the insert it was not possible to 
determine the orientation of the insert in pCR®2.1-TOPO by restriction digest analysis. Plasmid 
DNA samples originating from each of 3 white and 3 light blue colonies were sequenced using 
pUC/M13 Reverse and pUC/M13 Forward (-40) primers. The sequencing results revealed that the 
plasmid DNA originating from the light blue colonies contained the insert in the sense orientation 
and that the plasmid DNA originating from the white colonies contained the insert in the anti-sense 
orientation. The sequences obtained from these clones are not given here as the insert was 
sequenced after sub-cloning into the pSEAP2-Promoter vector and these sequences are shown in 
Appendix I(b-e). The vector containing anti-sense insert was named pCR®2.1-T0P04A1 rev and 
the vector containing sense insert was named pCR®2.1-TOP04Al(171/273).
3.3.4 Sub-Cloning of 4Al(171/273) Fragments into pSEAF2-Promoter
To insert the 4A1 (171/273) fragment into the reporter vector pSEAP2-Promoter, in both the sense 
and anti-sense orientations, the strategy outlined in Figure 3-8 was employed. The sense and anti­
sense inserts were isolated from pCR®2.1-T0P04A1(171/273) and pCR®2.1-T0P04Alrev by 
Kpnl and Xhol double restriction digest and agarose gel purification (Figure 3-10).
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Figure 3-10. Isolation of 4Al(171/273) Fragment from pCR®2.1-T0P04Al(171/273) by 
Kpnl and Xhol Double Digest; 1.5% Agarose Gel Electrophoresis
Ikb Mkr 1 2
4000bp >
1 0 0 0 bp>
250bp >
< 3819bp plasmid fragment
< 195bp fragment containing 
4Al(171/273) insert
15pl loading per lane:
1 and 2 Kpnl and Xhol double digested pCR®2.1-T0P04Al(171/273): 2 fragments
produced of 2819bp and 195bp as expected
Kpnl and Xhol double digested pCR®2.1-T0P04Al(171/273) is shown in Figure 3-10. The 
vector pSEAP2-Promoter, into which the 4A1 (171/273) digest fragments were to be inserted, was 
prepared for ligation by Kpnl and Xhol double restriction digest. Kpnl and Xhol digest of 
pSEAP2-Promoter produces a large vector fragment of 4843bp and a very small fragment of 27bp 
which cannot be seen on agarose gel analysis, see Figure 3-11. The large vector fragment was 
purified from the agarose gel.
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Figure 3-11. Results of Double Digest of pSEAP2-Promoter with Kpnl and Xhol, 0.9% 
Agarose Gel Electrophoresis
1Kb
6000bp > 
3000bp >
lOOObp >
250bp >
-
t r i i r  I
<4900bp approx.
1 Uncut pSEAP2-Promoter (4870bp), supercoiled plasmid DNA runs further down the gel 
that equivalent sized linear marker fragment
2 pSEAP2-Promoter digested with Kpnl produces band of size 4900bp approx. indicating 
enzyme is active
3 pSEAP2-Promoter digested with Xhol produces band of size 4900bp approx. indicating 
enzyme is active
4 pSEAP2-Promoter double digested with Kpnl and Xhol produces a band of approx. size 
4900bp approx., as both enzymes appear to be cutting (2 and 3) the double digest should 
have worked
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The sense and anti-sense 4A1(171/273) fragments with 5' Kpnl and 3' Xhol ends were 
directionally cloned into the KpnI/XhoI digested pSEAP2-Promoter by ligation reactions set up 
using a variety of conditions (Table 3-2). The ligations were transformed into competent TOPI OF' 
cells and transformants selected on ampicillin agar plates. Table 3-2 shows the results of these 
transformations. A greater number of colonies were produced using insert DNA that had been 
purified from agarose using the QIAquick Gel Extraction Kit procedure than with Wizard^^ PCR 
Preps DNA Purification System. This is probably because the QIAquick procedure produces higher 
quality DNA that is free of contaminants that can inhibit ligation reactions.
12 colonies were picked from plates containing cells that had been tranformed with pSEAP2- 
Promoter/sense 4A1 (171/273) ligation reaction. 12 colonies were also picked from plates 
containing cells that had been tranformed with pSEAP2-Promoter/anti-sense 4Al(171/273) ligation 
reaction. These colonies were cultured in LB with ampicillin and used to prepare plasmid DNA by 
Wizard® Plus SV Minipreps DNA Purification System. Digestion of miniprep plasmid DNA with 
EcoRI would produce 3 bands where the insert was present and only one band where the insert was 
absent. EcoRI digestion of these minipreps showed that the inserts had been successfully ligated 
into pSEAP2-Promoter to produce p4Al(171/273)seap and p4Alrevseap, see Figure 3-12. One 
p4Al(171/273)seap and one p4Alrevseap miniprep was selected from each set of 12 minipreps and 
sequenced across the insert using oligonucleotides 4A1.171 and 4A1.273 as primers. The 
nucleotide sequences are given in Appendix I(b-e) and confirm the identity of p4Al(171/273)seap 
and p4Alrevseap.
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Table 3-2. 4Al(171/273) and pSEAP2-Promoter Ligations: Transformation Results
Ligation Reaction
Digested
pSEAP2-
Promoter
4Al(171/273)
Insert
Vector: Insert 
Ratio
Reaction
Temperature
Reaction
Time
Transformatio 
n Results
Wizard anti-sense
Qiagen
1:1 22°C 3 hours approx. 600 
colonies
Wizard anti-sense
Wizard
1:1 22°C 3 hours 3 colonies
Wizard anti-sense
Qiagen
1:3 22°C 3 hours approx. 400 
colonies
no DNA control 22°C 3 hours 0 colonies
Wizard anti-sense
Qiagen
1:1 4°C 16 hours approx. 400 
colonies
Wizard anti-sense
Wizard
1:1 4°C 16 hours 18 colonies
Wizard anti-sense
Qiagen
1:3 4°C 16 hours approx. 800 
colonies
no DNA control 4°C 16 hours 0 colonies
Wizard sense 1:1 4°C 16 hours 13 colonies
Wizard sense 1:2 4°C 16 hours 25 colonies
Wizard sense 1:3 4°C 16 hours 34 colonies
no DNA control 4°C 16 hours 0 colonies
Qiagen; Fragment purified using QIAquick Gel Extraction Kit; Wizard; Fragment purified using 
Wizard"*^  ^PCR Preps DNA Purification System.
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Figure 3-12. EcoRI Digest of p4Al(17I/273)seap and p4Alrevseap; 2% Agarose Gel 
Electrophoresis
lOObp
ladder la lb le 2a 2b 2c
300bp > 
200bp >
lOObp >
tir
< 4653bp
additional band (probably 
undigested supercoiled DNA - 
result o f prolonged lysis during 
lysate production)
< 260 bp
< 119bp (very faint, can be 
seen on original)
1 a-c EcoRI digest of p4A1(171/273)seap produced three bands confirming presence of insert
2a-c EcoRI digest p4Al revseap produced three bands confirming presence of insert
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3.4 CYPlAl Reporter Plasmid Construction
3.4.1 Summary of plA l(-l/-1171)seap Construction
A CYPlAl SEAP reporter plasmid was constructed containing a 1171bp element (-1 to -1171) 
from the promoter region of rat CYPlAl. This 1171 bp element was generated by PCR using 
pMClcat (Figure 2-5) as a template. This PCR generated element was inserted into pCR®2.1- 
TOPO by TOPO TA cloning in the same manner as for the CYP4A1 SEAP constructs (section 3.3), 
as shown in Figure 3-13. Figure 3-14 illustrates how the PCR insert was isolated by Spel and Xhol 
double restriction digest and subsequently sub-cloned into pSEAP2-Promoter. pSEAP2-Promoter 
was prepared for ligation by double restriction digest with Nhel and Xhol. The Nhel restriction site 
was used because pSEAP2-Promoter does not have a Spel site in the MCS, but Nhel and Spel 
produce compatible ends. The Spel/Xhol CYPlAl fragment was ligated with Nhel/Xhol digested 
pSEAP2-Promoter to produce p lA l(-l/-l 171)seap.
3.4.2 Generation of 1A1(-1/-1171) Element By PCR
Initially, PCR reactions were set up to tiy to generate the following CYPlAl elements: 1A1(-1/- 
3200), 1A1(-1/-1171), lAl(-1171/-3200) and lAl(-1171/+2545). To produce these CYPlAl 
elements, the following primer pairs were used: lAl-1 and lAl-3200, lAl-1 and lAl-1171, lA l- 
1171 and lAl-3200, lAl-1171 and lAl+2545 (see Table 2-3 for oligonucleotides). PCRs were 
carried out as described previously (section 2.6.8), using pMClcat as a template, with the following 
modifications to the general method. The dénaturation step was reduced to 30 seconds, the 
annealing temperature was set to 47°C, the extension step time was increased to 3 minutes and the 
final extension step was lengthened to 30 min. The extension times were increased due to the large 
size of the PCR products. These PCR reactions produced unsatisfactory results, with multiple 
banding and smearing evident when analysed by agarose gel electrophoresis. For each of the four
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CYPlAl elements a second set of PCR reactions were set up and this time the annealing 
temperature was increased to 52°C. Using a higher annealing temperature helps to minimise non­
specific primer annealing, increasing the amount of specific product produced and reduces primer- 
dimer formation. A range of magnesium chloride concentrations were tried with each set of 
primers, namely 2mM, 3mM, 4mM, 5mM and 6mM. The most satisfactory PCR products produced 
were for the 1A1(-1/-1171) and the lAl(-1171/+2545) elements. The 1A1(-1/-1171) element was 
chosen for use in a CYPlAl SEAP reporter construct because it is a reasonable size for efficient 
cloning processes and more importantly it contains the majority of the Aromatic Hydrocarbon 
Receptor response elements that are found in the rat CYPlAl promoter (see section 1.3.2.3). 
Figure 3-15 shows agarose gel electrophoresis of the 1A1(-1/-1171) PCR products on a 1% gel. 
Lane 1 of Figure 3-15 shows that using the stated PCR reaction conditions with a MgCE 
concentration of 2mM produces a single discrete band of the anticipated size.
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Figure 3-13. TOPO TA Cloning of CYP1A1(-I/-1171) Element
1171 
c>
-3200 rat C Y PlA l +2545 CAT
pM C lcat
Generate 1A1(-1/-1171) element by PCR
lAl Element
TOPO TA 
Cloning
Hindlll Sacl Spel EcoRI 
Kpnl BamHI BstXI
_ J  L _ 1 _______ 1___ l
Insert PCR generated element into 
pCR ©2.1-TOPO multiple cloning site
EcoRI BstXI Xhol Apal 
EcoRV Notl Nsil Xbal
Amp^
pCR ©2.1-TOPO
Transform into competent cells
Blue/white colour screening on kanamycin selective plates
Analyse transformants by BamHI restriction digest 
to determine presence/absence, size and orientation of insert. 
Sequence to confirm identity.
Subclone insert into pSEAP2-Promoter
CAT, chloramphenicol acetyltransferase reporter gene; Amp% ampicillin resistance gene; Kafr, 
kanamycin resistance gene.
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Figure 3-14. Sub-cloning CYP1A1(-1/-1171) insert from pCR®2.1-T0P01Al(-l/-1171) into 
pSEAP2-Promoter
Hindlll Sacl Spel EcoRI 
Kpnl BamHI BstXI
_ L _ i . .... 1..... 1,__ U _ L _
EcoRI BstXI Xhol Apal 
EcoRV N otl N sil Xbal
J _ J  I L _ 1 _ L
-Kan'Amp' ^  I A i Element ^  |  A T
Spel and Xhol double digest 
and gel purify fragment
spel EcoRI 
BstXI
EcoRI BstXI Xhol 
EcoRV Notl
 I I L
Ligate with purified fragment of 
Nhel/XhoI digested pSEAP2-Promoter 
and transform into competent cells
M lul EcoRl 
K pnl BstXI
-i L
EcoRl BstXI Xhol 
EcoRV Notl
Amp» 1A1 Element  ^^  * 
A X
Nhel/Spel
p1A1(-1/-1171)seap
Xhol B glll
Analyse by restriction digest. 
Confirm identity by sequencing.
Amp% ampicillin resistance gene; Kafr, kanamycin resistance gene; TB, transcription blocker; ?sv4o, 
SV40 promoter; SEAP, secretory alkaline phosphatase reporter gene.
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Figure 3-15. Optimization of Magesium Chloride Concentration for PCR Generation of 
1A1(-1/-1171) Element
SOOObp > 
2500bp > 
2 0 0 0 bp >
1500bp > 
lOOObp>
<  template
< 2500bp
< 1171bp 
PCR product
lOpl loading per lane:
1-5 1171 bp desired PCR products from PCR reactions set up using stated [MgCb]
6 negative control PCR: no contamination
3.4.3 TOPO TA Cloning of PCR Generated 1A1(-1/-1171) Element
Ipl of fresh PCR product was used in a TOPO Cloning™ Reaction (section 2.6.9) and 2pi of this 
reaction was used to transform competent TOP 10 cells. Transformants were blue/white colour 
screened on kanamyein seleetive plates. Kanamycin agar plates were used to select pCR®2.1- 
TOPO transformants only and not template transformed cells as pMClcat has only an ampicillin
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resistance gene. 150|xl of transformation reaction produced approximately 300 white colonies and 
7 blue colonies. 6 white colonies were picked and cultured in LB with ampicllin. Wizard® Plus 
SV Minipreps DNA Purification System was used to prepare plasmid DNA from these mini­
cultures. Plasmid DNA was digested with BamHI and analysed by 2% agarose gel electrophoresis 
in order to determine whether the insert had been successfully cloned into pCR®2.1-T0P0. 
Successful incorporation of the insert into pCR®2.1-T0P0 in the sense direction was indicated by 
a two band fragment pattern of sizes 4713bp and 366bp by analysis on a agarose gel. BamHI 
digestion of pCR®T0P02.1 containing anti-sense 1A1(-1/-1171) also produces two bands on an 
agarose gel but these fragments correspond to sizes of 4192bp and 887bp. Figure 3-16 shows 
agarose gel electrophoresis of BamHI digested plasmid DNA preparations from 6 clones. Plasmid 
DNA samples corresponding to the samples in lanes 3 and 5 of Figure 3-16 were sequenced using 
pUC/M13 Reverse and pUC/M13 Forward (-40) primers. Sequencing confirmed the results of the 
BamHI digests; one clone contains 1A1(-1/-1171) in the sense orientation and one clone contains 
insert in the anti-sense orientation in pCR®2.1-TOPO. Sequence results are not given here because 
the insert was sequenced in pSEAP2-Promoter as well and this sequence is given in Appendix I. 
The clone containing sense 1A1(-1/-1171) insert in pCR®2.1-TOPO was named pCR®2.1- 
T0P01A1(-1/-1171).
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Figure 3-16. Results of BamHI Digests of 1AI(-1/-1171) TOPO TA Clones, 0.9% Agarose Gel
Electrophoresis
Mkr 1
< 887bp
< 366bp
10000 bp 
8000 bp,
6000 bp.
5000 4713 bp
Z>  4192 bp
2500 bp 
2000 bp 
1500 bp 
1 0 0 0  bp 
750 bp >
500 bp >
250 bp >
15pl loading per lane:
1 and 2 Unexpected banding pattern produced on BamHI digested, unsuccessful cloning
3 and 4 Expected fragments of size 4713bp and 366bp, 1A1(-1/-1171) insert in sense
orientation in pCR®2.1-TOPO
5 and 6 Expected fragments of size 4192bp and 887bp, 1A1(-1/-1171) insert in sense
orientation in pCR®2.1-TOPO
3.4.4 Sub-Cloning of IA1(-1/-1171) Fragment Into pSEAP2-Promoter
The strategy for sub-cloning the 1A1(-1/-1171) element from pCR®2.1-T0P01Al(-l/-1171) into 
pSEAP2-Promoter is illustrated in Figure 3-14. 1A1(-1/-1171) was isolated from pCR®2.1-
T0P01A1(-1/-1171) by a double digest with Spel and Xhol. The digested DNA fragments were 
separated on a 1.5% agarose gel, see Figure 3-17, and the insert fragment was purified using 
Wizard™ PGR Preps DNA Purification System, pSEAP2-Promoter was prepared for ligation with 
the 1246bp fragment (refer to Figure 3-17) by a Nhel and Xhol double digest, see Figure 3-18.
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Figure 3-17. Spel and Xhol Double Digest of pCR®2.1-T0P01Al(-l/-1171), 1.5% Agarose 
Gel Electrophoresis
Ikb
Mkr
4000 bp-s
3000 b p -
1500bp >
1 0 0 0 bp>
B 9
1
< 3833bp
<1246bp
1 and 2 Spel/Xhol digested pCR®2.1-T0P01Al(-l/-l 171) produces expected fragments
of size 3833bp and 1246bp, the smaller fragment containing the 1A1(-1/-1171) 
element
Figure 3-18. Nhel and Xhol Double Digest of pSEAP2-Promoter, 1% Agarose Gel 
Electrophoresis
4859bp > 
3000 bp
Mkr 1 2 3
< 4870bp
m ■
m 1
Nhel/Xhol double digest of pSEAP2-Promoter, 4859bp fragment and 1 Ibp fragment (too 
small to visualize by 1% agarose gel electrophoresis)
Xhol digest of pSEAP2-Promoter, linearised plasmid 4870bp
Nhel digest of pSEAP2-Promoter, linearised plasmid 4870bp
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The purified Spel/Xhol 1A1(-1/-1171) fragment was ligated with the Nhel/Xhol prepared pSEAP2- 
Promoter using vector:insert ratios of 1:1 and 1:3. These ligations were carried out at 4°C for 16 
hours and were used to transform competent cells. Transformants were selected on ampicillin agar 
plates. The 1:1 vector:insert ratio produced approximately 200 colonies and the 1:3 ratio produced 
approximately 100 colonies. 5 clones were picked and cultured in ampicillin LB. Wizard® Plus 
SV Minipreps DNA Purification System was used to prepare plasmid DNA from these mini­
cultures. pCR®2.1-T0P0 has two BamHI sites at 481 and 2056; the 1A1(-1/-1171) insert has one 
BamHI site at -847. Therefore, BamHI digestion of the plasmid DNA isolated from the clones was 
expected to produce a 3 band fragment pattern, with fragments of sizes: 3199bp, 1575bp and 
1332bp. Successful ligation of the 1A1(-1/-1171) fragment with pSEAP2-Promoter to produce 
plAl(-l/-1171)seap was confirmed by BamHI restriction digest analysis, see Figure 3-19. The 
integrity of the 1A1(-1/-1171) nucleotide sequence in plAl(-l/-1171)seap was checked by 
sequencing across the insert using the following oligonucleotides as primers: lAl-1, lAl-530, 
lAl-820 and lA l-1171. The nucleotide sequence results are given in Appendix I(f-i).
Figure 3-19. BamHI Digest of plAl(-l/-lI71)seap, 1% Agarose Gel Electrophoresis
Mkr 1
4000 bp :
500 bp 
1000 bp
1500 b p   M  ' d i S I < 1332 bp
1-5 BamHI digests of clones 1-5 produced 3 fragments of sizes 3199bp, 1575bp and 1332bp, 
confirming that the 1A1(-1/-1171) fragment had been inserted into pSEAP2-Promoter
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3.5 Conclusions
The successful construction of reporter vectors pGCAT2, p4Al(171/273)seap, p4Alrevseap and 
plAl(-l/-1171)seap has been described and verified by both restriction digest analysis and 
nucleotide sequence analysis. The cloning strategies used to produce p4Al(171/273)seap and 
plAl(-l/-1171)seap employ TOPO TA Cloning® (Invitrogen). TOPO TA Cloning® is very rapid 
and efficient. Using such a system it is possible to isolate virtually any element of interest from a 
cytochrome p450 gene promoter for sub-cloning into a reporter vector.
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4. Development and Optimisation of CYP4A1- and CYPIAI- 
Dependent Reporter Gene Assays
4.1 Introduction
The transcriptional activity of cloned DNA sequences can be examined by the introduction of such 
sequences into appropriate cells, using a procedure known as ‘transfection.' DNA can be 
transfected into mammalian cells by a variety of means that either enhance DNA interactions with 
the cell surface, and hence augment DNA uptake by endocytosis, or by the electrical induction of 
pores in the cell membrane by electroporation, through which the DNA can enter passively (Alam 
and Cook, 1990).
Calcium phosphate-, DEAE-dextran- and lipofection-mediated transfection are all methods which 
enhance DNA interactions with the cell surface (Lopata et a l, 1984; Sambrook et a l, 1989; Alam 
and Cook, 1990; Feigner et al, 1994). The choice of transfection method is largely determined by 
cell type and whether the DNA is to be introduced transiently or stably (Sambrook et a l, 1989; 
Alam and Cook, 1990; Beckler et a l, 1996). Expression of transfected DNA does not require 
integration of the DNA into cellular chromatin which is a low frequency event occurring between 
0.001% and 1% to form stable transformants. Expression can be detected as soon as 12 hours after 
transfection and as late as 72 hours after transfection. In transient transfection the expression 
products have to be assayed during this time interval. The trans-genes are gradually lost after about 
72 hours. Clones that have taken up the transfected DNA stably can be selected with the 
introduction, for example, of a neomycin resistance gene which may be inserted into the transfected 
plasmid DNA or co-transfected as a separate plasmid. Stably transformed cell lines have the 
advantage that experimental work can be carried out on them without the need to transfect the DNA 
each time which improves reliability and reproducibility. The DNA is also in a ‘natural’ DNA
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environment and the cells have not been exposed to transfection procedures which can lower their 
viability, although the site of chromosomal integration and the copy number of the stably 
incorporated DNA may affect transcription (Sambrook et a l, 1989; Alam and Cook, 1990).
The study of the transcriptional activity of cloned DNA sequences has been greatly simplified by 
the development of reporter gene vectors. Reporter genes code for proteins that have characteristic 
enzymatic activity or can be easily distinguished from cellular proteins (Alam and Cook, 1990; 
Wood, 1995). Reporter genes are most frequently used in the analysis of cw-acting transcriptional 
elements. For this type of study the promoter sequence of interest is cloned upstream of the 
reporter gene. The resultant reporter gene vector is then transfected, possibly along with a control 
vector and/or /mw-acting factor expression vector/s, into an appropriate cell line (Alam and Cook, 
1990; Beckler et al, 1996). The transfected cells can be treated or dosed with potential regulators 
for 24-72 hours and then analysed for reporter gene expression (Alam and Cook, 1990; Wood,
1995). Reporter genes are also used to examine receptor function, intracellular signal transduction, 
transcription factors, RNA processing, translation and protein folding (Wood, 1995; Beckler et a l,
1996). The pharmaceutical industry has used reporter genes for use in rapid screens, to search for 
new molecules that may serve as agonists or antagonists for receptor function. Gene therapy and 
targeted genetic suppression, using antisense RNA or ribozymes, also employ reporter gene 
technology (Wood, 1995).
Chloramphenicol acetyltransferase (CAT) was the first gene to be used in reporter gene studies 
(Gorman et a l, 1982). Traditional assays for CAT require metabolite extraction procedures and 
thin-layer chromatography followed by radioisotopic detection, and were therefore limited in their 
sensitivity and usefulness (Bronstein ef al, 1994a). CAT levels can now be measured simply and 
with greater sensitivity by ELISA (see section 2.12.4.6). Reporter genes have been incorporated 
into a range of commercially available reporter gene vectors. The utility of these reporter vectors is 
determined by the properties of the reporter gene and the number and position of unique restriction
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sites within the vector (Alam and Cook, 1990). The effectiveness and sensitivity of a reporter gene 
depends on several factors including the level of expression in a cell, the stability of the expressed 
protein and the sensitivity of detection of the expressed protein (Bronstein et a l, 1994b). The 
available repertoire of reporter genes has expanded considerably in recent years and include genes 
encoding for luciferase, p-galactosidase, secretory alkaline phosphatase, human growth hormone 
and green fluorescent protein (GFP) (Yoon et a l, 1988; Alam and Cook, 1990; Bronstein et a l, 
1994a; Bronstein et a l, 1994b; Wood et a l, 1995). The choice of reporter gene is dependent on the 
application and the sensitivity required. For example, luciferase and GFP can be measured in living 
cells (Wood, 1995), secretory alkaline phosphatase and human growth hormone can be measured in 
media samples (Alam and Cook, 1990; Bronstein et a l, 1994a), and (3-galactosidase can be 
detected by histochemical staining (Alam and Cook, 1990). Currently, chemiluminescent and 
bioluminescent assays for reporter gene products are widely used, due to their great sensitivity and 
high-throughput capacity (Bronstein et a l, 1994b).
The optimisation of reporter gene assays for the detection of xenobiotics (inducers) that can 
mediate transcriptional activation of CYP4A1 and rat CYPlAl promoter elements is described in 
this chapter. Included in this section is the choice of cell line, the optimisation of transfection 
efficiency in the chosen cell line, the characterisation of this cell line for suitability for rat CYP4A1 
and rat CYPlAl reporter gene assays and development of the system for high-throughput screening. 
Refer to Figure 2-14 for a general scheme of the reporter gene assays developed in this project.
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4.2 Choice of Cell Line
Four cell lines were immediately available to me for use in the development of the CYP4A1 and 
CYPlAl reporter gene assays, these included the HepG2 human hepatoma cell line (Figure 4-2), 
the H4IIEC3 rat Reuber hepatoma cell line (Figure 4-lc), the Hepalclc? mouse hepatoma cell line 
(Figure 4-la) and the CHO Chinese hamster ovary cell line (Figure 4-Id). As described in sections
1.3.2.2 and 1.3.2.3, the response elements of interest for CYP4A1 and CYPlAl had been isolated 
from rat genes and it was initially hoped that the rat H4IIEC3 hepatoma cell line would be suitable 
for use in transient transfections. Transfection efficiencies obtained using H4IIEC3 cells were not 
high enough for use in sensitive reporter gene assays, see Table 4-1 and Table 4-2. Using a fully 
optimised liposome-mediated transfection procedure for the Hepalclc? mouse hepatoma cell line 
(optimised by Joanna Owens, University of Surrey), a transfection efficiency of 5-10% was 
obtained, as determined by histochemical staining for p-galactosidase, described in section 2.12.5 
(Figure 4-lb). The method for transfecting Hepalclc? cells using the liposome reagent DOTAP is 
outlined in 2.12.2.3. For optimal transfection efficiency in Hepalclc? cells a DNAiDOTAP ratio 
of Ipgillpg  was used and the DNA/DOTAP transfection mixture was incubated on the cells for 4 
hours. Table 4-1 and Table 4-2 show that CHO cells were unsuitable for use in reporter gene 
studies due to low transfection efficiency.
The human hepatoma cell line, HepG2, transfected with the highest efficiency of the 4 cell lines 
examined. HepG2s transfected with an efficiency of approximately 10% (Table 4-2), as determined 
by histochemical staining for p-galactosidase (Figure 4-2d), using a calcium phosphate-DNA co­
precipitate method (2.12.2.4, method 1). HepG2 cells were chosen for use in subsequent reporter 
gene studies because (a) they transfected with higher efficiency than Hepalclc?, H4IIEC3 and 
CHO cells, (b) they transfected using a calcium phosphate-DNA co-precipitation method which is 
inexpensive and straightforward to perform, and (c) the calcium phosphate-DNA co-precipitation
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method was more adaptable than the liposome mediated method, required for Hepalclc? 
transfection, for development of a high-throughput system.
Figure 4-1. Hepalclc?, H4HEC3 and CHO Cells.
“•Îsesa-îÿ'i'.
(a) Low density mouse Hepalclc? cells viewed in culture, x 200 magnification, (b) Confluent 
mouse Hepalclc? cells, fixed and stained for p-galactosidase. Cells expressing P-galactosidase are 
stained blue, x 50 magnification, (c) Nearly confluent rat H4IIEC3 cells viewed in culture, x 200 
magnification, (d) Confluent Chinese hamster CHO cells viewed in culture, x 200 magnification.
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Figure 4-2. HepG2 Cells.
M
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(a) Human HepG2 cells viewed in culture, showing characteristic growth pattern. Under normal 
growth conditions HepG2 cells grow in colony-like formations, growing in layers over each other. 
HepG2 cells show a preference for growing in ‘clumps’ and not in a continuous monolayer. 
Although some cells within the population do favour a monolayer formation. If the HepG2 cells 
are passaged for several months this ‘clumping’ growth pattern is lost and the cells grow in the 
more familiar monolayer fashion, x 200 magnification, (b) HepG2 cells grown on a poly-D-lysine 
coated plate, viewed in culture. The cells pictured in (b) do not resemble those shown in (a), the 
HepG2 cells form a uniform monolayer when grown on poly-D-lysine coated plates, and lose their 
characteristic ‘clumping’ growth pattern, x 200 magnification, (c) HepG2 cells grown on poly-D- 
lysine coated plates, coated with calcium phosphate-DNA co-precipitate, viewed in culture, x 200 
magnification, (d) HepG2 cells fixed and stained for p-galactosidase, cells expressing p- 
galactosidase are stained blue, x 200 magnification.
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Table 4-1. Preliminary Optimisation of Liposome Mediated Transfection in H4IIEC3, 
HepG2 and CHO Cells
DNA (pg) : 
DOTAP (ug) ratio
Amount of 
DOTAP (pg) 
Added Per 35mm 
Dish
Incubation Time 
with 
DNA/DOTAP 
(hrs)
Summary of 
Results
H4IIEC3 Cells 7.5 5 /10 Transfection
1 :5 15 5 /1 0 efficiency <1%
30 5/10 for all conditions
7.5 5 /10
1 :7.5 15 5 /10
30 5 /10
7.5 5 /10
1 : 10 15 5 /10
30 5 /10
HepG2 Cells 7.5 5 /10 Transfection
1 :5 15 5 /10 efficiency <1%
30 5/10 for all conditions
7.5 5 /10
1 :7.5 15 5 /10
30 5 /10
7.5 5 /10
1 : 10 15 5 /10
30 5 /10
CHO Cells 7.5 5 /10 Transfection
1 :5 15 5 /10 efficiency <1%
30 5/10 for all conditions
7.5 5 /10
1 :7.5 15 5 /1 0
30 5 /10
7.5 5 /10
1 ; 10 15 5 /1 0
30 5 /10
Cells were transfected using the liposome reagent DOTAP as described in section 2,12.2.3, with 
modifications to the method as detailed above. Plasmid DNA was prepared using Promega 
Wizard '^  ^Maxipreps DNA Purification System (2.5.7.1). For monitoring transfection efficiency the 
P-galactosidase expression vector pCHllO was transfected. The DNA mixture used contained the 
following ratio of plasmid DNA by mass - 3 pCHllO : 7 pBluescript. Cells were transfected in 
35mm dishes in 6-well plates, in triplicate. Transfection efficiency was assessed by histochemical 
staining for p-galactosidase, as described in section 2.12.5.
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Table 4-2. Results of Calcium Phosphate-DNA Co-Precipitate Mediated Transfection In 
H4IIEC3, HepG2, CHO, and Hepalclc? Cells
DNA Concentration (pg/ml) Result
H4IIEC3 Cells 20 Transfection efficiency <1%
40 for all conditions
80
HepG2 Cells 20 Highest transfection efficiency
40 achieved (10%) using 40pg/ml
80 DNA mixture
CHO Cells 20 Transfection efficiency <1%
40 for all conditions
80
Hepalclc? Cells 20 Transfection efficiency <1%
40 for all conditions
80
Cells were transfected using the calcium phosphate-DNA co-precipitate method (1) described in 
section 2.12.2.4, with modifications to the method as detailed above. Plasmid DNA was prepared 
using Promega Wizard™ Maxipreps DNA Purification System (section 2.5.7.1). For monitoring 
transfection efficiency the p-galactosidase expression vector pCHllO was transfected. The DNA 
mixture used contained the following ratio of plasmid DNA by mass - 3 pCHllO : 7 pBluescript. 
Cells were transfected in 35mm dishes in 6-well plates, in triplicate. Transfection efficiency was 
assessed by histochemical staining for p-galactosidase, as described in section 2.12.5.
A more comprehensive optimisation of transfection efficiency in HepG2 cells was then carried out, 
described in the following section.
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4.3 Optimisation of Transfection Efficiency in HepG2 Cells
4.3.1 Determination of Optimum Cell Seeding Density
It has been reported that actively dividing cells are generally transfected more efficiently than 
quiescent cells (Nicolau and Sene, 1982). As a cell progresses through the G2 phase of the cell 
cycle towards mitosis, the nuclear membrane breaks down, which may favour the entry of 
exogenous DNA into the nucleus (Lascombe et a l, 1996). Therefore, it is important that cells for 
use in transfections have been regularly passaged and are seeded at the correct density to ensure 
that they are actively dividing. For optimum transfection efficiency, cells should be seeded so that 
they are between 60% and 80% confluency at the time of transfection (Sambrook et a l, 1989; 
Beckler et a l, 1996). It was determined that the optimal transfection efficiency in HepG2 cells was 
obtained by seeding 6 x 10^  cells per 35mm dish (6.24 x 10'^  cells/cm^), 24 hours prior to 
transfection (Table 4-3).
Table 4-3. Optimisation of HepG2 Cell Seeding Density for High Transfection Efficiency
Number of Cells Seeded Per 35mm Dish Mean Transfection Efficiency (%)
3x10^ 11.4
6x10^ 11.9
1.2x10^ 5
Cells were transfected using the calcium phosphate-DNA co-precipitate method (1) described in 
section 2.12.2.4. Plasmid DNA was prepared using Promega Wizard™ Maxipreps DNA 
Purification System (2.5.7.1). For monitoring transfection efficiency the p-galactosidase
expression vector pCHllO was transfected. The DNA mixture used contained the following ratio 
of plasmid DNA by mass - 3 pCHl 10 : 7 pBluescript. Cells were transfected in 35mm dishes in 6- 
well plates, n=6. Transfection efficiency was assessed by histochemical staining for p- 
galactosidase, as described in section 2.12.5.
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4.3.2 Choice of p-galactosidase Expression Vector for Normalisation of Transfection 
Efficiencies
Two p-galactosidase vectors were examined for transient transfection, namely pCHllO (Pharmacia 
Biotech) and pSV-p-gal (Promega). pSV-P-gal is 6821 bp and pCHllO is 7128 bp in size (see 
section 2.2.3). pCHllO contains a functional lacZ gene which is expressed from the SV40 early 
promoter in eukaryotes. In p SV-P-gal the SV40 early promoter and enhancer drive transcription of 
the bacterial lacZ gene. It was thought that transfection of pSV-p-gal might result in higher p- 
galactosidase activities because as a slightly smaller plasmid it would be taken up by the cells more 
readily than pCHl 10.
Cells were transfected using the calcium phosphate-DNA co-precipitate method (1) described in 
section 2.12.2.4. Plasmid DNA was prepared using Promega Wizard™ Maxipreps DNA 
Purification System (section 2.5.7.1). The DNA mixture used contained the following ratio of 
plasmid DNA by mass - 3 pCHllO : 7 pBluescript. Cells were transfected in 35mm dishes in 6- 
well plates (n=6). It was found that transfection of pCHllO gave nearly twice the p-galactosidase 
activity than transfection of pSV-p-gal, as measured using an ELISA for p-galactosidase (section
2.12.5). ; Mean p-galactosidase activity produced using pCHllO was 97U/ml.hr (SD +6.6), and 
using pSV-p-gal was 51U/ml.hr (SD ±4.3). pCHllO was therefore chosen to be used as a control 
vector for transfection efficiency and was used in all subsequent transfections.
4.3.3 Cell Passage Number
It has been reported that HepG2 cells transfected with a human CYP3A4 reporter gene construct, 
rapidly lose response to the CYP3A4 inducer dexamethasone after repeated subculture (Williams,
1997). Further investigation into the relationship between cell passage number and loss of 
CYP3A4-dependent reporter gene activation, found that the loss of response did not correlate well
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Table 4*. Transcriptional Activation of CYP4A1(171/273)GCAT in HepG2 Cells Is Lower 
When Cells have been Cultured In Poly-D-Lysine Coated Dishes Compared to Non-coated 
Dishes
Dose
Mean Fold Induction of Reporter Gene Expression
Poly-D-lysine Coated dishes Non-Coated dishes
lOpMWy-14,643 1.77+0.21 1.92+0.14
lOpM Nafenopin 1.75+0.23 1.88+0.19
lOOpM Clofibric acid 1.41+0.18 1.52+0.15
HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained following ratios of plasmid DNA by mass - 
3 pCHllO: 1 p4Al(171/273)GCAT : lpSG5 +1 pSGSPPAR. n = 3 for each value, mean values ± 
SD are given. In order to account for variation in transfection efficiency between replicates, CAT 
levels were normalised against p-galactosidase activity. Cells were exposed to the stated 
concentration of peroxisome proliferator for 48 hours. The normalised CAT levels for peroxisome 
proliferator dosed cells was divided by the normalised CAT levels for solvent control treated cells 
to give the fold activation of p4Al(171/273)GCAT reporter gene expression.
with increasing passage number (Dr Malcolm Ogg, personal communication). It was observed that 
the HepG2 cells lose their characteristic ‘clumping’ growth pattern (Figure 4-2) during repeated 
subculture (personnel observation), this change in morphology may be associated with changes in 
cellular function. In order to overcome any variation in response by the transfected cells that due to 
cellular changes caused by repeated passaging, a bank of HepG2 cells in low passage number was 
established for use in reporter gene studies (see section 2.11.2).
4.3.4 The Effect o f Growing HepG2 Cells on Poly-D-Lysine Coated Dishes
It has been reported that HepG2 cells seeded into poly-D-lysine coated dishes have a higher plating 
efficiency and also transfect with a higher efficiency than HepG2 cells grown in dishes that are not 
coated (Hines et a l, 1988). Hines et al suggest that this may result from increased cell spreading 
which increases the surface area of the cell that is exposed to DNA. Figure 4-2 shows HepG2 cells 
that had been seeded into (a) a non-coated dish and (b) a poly-D-lysine coated dish. It is clear that 
the cells grow differently on poly-D-lysine, forming a more typical monolayer than on a non-coated 
dish. An experiment was carried out to determine whether HepG2 cells did transfect with a higher 
efficiency when grown on poly-D-lysine coated dishes compared to dishes that were untreated, this 
experiment being described in Figure 4-3. It was found that the mean p-galactosidase activity in 
transfected HepG2 cells was 26% higher in HepG2 cells grown on coated dishes as compared to 
cells grown on non-coated dishes, in agreement with the findings of Hines et al (1988). In later 
experiments it was found that the fold-activation by peroxisome proliferators measured in HepG2 
cells transfected with CYP4A1 reporter gene constructs, was on average lower in cells that had
been grown in poly-D-lysine coated dishes than in non-coated dishes (see Table 4*). Dishes 
were therefore not coated with poly-D-lysine in reporter gene assays. It is possible that the poly-D- 
lysine is slightly toxic to the HepG2 cells and in combination with exposure to peroxisome 
proliferators this may explain the reduction in reporter gene activation.
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Figure 4-3. Comparison of Transfection Efficiency in HepG2 Cells Grown in Poly-D-Lysine 
Coated Dishes Compared to Cells Grown in Non-Coated Dishes
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (1) 
described in section 2.12.2.4 . Error bars show the S.E.M., n=6. DNA mixture contained following 
ratios of plasmid DNA by mass - 3 pCHl 10: 7 pBluescript.
4.3.5 Choice o f Plasmid DNA Purification Method
It has been found that higher transfection efficiency of plasmid DNA into mammalian cells is 
achieved when the DNA has been purified using anion-exehange chromatography, or by two rounds 
of CsCl-gradient centrifugation, than with DNA purified by siliea-based DNA adsorption (Weber et 
al, 1995). This has been correlated to the higher levels of impurities that are found in DNA 
prepared by silica-based DNA adsorption and also to the lipopolysaccharide (EPS) content in these 
preparations (Weber et al, 1995; Weber et al, 1996). EPS is also known as endotoxin and is a 
component of the outer-membrane of Gram-negative bacteria. An experiment was carried out to 
investigate whether the transfection efficiency in HepG2 cells was affected by the method of 
plasmid DNA purification.
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Initial transfection experiments had been carried using DNA that had been purified using 
Promega's Wizard™ Plus Maxiprep DNA Purification System (section 2.5,7.1), this method 
involving silica-based DNA adsorption. The transfection efficiency obtained using DNA prepared 
with this Promega kit was compared to that achieved using a new product, the Qiagen EndoFree 
Maxi Kit DNA Purification System (section 2.5.12). The Qiagen Endoffee Kit contains a special 
buffer (proprietary composition) to eliminate endotoxins from the preparation. Three purifications 
of pCHllO were carried out using each method, from the same bacterial culture. Transfections 
were carried out in triplicate using method (1) (see section 2.12.2.4) with each DNA preparation. 
In agreement with the work published by Weber et al. (1995), a higher transfection efficiency was 
achieved using DNA purified using an anion-exchange chromatography method compared to DNA 
purified by silica-based DNA adsorption, p-galactosidase activity was assessed by a 
chemiluminescent p-galactosidase assay (section 2.12.4.5). The mean RLU, correlating to P- 
galactosidase activity of transfected cell lysates, was 5.7-fold higher with cells transfected using 
DNA prepared with the Qiagen anion-exchange chromatography method, as compared to the 
Promega silica-based DNA adsorption method. The Qiagen EndoFree Maxi Kit DNA Purification 
System (see section 2.5.1.2) was therefore used to prepare plasmid DNA for all subsequent work.
4,3.6 Modification of Calcium Phosphate-DNA Precipitation Method
At the start of my PhD project, transfections were carried out using the calcium phosphate-mediated 
DNA transfection method (1), described in section 2.12.2.4. Transfection efficiencies were found 
to be highly variable using this method (data not shown). It has been reported that effective 
precipitates for transfection purposes, can be generated only over a very narrow range of physico­
chemical conditions that control initiation and growth of precipitate complexes (Jordan et a l,
1996). Work by Jordan et al (1996) reported that parameters such as temperature, DNA 
concentration and precipitate formation reaction time are important in the development of 
reproducible, high efficiency transfection protocols. A series of experiments were carried out using
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the calcium phosphate-DNA co-precipitate transfection method described by Jordan et al (method 
(2) in section 2.12.2.3) to fully optimise the transfection efficiency in HepG2 cells and improve 
reproducibility.
4.3,6.1 Effect of Temperature, DNA Concentration and Glycerol Shock on Transfection 
Efficiency of HepG2 Cells
Method (1) for the formation of a calcium phosphate-DNA co-precipitate (section 2.12.2.3) uses a 
20 minute incubation of the reaction mixture at room temperature. It was considered that the room 
temperature incubation was a possible source of variation in the formation of an effective 
precipitate. The temperature of the laboratory, which is not air conditioned, has been recorded to 
reach as high as 34°C in the summer. An experiment was carried out to investigate the 
effectiveness of precipitates formed at 23°C and 27°C, representing the usual minimum and 
maximum room temperatures encountered in the laboratory (Figure 4-4). The experiment was 
carried out using a range of DNA concentrations, in order to see if there was any correlation 
between temperature and DNA concentration in the formation of an effective precipitate. 
Transfection efficiency has also been found to be enhanced by the application of glycerol shock to 
the cells following transfection (Beckler et a l, 1996). Hence a third parameter was investigated in 
this experiment, namely the application of glycerol shock to the transfected cells.
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Figure 4-4. Effect of Temperature and Glycerol Shock on Transfection of HepG2 Cells
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p-galactosidase activity was plotted against the concentration of DNA per ml of precipitate. DNA
mixture contained following ratios of plasmid DNA by mass - 3 pCHllO: 7 pBluescript. p-
galactosidase activity was assessed by ELISA (section 2.12.4.4). Each transfection was carried out
in triplicate and error bars show the S.E.M. HepG2 cells were transfected by calcium phosphate
mediated DNA transfection using the method (2) described in section 2.12.2.4 with the following
modifications: the precipitation reagents and the reaction mixture were incubated at 23°C and 27°C
for 20 minutes. (+) indicates that the cells were exposed to a 20% glycerol shock for 1 minute after
the precipitate was removed from the cells. (-) indicates that the cells were not glycerol shocked, 
p-galactosidase activity was measured as a marker for transfection efficiency.
Figure 4-4 demonstrates that a higher mean P-galactosidase activity is obtained in cell extracts 
where the precipitate reaction was carried out at 23°C as compared to 27°C. A better precipitate 
seems to be formed at the lower temperature. Figure 4-4 also shows that there is a non-linear 
relationship between the DNA concentration of the precipitate and the level of P-galactosidase 
activity. Since the reaction mixtures for each temperature were made up separately it seems unlikely 
that an error was made twice to produce a similar effect. The decrease in activity at 35pg compared 
to 25)Lig of DNA per ml of precipitate and the increase seen at 45pg of DNA compared to 25pg may 
be due to the nature of the precipitate formation itself. At 3 5 jig of DNA it may be that the DNA 
partially inhibited the formation of the precipitate. At 45jig of DNA the cells may be swamped 
with DNA and there may be more DNA to be taken up by the cells even though the precipitate itself
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may not be of such a good quality. Jordan et a l (1996) reported that an excess of soluble DNA in a 
supersaturated solution of calcium and phosphate may prolong the period during which a precipitate 
forms. They also reported that high concentrations of DNA can even prevent precipitate formation 
entirely. A 20% glycerol shock applied to the cells for 1 minute did not increase p-galactosidase 
activity, in fact at all three DNA concentrations, at both 23°C and 27°C, the activity was decreased 
slightly. This may be due in part that the HepG2 cells did not tolerate 20% glycerol shock well and 
some cell death occured (observed under phase contrast microscopy).
The results shown in Figure 4-4 indicate that a more effective precipitate was formed at 23 °C 
compared to 27®C A 20% glycerol shock applied to the cells after transfection, for 1 minute, did 
not enhance transfection efficiency. An effective precipitate was formed using a DNA 
concentration of 25pg per ml of precipitate. Slightly higher p-galactosidase activities were 
obtained using a DNA concentration of 45 pg per ml of precipitate but the variation between 
replicates is considerably higher. For ftiture work it was decided that a DNA concentration of 25pg 
per ml of precipitate would be used.
4,3,6,2 The Effect of Precipitate Formation Time on Transfection Efficiency in HepG2 
Cells
Figure 4-4 shows that a more effective precipitate was produced at 23°C as compared to 27°C. 
This result showed that the temperature at which the precipitate is formed is an important 
determinant in the effectiveness of precipitate. It was difficult to maintain these temperatures for 
the 20 minute precipitate formation time, especially since the reaction has to carried out under 
sterile conditions, so as not to cause infection to the transfected HepG2 cells. For reproducible 
tiransfection efficiency it was important to be able to maintain the temperature at which the 
precipitate was formed. Carrying out the reaction on ice (4°C) was easy to perform in a laminar air 
flow hood, and readily reproducible. An experiment was carried out at 4°C to see if an effective
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precipitate for transfection could be formed. The precipitate reaction mixture was incubated at 10 
different reaction times, from 1 minute to 165 minutes, to investigate the optimum precipitate 
formation time at 4°C. The results of this experiment are shown in Figure 4-5. The most effective 
precipitates were produced within 5 minutes, at 4°C. This agrees with the work of Jordan et al, 
1996, where it was reported that almost all of the soluble DNA in a reaction mix can be bound into 
an insoluble complex in less than 1 minute. They also reported that extending the reaction time to 
20 minutes results in aggregation and/or growth of particles that reduced the level of expression of 
transfected DNA.
Figure 4-5, Optimisation of Precipitate Formation Time at 4°C In HepG2 Cells
B ^
P  450 
400
350>
300Ï
I
250
200
150 
P  100I
a
CO. 1000 50 150 200
Reaction Time For Precipitate Formation (minutes)
HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4 with the following modification: precipitate formation time was 
carried out over a range of ten different time periods between 1 minute to 165 minutes. DNA 
mixture contained following ratios of plasmid DNA by mass - 3 pCHllO: 7 pBluescript. Each 
transfection was carried out in triplicate and error bars show the S.E.M.
P-galactosidase activity was measured as a marker for transfection efficiency.
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4.3,63 Effect of DMSO Shock and Precipitate Formation Time on Transfection 
Efficiency in HepG2 Cells
Figure 4-5 demonstrates that an effective precipitate was produced in a reaction time of less than 5 
minutes, at 4°C. In order to determine the reaction time at which the most effective precipitate is 
formed at 4°C, a range of reaction times were investigated. Reaction times of 4, 3, 2 and 1 minute 
were carried out. Precipitate formation times of under 1 minute were not tried because these are 
practically difficult to reproduce. The results given in Figure 4-6 show that there is a clear 
relationship between precipitate formation time and P-galactosidase activity in transfected cell 
lysates. The optimum reaction time for precipitate formation was found to be 1 minute, at 4°C.
Transfection efficiency has been reported to be enhanced by the application of a DMSO shock to 
the cells following transfection (Beckler et a l, 1996). A 5% and a 10% DMSO shock was tried on 
HepG2 cells that were transfected in parallel with the experiment described above. Neither a 5% or 
10% DMSO shock was found to enhance the p-galactosidase activity in transfected cell lysates 
(Figure 4-6).
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Figure 4-6. Effect of DMSO Shock and Time of Precipitate Formation on Transfection 
Efficiency In HepG2 Cells
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P-galactosidase activity is plotted against the precipitate formation time and percentage DMSO 
shock treatment. Error bars show the S.E.M., n=6. HepG2 cells were transfected by calcium 
phosphate mediated DNA transfection at 4°C using method (2) described in section 2.12.2.4. DNA 
mixture contained following ratios of plasmid DNA by mass - 3 pCHl 10: 7 pBluescript. 
P-galactosidase activity was measured as a marker for transfection efficiency.
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4.4 Characterisation of HepG2 Cells for CYP4A1- and CYPIAI- 
Dependent Reporter Gene Activation
4.4.1 CYP4A1-Dependent Reporter Gene Activation In HepG2 Cells Requires Co- 
Transfection of PPARa Expression Plasmid
The transcriptional activation of the reporter construct p4Al(171/273)GCAT (see sections 1.3.2.2 
and 2.2.3), co-transfected with and without expression vectors encoding mPPAR and mRXRa, has 
been investigated previously in Hepalclc7 cells (Aldridge et a l, 1995). In order to determine 
whether the reporter construct p4Al(171/273)GCAT could be similarly transcriptionally activated 
by Wy-14,643 and/or 9-cis retinoic acid in HepG2 cells, some of the co-transfection experiments 
carried out originally by Aldridge et al (1995) were repeated (Figure 4-7). The pattern of induction 
seen in HepG2 cells (Figure 4-7) is strikingly similar to that reported in Hepalclc7 cells (Aldridge 
et al, 1995). One major difference between the transcriptional activation of p4Al(171/273)GCAT 
in HepG2 cells compared to Hepalclc7 cells, was the transcriptional activation observed in the 
absence of added ligand on co-transfection with pSG5PPARa. Co-transfection of the PPARa 
expression vector with p4Al(171/273)GCAT in HepG2 cells gave a 3.8-fold higher level of 
activation than co-transfection with pSG5 alone. In Hepalclc7 cells, co-transfection of the PPARa 
expression vector with p4A1(171/273)GCAT resulted in only a 1.5-fold higher level of activation 
than co-transfection with pSG5 alone. The fold-activation seen in response to 9~cis retinoic acid on 
co-transfection with p4Al(171/273)GCAT and pSG5PPAR is higher in HepG2 cells than in 
Hepalclc7 cells. From these results it appears that HepG2 cells express higher levels of 
endogenous RXR than Hepalclc7 cells, and that either the HepG2 cells themselves or their culture 
media contain natural activators of PPAR/RXR heterodimers. In HepG2 cells, as in Hepalclc7 
cells, there is no significant transcriptional activation of p4A1(171/273)GCAT by Wy-14,643 seen 
in the absence of co-transfected pSG5PPAR. For transcriptional activation of
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p4Al(171/273)GCAT by Wy-14,643 in HepG2 cells it is therefore necessary to co-transfect 
pSGSPPAR.
Figure 4-7. Transcriptional Activation of the Reporter Construct p4Al(171/273)GCAT, by 
Wy-14,643 and 9-cis Retinoic Acid, in the Presence and Absence of Exogenous PPARa and/or 
RXRa
25
(-) ligand SB (+) Wy □  (+) 9-cis W (+) Wy/9-cis
* *
PPAR PPAR
HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained following ratios of plasmid DNA by mass - 
3 pCHllO: 1 p4Al(171/273)GCAT : 2 pSG5 or (lpSG5 +1 pSG5PPAR) or (1 pSG5 + 1 
pSG5RXR) or (1 pSG5PPAR + 1 pSG5RXR). n = 3 for each value, error bars show standard error 
of mean. Statistical significance was determined using one-way Anova with Bonferroni/Dunn post- 
hoc test. Significant induction above background {(-) ligand, for each group: pSG5, PPAR, RXR, 
PPAR + RXR} is marked by asterisks (*P = < 0.001). In order to account for variation in 
transfection efficiency between replicates, CAT levels were normalised against P-galactosidase 
activity. (-) ligand, DMSO; (+) Wy, lOpM Wy-14,643; (+) 9-cis, 1 pM 9-c/s retinoic acid; (+) 
Wy/9-c/5, lOpM Wy-14,643 and IpM 9-ch retinoic acid.
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4.4.2 Transcriptional Activation of the Reporter Construct p4Al(171/273)GCAT in
HepG2 Cells by a Range of Peroxisome Proliferators
p4Al(171/273)GCAT was co-transfected with either pSG5 or pSGSPPAR and the transfected cells 
dosed with a range of concentrations of the peroxisome proliferators: Wy-14,643 (Figure 4-8), 
ciprofibrate (Figure 4-9), nafenopin (Figure 4-10), and clofibric acid (Figure 4-11). The activation 
of the CYP4A1 reporter construct by co-transfection of pSGSPPAR in the absence of ligand ranged 
between 3.5- and 4.8-fold in the four experiments shown. Significant induction by the peroxisome 
proliferators was seen at lower concentrations in the presence of mPPARa than in the absence of 
this receptor. This suggests that HepG2 cells may contain low levels of endogenous PPAR or that, 
at high concentrations of ligand, cytotoxic effects are causing an artifactual rise in normalised CAT 
levels. Significant induction by Wy-14,643 in the presence of mPPARa was observed at a 
concentration of IpM. The highest induction by Wy-14,643, at concentration of lOpM, was 1.7- 
fold. In the presence of mPPARa, normalised CAT levels were significantly increased at lOOpM 
ciprofibrate, by 1.75-fold and at lOOpM clofibric acid by 1.9-fold. Nafenopin caused a significant 
induction in the presence of PPARa at a concentration of lOpM and an even higher induction, 
2.25-fold, at lOOpM. These results show that the CYP4A1 element cloned into 
p4A1(171/273)GCAT is transcriptionally activated in HepG2 cells, co-transfected with 
pSG5PPAR, by a number of different peroxisome proliferators.
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Figure 4-8. Transcriptional Activation of the Reporter Construct p4Al(171/273)GCAT in 
HepG2 Cells, by a Range of Doses of Wy-14,643, in the Presence and Absence of PPARa
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) described in 
section 2.12.2.4. DNA mixture contained following ratios of plasmid DNA by mass - 3 pCHllO: 1 
p4Al(171/273)GCAT ; 2 pSG5 or (lpSG5 +1 pSGSPPAR). n = 3 for each value, error bars show standard 
error o f mean. In order to account for variation in transfection efficiency between replicates, CAT levels were 
normalised against P-galactosidase activity. Statistical significance was determined using one-way Anova 
with Bonferroni/Dunn post-hoc test. Significant induction above background {dmso, for each group: (-)ppar, 
(+)ppar} is marked by asterisks (*P = < 0.001).
Figure 4-9. Transcriptional Activation of the Reporter Construct p4Al(171/273)GCAT in 
HepG2 Cells, by a Range of Doses of Ciprofibrate, in the Presence and Absence of PPARa
I
’2
c/3
(+)ppar □ (-)ppar
D M SO 0.01 0.1 10 100
Ciprofibrate (pM)
HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) described in 
section 2.12.2.4. DNA mixture contained following ratios of plasmid DNA by mass - 3 pCHllO: 1 
p4Al(171/273)GCAT : 2 pSG5 or (lpSG5 +1 pSGSPPAR). n = 3 for each value, error bars show standard 
error o f mean. In order to account for variation in transfection efficiency between replicates, CAT levels were 
normalised against p-galactosidase activity. Statistical significance was determined using one-way Anova 
with Bonferroni/Dunn post-hoc test. Significant induction above background {dmso, for each group: (-)ppar, 
(+)ppar} is marked by asterisks (*P = < 0.001).
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Figure 4-10. Transcriptional Activation of the Reporter Construct p4Al(I71/273)GCAT in
HepG2 Cells, by a Range of Doses of Nafenopin, in the Presence and Absence of PPARa
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) described in 
section 2.12.2.4. DNA mixture contained following ratios o f plasmid DNA by mass - 3 pCHllO: 1 
p4A 1(171 /273)GCAT : 2 pSG5 or (IpSGS +1 pSGSPPAR). n = 3 for each value, error bars show standard 
error o f mean. In order to account for variation in transfection efficiency between replicates, CAT levels were 
normalised against p-galactosidase activity. Statistical significance was determined using one-way Anova 
with Bonferroni/Dunn post-hoc test. Significant induction above background {dmso, for each group: (-)ppar, 
(+)ppar} is marked by asterisks (*P = < 0.001).
Figure 4-11. Transcriptional Activation of the Reporter Construct p4Al(171/273)GCAT in 
HepG2 Cells, by a Range of Doses of Clofibric Acid, in the Presence and Absence of PPARa
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) described in 
section 2.12.2.4. DNA mixture contained following ratios of plasmid DNA by mass - 3 pCHllO: 1 
p4A 1(171 /273)GCAT : 2 pSG5 or (lpSG5 +1 pSGSPPAR). n = 3 for each value, error bars show standard 
error o f mean. In order to account for variation in transfection efficiency between replicates, CAT levels were 
normalised against p-galactosidase activity. Statistical significance was determined using one-way Anova 
with Bonferroni/Dunn post-hoc test. Significant induction above background {dmso, for each group: (-)ppar, 
(+)ppar} is marked by asterisks (*P = < 0.001).
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4.4.3 Investigation of PPAR Subtypes Expressed in HepG2 Cells
To determine which, if any, PPAR subtypes are expressed in HepG2 cells, SDS-PAGE and 
Western blotting were carried out with HepG2 cell lysates and cell homogenates, using the method 
described in section 2.8. Proteins were transferred from gels onto PVDF membranes which have a 
high protein binding capacity. Ponceau S staining of membranes showed that proteins were being 
successfully transferred. Amersham’s highly sensitive ECL Plus chemiluminescence system was 
used for detection. Despite the high sensitivity of the system that was employed, attempts to 
optimise the western blotting procedure gave poor results and the PPAR subtype status of the 
HepG2 cells remains undefined in my hands. Parameters that were modified in the optimisation 
procedure included: protein loading (l-50pg), membrane blocking (5%-10% dried skimmed milk in 
0.1%(v/v) TBS-Tween, for 1 hour or overnight), primary antibody incubation (1:500 to 1:20000 
dilution, for 30 min-2 hour) and secondary antibody incubation (1:500 to 1:2000 dilution, for 30 
min-1 hour).
The most satisfactory Western blot result is shown in Figure 4-12. HepG2 cells that had been 
transfected with an expression plasmid for mPPARa were used to produce positive control lysate 
and were analysed alongside untransfected HepG2 cell lysate. HepG2 cell lysates were found to 
run better on polyacrylamide gels than HepG2 cell homogenates. HepG2 cell lysate in lane 1 
(Figure 4-12) was not incubated with primary antibody, to provide a negative control. As described 
in Figure 4-12, the membrane was cut into strips and incubated with a range of concentrations of 
primary antibody. A band can be seen in lanes 2, 3, 4, 5, 6, and 7, that is not found in the negative 
control lane (1). This band corresponds with the expected size of PPARa {mouse PPARa
52.4kDa, human PPARa 52.3kDa (Savory, 1996)}. I  This band cannot be identified as 
corresponding to PPARa because of the high degree of non-specific binding. Similar results were 
obtained with Western blots for PPARp and PPARy. In my hands it was not possible to determine 
whether HepG2 cells express PPARa, PPARp or PPARy protein by Western blotting.
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Figure 4-12. Western Blotting For PPARa in HepG2 Cell Lysates
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Top - positive image of western blot, bottom - negative image of western blot. Each lane was 
loaded with 25pg of protein. (1) negative control (2) positive control (3) HepG2 cell lysate (4) 
positive control (5) HepG2 cell lysate (6) positive control (7) HepG2 cell lysate (M) ECL protein 
molecular weight marker. The membrane was cut into sections and immunoblotting carried out as 
follows:
Lane 1 2 3 4 5 6 7
[Primary Ab] 0 1/5000 1/5000 1/10000 1/10000 1/20000 1/20000
[secondary Ab] 1/2000 1/2000 1/2000 1/2000 1/2000 1/2000 1/2000
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4.4.4 Endogenous Inducible C Y PlA l Activity in HepG2 Cells
Ethoxyresorufin 0-deethylation (EROD) activity, a marker for CYPlAl, has been previously 
reported to be induced in HepG2 cells by benz(a)anthracene (Grant et al, 1988) and by p- 
naphthoflavone (Wang et al, 1997). HepG2 cells have also been reported to have high 
benzo(a)pyrene metabolising activity (Diamond et al., 1980). In association with conserving 
CYPlAl drug-metabolising activity, HepG2 cells have been found to contain functional AH 
receptor (Roberts et al., 1990). To confirm the suitability of the HepG2 cell line for use in 
CYPlAl reporter gene assays, the EROD activity of our HepG2 cells was investigated. EROD 
activity in HepG2 cell homogenates and HepG2 cells lysates was measured using the method 
described in section 2.9.2. Sample preparation was found to be a critical parameter in measurement 
of EROD activity (Table 4-4). EROD activity was destroyed by lysis of the HepG2 cells.
EROD activity was undetectable in untreated HepG2 cell homogenates. This agrees with the 
results of Roberts et al (1990), where aryl hydrocarbon hydroxylase activity was undetectable prior 
to treating HepG2 cells with inducers. lOpM p-naphthoflavone treatment resulted in 2-fold 
induction of EROD activity as compared to 2pM P-naphthoflavone treatment. Treatment of HepG2 
cells with 50pM p-naphthoflavone resulted in EROD activity that was lower than produced by 2pM 
P-naphthoflavone treatment. This reduction in activity at a higher concentrations is probably the 
result of toxicity.
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Table 4-4. p-Naphthoflavone Induced EROD Activity in HepG2 Cells
Treatment EROD Activity (pmol/min/mg 
protein) in HepG2 Homogenates
EROD Activity 
(pmol/min/mg protein) in 
HepG2 Lysates
No treatment 0 0
DMSO 0 0
2pM p-naphthoflavone 11.81 ±0.6 0
10 pM P- 
naphthoflavone
23.52 ±2.9 0
50 pM p- 
naphthoflavone
7.07 ±1.3 0
Results are expressed as mean ± S.E.M. (n=3). EROD - ethoxyresorufin O-deethylation.
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4.5 Modifications to Transfection Procedure For High-Throughput of 
Samples
Initially, transfections were carried out in 6-well plates, which required large quantities of plasmid 
DNA, and transfections were time consuming to carry out and harvest. 400pl of transfected cell 
lysate could be harvested from one dish of a 6-well plate, this was sufficient to carry out p- 
galactosidase and CAT ELISAs in triplicate. At least 300pl of transfected cell lysate was required 
for ELISA analysis of CAT and p-galactosidase levels, this limited the culture dish size in which 
transfections could be performed. To address this problem, several changes to the reporter gene 
assay design were made. In place of using the ELISA method, p-galactosidase levels were 
determined by chemiluminescent assay, which requires only 10-20pl cell lysate (section 2.12.4.5). 
The reporter gene vector was changed from one encoding CAT to one that encodes SEAP, which 
allowed reporter gene levels to be measured using only 15pl of media sample (see section 2.12.4.7). 
These changes allowed transfections to be carried out in a 96-well plate format and hence reduced 
the amount of plasmid DNA required, increased the number of samples that could processed at one 
time and reduced the overall ‘hands-on’ time for the whole reporter gene study. Using 
multichannel pipettes, large assays could be carried out simply, media samples could be transferred 
directly into 96-well plates for SEAP level determination and lysates could be prepared rapidly.
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4.6 Conclusions
(i) HepG2 cells were chosen for use in CYP4A1 and CYPlAl reporter gene studies because they 
transfected with much higher efficiency than the other cell lines that were tried (H4IIEC3, CHO 
and Hepalclc?).
(ii) In CYP4A1 reporter gene assays using HepG2 cells co-transfected with PPARa, transcription
i
was activated by a range of peroxisome proliferators .
(iii) EROD activity, an indicator of CYPlAl activity, was induced in HepG2 cells by P- 
naphthoflavone.
(iv) Inducible EROD activity indicated that our HepG2 cells contained functional AH receptor and 
other factors required for CYPlAl induction and /mw-activation of CYPlAl-dependent reporter 
gene activation.
(v) Using the optimised method for HepG2 transfection (described by method (2) in section 
2.12.2.4) a routine transfection efficiency of >20% was achieved, as assessed by histochemical 
staining for p-galactosidase.
(vi) Calcium phosphate-DNA co-precipitate mediated transfection of HepG2 cells was optimised 
for:
• high transfection efficiency
• reproducibility
• high sample number throughput
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(vii) One of the most important parameters for reproducible and high efficiency transfections was 
found to be the method by which the plasmid DNA is purified. Qiagen EndoFree Maxi Kit DNA 
Purification System (see section 2.5.7.2), based on anion-exchange chromatography, was found to 
give the most satisfactory results.
(viii) It was found that the conditions under which the calcium phosphate-DNA co-precipitate was 
formed, including the reaction temperature, precipitate formation time and DNA concentration, 
were important in the production of an effective transfection precipitate.
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5. Rat CYP4A1 Reporter Gene Assay Results 
5.1 Introduction
The underlying mechanisms of the carcinogenic effect of peroxisome proliferators (section 1.3.2.2) 
remains undetermined and so although humans appear resistant to the PP mediated 
hepatocarcinogenesis that has been observed in rodents, it remains of interest that these compounds 
should be identifiable (Moody et a/., 1991; Rao et a l, 1991). Peroxisome proliferators are typically 
non-genotoxic carcinogens and hence in vivo and in vitro genotoxicity tests cannot be used for their 
identification (Ashby et a l, 1994). Identification of peroxisome proliferators is also hampered by 
the structural diversity of these compounds (section 1.3.2.2).
Transcriptional activation of the CYP4A1 response element (Figure 1-8) vyas investigated in 
HepG2 cells using the CAT reporter construct p4Al(171/273)GCAT, containing the rabbit p-globin 
promoter (Figure 2-3) and using the SEAP reporter construct p4Al(171/273)seap containing the 
SV40 early promoter (section 3.3). A range of compounds that included known peroxisome 
proliferators, PPAR activators and a number of cytochrome P450 inducers were also tested using 
the CYP4A1 reporter gene assay (development described in Chapter 4).
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5.2 Results
5.2.1 p4Al(171/273)GCAT Reporter Gene Activation By Wy-14,643 Is Due to the 
Presence of the CYP4A1 Response Element
Figure 5-1 shows the results of an experiment to test that the transcriptional activation of the 
reporter construct p4Al(171/273)GCAT by Wy-14,643, was due to the presence of the 102bp 
element from the CYP4A1 promoter. The results show that the empty reporter vector pGCAT2 was 
not transcriptionally activated by either Wy-14,643 or by the solvent DMSO. 
p4Al(171/273)GCAT was transcriptionally activated significantly by Wy-14,643 but not by 
DMSO. There was no significant difference between p4Al(171/273)GCAT reporter gene levels in 
untreated or in dmso treated cells.
5.2.2 p4AlBam+20CAT Is Non-Responsive to Wy-14,643 and/or 9-cis Retinoic Acid 
In HepG2 Cells
The construct p4AlBam+20CAT (Figure 2-4) was found to be unresponsive in HepG2 cells to Wy-
14,643 , 9-cis retinoic acid or Wy-14,643 and 9-cis retinoic acid in combination. p4AlBam+20CAT 
remained unresponsive to these treatments when co-transfected with expression plasmids for 
PPARa, or RXRa, or both PPARa and RXRa (data not shown).
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Figure 5-1. Transcriptional Activation of p4Al(171/273)GCAT by Wy-14,643 in HepG2 Cells
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass - 3 pCHllO : 1 pGCAT2 or 1 p4Al(171/273)GCAT : 1 pSGSPPAR. n = 3 for each value, 
error bars show standard error of mean. CAT levels were normalised for transfection efficiency 
against p-galactosidase levels and their mean values are given above each bar. Statistical 
significance was determined using one-way Anova with Bonferroni/Dunn post-hoc test. Significant 
induction by lOpM Wy-14,643 compared to solvent treated and untreated cells is marked by 
asterisks (*P< 0.001 for Wy-14,643 treatment compared to untreated cells; *P<0.001 for Wy-
14,643 treatment compared to DMSO treated cells).
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5.2.3 Transcriptional Activation of p4Alrevseap by Wy-14,643 in HepG2 Cells
The transcriptional activation of the reporter vectors p4Al(171/273)seap (section 3.3) and 
p4Alrevseap (section 3.3) by Wy-14,643 was investigated. p4Alrevseap contains the 102bp 
CYP4A1 promoter element in the anti-sense orientation. The empty reporter vector pSEAP2- 
promoter (Figure 2-9) was also tested for response to Wy-14,643. Consistent with the data for the 
CYP4A1 CAT reporter constructs shown in Figure 5-1, the results in Figure 5-2 show that the 
empty reporter vector was non-responsive to Wy-14,643. In response to Wy-14,643 treatment, 
p4A 1(171 /273)seap transcription was significantly induced by 2.1-fold, 20% higher than the 1.7- 
fold induction observed with p4Alrevseap.
Figure 5-2. Transcriptional Activation of p4Alrevseap by lOpM Wy-14,643 is 20% Lower 
Than Transcriptional Activation of p4Al(171/273)seap by lOpM Wy-14,643 in HepG2 Cells
□  dmso 
E Wy-14,643
0^5 012
pSEAP2-
promoter
p4A1 (171/273) 
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass - 3 pCHllO ; 1 pSEAP2-promoter or 1 p4Al(171/273)seap or 1 p4Alrevseap : 1 pSG5PPAR. 
n = 8 for each value, error bars show standard error of mean. SEAP levels were normalised for 
transfection efficiency against |3-galactosidase levels and their mean RLU values are given above 
each bar. Statistical significance was determined using one-way Anova with Bonferroni/Dunn 
post-hoc test. Significant induction by Wy-14,643 treatment as compared to dmso treatment is 
marked: *P<0.001 jP<0.05.
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5.2.4 Peroxisome Proliferators Show Specificity for Activation of CYP4A1 Reporter 
Gene Transcription
A range of compounds that induce cytochrome P450s other than CYP4A1 were tested to see if they 
activated transcription of p4Al(171/273)seap (Figure 5-3). These included the CYP3A1/3A4 
inducer pregnenolone-16a-carbonitrile (PCN), the CYP2B2/3A1/3A4 inducer dexamethasone 
(DEX), the CYP2E1 inducer isoniazid (ISN), the CYP2A1/2A6/2B1/2B2/2B12/2C6/ - 
2C8/2C9/2C18/2C19/2D1/3A1/3A2/3A4 inducer phénobarbital (PB), and the CYP1A1/2A1 
inducer p-naphthoflavone (BNF) (Soucek and Gut, 1992). The peroxisome proliferators clofibrate, 
clofibric acid, ciprofibrate, nafenopin and Wy-14,643 were observed to significantly induce 
p4Al(171/273)seap reporter gene expression. As expected, PCN, DEX, ISN, PB or BNF exposure 
did not induce p4Al(171/273)seap reporter gene expression, confirming that the CYP4A1 reporter 
construct is specifically activated by peroxisome proliferators.
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Figure 5-3. Specificity of Transcriptional Activation of p4Al(171/273)seap by Peroxisome 
Proliferators
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass - 3 pCHllO : 1 pSEAP2-promoter or 1 p4Al(171/273)seap : 1 pSGSPPAR. n = 4 for each 
value, error bars show standard error of mean. Statistical significance was determined using one­
way Anova with Bonferroni/Dunn post-hoc test. Significant induction by drug treatment as 
compared to DMSO treatment is marked: tP<0.05.
5.2.5 Dose-Response Studies For p4Al(171/273)seap Transcriptional Activation by a 
Range of Compounds
A range of peroxisome proliferators and PPAR activators were tested for activation of the reporter 
gene construct p4Al(171/273)seap when co-transfected into HepG2 cells with an expression 
plasmid for PPARa. Wy-14,643 was found to cause significant induction at concentrations of 
0.1 pM, IpM, lOpM and lOOpM (Figure 5-4a). Clofibrate (Figure 5-4b), ciprofibrate (Figure 5-4d)
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and bezafibrate (Figure 5-4f) were found to cause significant induction at lOpM, lOOpM and 
lOOOpM. Significant induction by clofibric acid was seen at lOOpM and lOOOpM (Figure 5-4c). 
Significant induction by nafenopin (Figure 5-4e) and bromopalmitate (Figure 5-4g) was observed at 
concentrations of IpM, lOpM and lOOpM. Linoleic acid was shown to induce at lOOOpM 
concentration (Figure 5-4h). ETYA induced at a concentration of lOpM (Figure 5-4i). BRL49653 
did not cause any significant induction over a concentration range of O.OlpM-lOOOpM (Figure 5-5).
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Figure 5-4. Transcriptional Activation of p4Al(171/273)seap in HepG2 Cells
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(c) Transcriptional Activation o f  p 4A l(171/273)seap  by Clofibric acid
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(e) Transcriptional Activation of p4Al(171/273)seap by Nafenopin
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(g) Transcriptional Activation of p4Al(171/273)seap by Bromopalmitate
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(h) Transcriptional Activation of p4Al(171/273)seap by Linoleic Acid
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(i) Transcriptional Activation of p4Al(171/273)seap byETYA
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass - 3 pCHllO : 1 pSEAP2-promoter or 1 p4Al(171/273)seap ; 1 pSGSPPAR (or 1 pSGS, 
marked by blue hatched bar). SEAP levels were normalised for transfection efficiency against (3- 
galactosidase levels and their mean RLU values are given above each bar. n = 8 for each value, 
error bars show standard error of mean. Statistical significance was determined using one-way 
Anova with Bonferroni/Dunn post-hoc test. Significant induction by Clofibrate treatment as 
compared to DMSO treatment is marked: *P<0.001, fP<0.05. Control - lOOpM Wy-14,643.
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Figure 5-5. BRL49653 Does Not Transcriptionally Activate p4Al(171/273)seap
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass - 3 pCHllO : 1 pSEAP2-promoter or 1 p4Al(171/273)seap : 1 pSGSPPAR (or 1 pSGS, 
marked by blue hatched bar). SEAP levels were normalised for transfection efficiency against p- 
galactosidase levels and their mean RLU values are given above each bar. n = 8 for each value, 
error bars show standard error of mean. Statistical significance was determined using one-way 
Anova with Bonferroni/Dunn post-hoc test. Significant induction is marked; *P<0.001. Control - 
lOOpM Wy-14,643.
5.2.6 Not All Compounds Tested Require Co-transfection of a PPARa Expression 
Plasmid For Induction of p4Al(171/273)seap Reporter Gene Expression In HepG2 
Cells
From initial transfection experiments (ref section 4.4.2) it was determined that co-transfection of 
the PPARa expression plasmid was required for induction of the p4A 1(171 /273)GCAT reporter 
gene by peroxisome proliferators. In order to test whether co-transfection of the PPARa expression 
plasmid was required for induction by all of the inducing compounds that had been analysed in 
section 5.2.5, further transfection experiments were carried out, both with and without co­
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transfected pSG5PPAR. Co-transfection of PPARa with p4Al(171/273)seap was required for the 
induction response in HepG2 cells by ciprofibrate, nafenopin, Wy-14,643, ETYA, clofibric acid, 
and linoleic acid (Figure 5-6 and Figure 5-7). However, significant induction responses were 
observed with the compounds bezafibrate and bromopalmitate (Figure 5-7), both in the absence and 
presence of co-transfected pSG5PPAR.
Figure 5-6. Transcriptional Activation of p4Al(171/273)seap by Ciprofibrate, Nafenopin, 
Wy-14,643 and ETYA in HepG2 Cells Co transfected with PPARa Expression Plasmid
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass - 3 pCHl 10:1 pSEAP2-promoter or 1 p4A 1(171/273)seap : 1 pSG5PPAR or 1 pSG5. SEAP 
levels were normalised for transfection efficiency against P-galactosidase levels and their mean 
RLU values are given above each bar. n = 8 for each value, error bars show standard error of mean. 
Statistical significance was determined using one-way Anova with Bonferroni/Dunn post-hoc test. 
Significant induction by drug treatment as compared to DMSO treatment, on co-transfection with 
the PPARa expression plasmid, is marked: *P<0.001.
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Figure 5-7. Transcriptional Activation of p4Al(171/273)seap by Bezafibrate and 
Bromopalmitate in HepG2 Cells Co-transfected with and without PPARa Expression 
Plasmid.
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass - 3 pCHllO : 1 pSEAP2-promoter or 1 p4Al(171/273)seap : 1 pSGSPPAR or 1 pSG5. SEAP 
levels were normalised for transfection efficiency against p-galactosidase levels and their mean 
RLU values are given above each bar. n = 8 for each value, error bars show standard error of mean. 
Statistical significance was determined using one-way Anova with Bonferroni/Dunn post-hoc test. 
Significant induction by drug treatment as compared to dmso treatment is marked: *P<0.001, 
tP<0.05.
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5.2.7 Conclusions
(i) p4Al(171/273)GCAT reporter gene expression in HepG2 cells was shown to be activated by 
Wy-14,643 and not by the solvent control DMSO (Figure 5-1).
(ii) Induction of p4Al(171/273)GCAT reporter gene expression, in HepG2 cells co-transfected 
with an expression vector for PPARa, was demonstrated to be driven by the 102bp element from 
the 5' flanking region of the CYP4A1 gene (Figure 5-1). The induction response to Wy-14,643 was 
absent on co-transfection of the empty reporter construct pGCAT2 with pSG5PPAR into HepG2 
cells (Figure 5-1).
(iii) Induction of p4Al(171/273)seap reporter gene expression by Wy-14,643 in HepG2 cells 
(Figure 5-2) was shown to be qualitatively the same as the reporter gene induction observed on 
transfection of p4A1(171/273)GCAT into HepG2 cells (Figure 5-1) . The differences in promoter 
environment [p4Al(171/273)GCAT contains the rabbit p-globin promoter and p4Al(171/273)seap 
contains the SV40 early promoter] and reporter gene [p4Al(171/273)GCAT contains the CAT gene 
and p4A1 (171/273)seap contains the SEAP gene] did not influence the induction response in 
HepG2 cells.
(iv) The construct p4AlBam+20CAT containing a 5kb genomic fragment of the rat CYP4A1 5’ 
regulatory region driven by the authentic CYP4A1 promoter was found to be unresponsive in HepG2 
cells to Wy-14,643 , 9-cis retinoic acid or Wy-14,643 and 9-cis retinoic acid in combination. 
p4AlBam+20CAT remained unresponsive to these treatments when co-transfected with expression 
plasmids for PPARa, or RXRa, or both PPARa and RXRa. p4AlBam+20CAT has been previously 
shown to be unresponsive to these treatments in Hepalclc7 cells (Aldridge et al, 1995).
(v) p4Alrevseap, containing the CYP4A1 102bp regulatory element in the anti-sense orientation, 
was shown to be responsive to Wy-14,643 in HepG2 cells (Figure 5-2).
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(vi) p4Al(171/273)seap reporter gene expression was shown to be specifically induced by 
peroxisome proliferators (Figure 5-3), at least in the range of compounds tested.
(vi) In dose-response studies Wy-14,643, clofibrate, clofibric acid, ciprofibrate, nafenopin, 
bezafibrate, bromopalmitate, linoleic acid, and ETYA (see Figure 5-4) were shown to induce 
p4Al(171/273)seap reporter gene expression in HepG2 cells co-transfected with an expression 
plasmid for PPARa. The maximum induction achieved for each compound in these dose-response 
studies are summarised in Figure 5-8; fold inductions are given as a percentage of the fold 
induction by lOOpM Wy-14,643 control.
Figure 5-8. Summary of Maximum p4Al(171/273)seap Fold Inductions Observed in HepG2 
Cells Co-transfected with PPARa Expression Plasmid
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass - 3 pCHllO : 1 pSEAP2-promoter or 1 p4Al(171/273)seap : 1 pSG5PPAR. n = 8 for each 
value. Fold inductions by the various compounds with respect to the solvent (DMSO) are given as 
a percentage of the fold induction by a lOOpM Wy-14,643 control.
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(vii) BRL49653, an anti-diabetic thiazolidinedione that binds PPARy with a Kd of approximately 
40nM (Jurgen et al., 1995), did not cause any significant induction over a concentration range of 
O.OlpM-lOOOpM (Figure 5-5).
(viii) Bezafibrate and bromopalmitate were the only two compounds out of those that were tested 
to show p4Al(l 71/273)seap induction in the absence of co-transfected pSG5PPAR (Figure 5-6 and 
Figure 5-7). Figure 5-9 summarises the results of Figure 5-6 and Figure 5-7.
Figure 5-9. Summary of p4Al(171/273)seap Fold Inductions Observed in HepG2 Cells Co­
transfected with and without PPARa Expression Plasmid
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass - 3 pCHl 10 : 1 pSEAP2-promoter or 1 p4Al(171/273)seap : 1 pSG5PPAR or 1 pSG5. n = 8 
for each value. Each bar represents the mean fold induction by test compound as compared to 
solvent control.
208
6. Rat CYPlAl Reporter Gene Assay Results
6.1 Introduction
CYPlAl is highly inducible in many tissues, such as liver, skin, kidney and lung (Nebert and 
Gonzalez, 1987). The mechanism by which CYPlAl is induced by TODD is well understood and 
has been described previously in section 1.3.2.3.
It is critical that a new drug should be examined for its influence on cytochrome P450 enzyme 
systems, since these are the enzymes involved in the oxidative catabolism of most drugs and foreign 
chemicals (Parkinson, 1996a). Induction of P450 enzymes can result in deleterious drug 
interactions and/or an increased toxic response (Cholerton et a l, 1992). In addition to their 
influence on drug interactions and toxicity, certain cytochromes P450 are known to activate pro­
carcinogens into chemically and biologically reactive species (Gonzalez et a l, 1991). The 
carcinogens: benzo(a)pyrene, 2-amino-l-methyl-6-pheylimidazo-[4,5-b]pyridine and polyaromatic 
hydrocarbons are well known to be activated by CYPlAl (Lewis, 1997).
As described for rat CYP4A1 in Chapters 4 and 5, a sensitive, high-throughput reporter gene assay 
has been developed for the detection of CYPlAl inducing compounds. Transcriptional activation 
of the CYPlAl response element (see Figure 1-11) was investigated in HepG2 cells using the 
SEAP reporter gene construct plA l(-l/-l 171)seap (see Figure 2-5).
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6.2 Results
6.2.1 plA l(-1171/-l)seap Reporter Gene Activation by P-Naphthoflavone Is Due to 
the Presence of the C Y PlA l Response Element
plA l(-l/-l 171)seap was found to be transcriptionally activated specifically by p-naphthoflavone, 
see Figure 6-1. pSEAP2-promoter, the empty reporter vector minus the CYPlAl promoter, was 
not transcriptionally activated by an identical treatment with p-naphthoflavone (Figure 6-1).
Figure 6-1. Transcriptional Activation of plAl(-l/-1171)seap by lOpM p-naphthoflavone
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. The DNA mixture contained the following ratios of plasmid DNA by 
mass - 1 pCHllO :.l pSEAP2-promoter or 1 plAl(-l/-1171)seap. SEAP levels were normalised 
for transfection efficiency against p-galactosidase levels and their mean RLU values are given 
above each bar. n = 8 for each value, error bars show standard error of mean. Statistical 
significance was determined using one-way Anova with Bonferroni/Dunn post-hoc test. Significant 
induction by BNF treatment as compared to DMSO treatment is marked: *P<0.001.
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6.2.2 Specificity of Transcriptional Activation of plA l(-1171/-l)seap by the C Y PlA l 
Inducer P-Naphthoflavone in HepG2 Cells
An identical panel of cytochrome P450 inducers to those described in section 5.2.4 were tested to 
determine the specificity of the system for CYPlAl inducers. As expected neither PCN, DEX, 
ISN, PB nor clofibric acid exposure induced plAl(-l/-1171)seap reporter gene expression (Figure 
6-2). Significant induction of reporter gene expression was observed in response to the CYPlAl 
inducer (3-naphthoflavone (BNF) (Figure 6-2).
Figure 6-2. Specific Activation of CYPlAl Reporter Gene Transcription by BNF
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. The DNA mixture contained the following ratios of plasmid DNA 
by mass - 1 pCHllO :.l p lA l(-l/-l 171)seap. SEAP levels were normalised for transfection 
efficiency against P-galactosidase levels, n = 4 for each value, error bars show standard error of 
mean. Statistical significance was determined using one-way Anova with Bonferroni/Dunn post- 
hoc test. Significant induction by BNF treatment as compared to dmso treatment is marked: 
tP<0.05.
211
6.2.3 Dose-Response Study for p-Naphthoflavone Induction of CYPlAl-dependent 
Reporter Gene Transcription
The CYPlAl reporter gene construct was transcriptionally activated by 0.05pM-100pM BNF 
treatment over the concentration range tested (Figure 6-3). A maximum induction of 2.6-fold as 
compared to solvent control (DMSO) was achieved using lOpM BNF (Figure 6-3).
Figure 6-3. Transcriptional Activation of plAl(-l/-1171)seap by p-naphthoflavone
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. The DNA mixture contained the following ratios of plasmid DNA 
by mass - 1 pCHllO :.l p lA l(-l/-l 171)seap. SEAP levels were normalised for transfection 
efficiency against p-galactosidase levels, n = 8 for each value, error bars show standard error of 
mean. Statistical significance was determined using one-way Anova with Bonferroni/Dunn post- 
hoc test. Significant induction by p-naphthoflavone (BNF) treatment as compared to dmso 
treatment is marked; *P<0.001.
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6.2.4 Dextran Coated Charcoal (DCC) Treatment of Serum in HepG2 Cell Culture 
Media Increases Fold-Activation of C Y PlA l Reporter Gene
For transient transfections HepG2 cells were routinely cultured in media supplemented with 10% 
DCC-treated (see section 2.12.1) foetal bovine serum. Charcoal stripping of foetal bovine serum 
removes low-molecular weight lipophilic compounds from serum including hormones, retinoids 
and fatty acid ligands of nuclear receptor transcription factors (Ausubel et a l, 1996). Table 6-1 
shows that the transcriptional activation of plAl(-l/-1171)seap by lOpM BNF treatment in HepG2 
cells was increased when the cells had been cultured in media supplemented with DCC-treated 
serum, as compared to cells cultured in media supplemented with normal serum. The mean fold 
induction in response to lOpM BNF with DCC-treated serum is 2-fold greater than with untreated 
serum. The mean fold induction in response to lOpM a-NF [it has been reported that at low doses 
ANF antagonises CYPlAl induction, but at high doses ANF acts as a weak agonist (Kikuchi et a l, 
1998)] with DCC-treated serum is 1.4-fold greater than with untreated serum. Using cells cultured 
in media supplemented with DCC-treated serum the mean fold-induction in response to lOpM BNF 
is 4, the mean fold-induction in similarly treated cells in response to lOpM ANF is only 2.1.
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Table 6-1. Fold-induction of CYPlAl-dependent Reporter Gene Transcription is Higher 
When HepG2 Cells Have Been Cultured With DCC-Treated Serum Than With Untreated 
Serum
FOLD INDUCTION
lOpM p-naphthoflavone lOpM a-naphthoflavone
Normal serum DCC treated serum Normal serum DCC treated serum
x2.4 x3.2 X 1.5 X 1.8
x2 x4.5 xL 7 x2.2
X 1.6 x4.3 X 1.4 x2.2
Cells were seeded for transfection and transfected in media supplemented with either (a) 10% 
normal foetal calf serum or (b) 10% dextran coated charcoal (DCC) treated foetal calf serum. 
HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. DNA mixture contained the following ratios of plasmid DNA by 
mass -1 pCHllO :.l p lA l(-l/-l 171)seap. SEAP levels were normalised for transfection efficiency 
against p-galactosidase levels, n = 8 for each value. The results of three independent experiments 
are shown.
6.2.5 ANF and BNF Treatment of HepG2 Cells Transfected with plA l(-l/-1171)seap
Transfected HepG2 cells cultured in media supplemented with normal serum did not show any 
significant induction of reporter gene expression in response to ANF, over the range of 
concentrations tested (Figure 6-4). Similarly treated HepG2 cells cultured in media supplemented 
with DCC-treated serum showed a significant induction response to lOpM BNF treatment. This 
induction was reduced, although not significantly, by co-administration of 0.1 pM or IpM ANF. 
Co-administration of lOpM, 50pM or lOOpM ANF with lOpM BNF resulted in apparent higher 
fold-inductions (although not significant) than observed with lOpM BNF administration alone.
Transfected HepG2 cells cultured in media supplemented with DCC-treated serum showed 
significant induction of reporter gene expression in response to lOpM ANF. In similarly treated 
cells, the fold-activation of reporter gene transcription was apparently lowered (although not 
significantly) by co-administration of 0.1 pM ANF with lOpM BNF, as compared to lOpM BNF 
administration alone. Co-administration of IpM or lOpM ANF with lOpM BNF resulted in
214
apparently higher fold-inductions (although not significant) of reporter gene transcription than 
observed with lOpM BNF administration alone.
Figure 6-4. Agonistic and Antagonistic Effects of a-Naphthoflavone in HepG2 Cells Cultured 
in Media Supplemented with DCC Treated Serum
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. The DNA mixture contained the following ratios of plasmid DNA 
by mass - 1 pCHl 10 :.l pSEAP2-promoter or 1 p lA l(-l/-l 171)seap. SEAP levels were normalised 
for transfection efficiency against p-galactosidase levels and their mean RLU values are given 
above each bar. n = 8 for each value, error bars show standard error of mean. Statistical 
significance was determined using one-way Anova with Bonferroni/Dunn post-hoc test. Significant 
induction by chemical treatment as compared to dmso treatment is marked: *P<0.001, fP<0.05.
6.2.6 PD98059 Treatment of HepG2 Cells Transfected with plA l(-l/-1171)seap
PD98059, a flavonoid, is a specific inhibitor of the activation of mitogen-activated protein kinase 
kinase (MEK) both in vitro and in vivo (Dudley et ai, 1995; Alessi et a l, 1995). MEK forms part 
of the three-kinase unit that constitutes the mitogen-activated protein kinase (MAPK) cascade 
(Robinson and Cobb, 1997). The MAPK cascade is a major signalling system by which cells 
transduce extracellular signals into intracellular responses (Cano and Mahadevan, 1995). In a 
recent study, PD98059 was used as a tool to assess the relationship between the activation status of
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MEK/ERK (mitogen-activated protein kinase kinase/extracellular signal regulated kinase) and 
AHR function in the cell line MCFlOA-NeoT (Reiners et a l, 1998). This cell line was produced by 
transfection of an Ela-ra5 oncogene into the normal human breast epithelial MCFIOA cell line and 
results in constitutive activation of the MAPK cascade (Basolo et a l, 1991). The introduction of 
oncogenic ras into cultured human breast cells has been previously shown to suppress the 
transcriptional activation of several members of the Ah battery by TCDD (Reiners et al., 1997). 
Unexpectedly, Reiners et al (1998) found that treatment of MCFIOA and MCFIOA-Neo cultures 
with PD98059 before TCDD addition strongly suppressed the subsequent accumulation of CYPlAl 
mRNA. They also found that PD98059 inhibited the binding of TCDD to the AHR. The latter 
authors postulated that the reduced mRNA levels noted in TCDD-treated cultures reflect a 
PD98059-mediated suppression of the transcriptional activation of CYPlAl. The possibility that 
PD98059 is both an antagonist of AHR and an inhibitor of MEK has important implications in the 
interpretation of experimental data where PD98059 is used in signal transduction studies. For 
example, the results of a study using PD98059 suggest that in addition to fiinctioning as a positive 
effector of growth, stimulation of the MEK/MAPK pathway can result in an inhibition of CDK (cell 
cycle-dependent kinase) activity and cell cycle arrest (Pumiglia et a l, 1997). The AHR has been 
found to modulate cell cycle progression (Ma and Whitlock, 1996), so if PD98059 is an antagonist 
of AHR then the findings of Pumiglia et al could possibly be interpreted differently.
In order to examine the possibility that PD98059 suppresses transcriptional activation of CYPlAl a 
series of experiments were carried out, the results of which are shown in Figure 6-5. The 
modulation of plAl(-l/-1171)seap reporter gene expression by PD98059 in the presence and 
absence of BNF and ANF was examined, using cells cultured in media supplemented with either 
normal serum or with DCC-treated serum. Supplementation of culture media with complete serum 
is known to stimulate the MAPK cascade via membrane-bound receptors (Troppmair er al, 1994).
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Figure 6-5. Agonistic and Antagonistic Effects of the Mitogen-Activated Protein Kinase 
Kinase Inhibitor PD98059
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(a) HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method
(2) described in section 2.12.2.4. The DNA mixture contained the following ratios of plasmid 
DNA by mass - 1 pCHllO :.l pSEAP2-promoter or 1 plAl(-l/-1171)seap. SEAP levels were 
normalised for transfection efficiency against p-galactosidase levels and their mean RLU values are 
given above each bar. n = 8 for each value, error bars show standard error of mean. Statistical 
significance was determined using one-way Anova with Bonferroni/Dunn post-hoc test. Significant 
induction by chemical treatment as compared to dmso treatment is marked: *P<0.001, fP<0.05. 
Significant reduction in reporter gene expression by PD treatment as compared to lOpM BNF 
treatment is marked: #P<0.05.
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(b) HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method
(2) described in section 2.12.2.4. The DNA mixture contained the following ratios of plasmid 
DNA by mass - 1 pCHllO :.l pSEAP2-promoter or 1 plAl(-l/-1171)seap. SEAP levels were 
normalised for transfection efficiency against P-galactosidase levels and their mean RLU values are 
given above each bar. n = 8 for each value, error bars show standard error of mean. Statistical 
significance was determined using one-way Anova with Bonferroni/Dunn post-hoc test. Significant 
induction by drug treatment as compared to dmso treatment is marked: *P<0.001, fP<0.05. 
Significant reduction in reporter gene expression by PD treatment as compared to lOpM ANF 
treatment is marked: #P<0.05.
The results shown in Figure 6-5 indicate that PD98059 significantly reduces CYPlAl-dependent 
reporter gene transcription. 1 pM PD98059 was observed to significantly reduce the
transcriptional activation of CYPlAl-dependent reporter gene expression by lOpM BNF, in cells 
cultured in complete serum supplemented media (Figure 6-5a). lOpM PD98059 was shown to 
significantly reduce the transcriptional activation of CYPlAl-dependent reporter gene expression 
by lOpM ANF, in cells cultured in DCC-treated serum supplemented media (Figure 6-5b). 
Although 0.1 pM and 1 pM ANF treatment did appear to reduce CYPlAl-dependent reporter gene 
expression, the data was not statistically significant (Figure 6-4). At a high concentration (lOOpM) 
PD98059 was observed to significantly induce CYPlAl reporter gene transcription, 1.7-fold in
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cells cultured in complete serum supplemented media, and 2.5-fold in cells cultured in DCC-treated 
serum supplemented media (Figure 6-5a).
6.2.7 9-cis Retinoic Acid Treatment of HepG2 Cells Transfected with p lA l(-l/-  
1171)seap
IpM 9-cis retinoic was not observed to significantly induce CYPlAl-dependent reporter gene 
transcription in cells cultured in media supplemented with either normal serum or with DCC-treated 
serum (see Figure 6-6).
Figure 6-6. Effect of 9-cis Retinoic Acid on CYPlAl-dependent Reporter Gene Transcription 
in HepG2 Cells
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. The DNA mixture contained the following ratios of plasmid DNA 
by mass -1 pCHl 10 :.l pSEAP2-promoter or 1 p lA l(-l/-l 171)seap. SEAP levels were normalised 
for transfection efficiency against p-galactosidase levels and their mean RLU values are given 
above each bar. n = 8 for each value, error bars show standard error of mean. Statistical 
significance was determined using one-way Anova with Bonferroni/Dunn post-hoc test. Significant 
induction by chemical treatment as compared to dmso treatment is marked: *P<0.001, "t"P<0.05.
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6.2.8 Epidermal Growth Factor Treatment of HepG2 cells Transfected with p lA l(-  
l/-1171)seap
In adult rat hepatocytes epidermal growth factor (EOF) has been shown to activate the ERK 
pathway (Robinson and Cob, 1997). Supplementation of culture media with 20pM EOF did not 
produce any significant effect on CYP1A 1 -dependent reporter gene transcription (see Figure 6-7).
Figure 6-7. Effect of Epidermal Growth Factor Supplementation on CYPlAl-dependent 
Reporter Gene Transcription in HepG2 Cells
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HepG2 cells were transfected by calcium phosphate mediated DNA transfection using method (2) 
described in section 2.12.2.4. The DNA mixture contained the following ratios of plasmid DNA 
by mass - 1 pCHl 10 :.l pSEAP2-promoter or 1 p lA l(-l/-l 171)seap. SEAP levels were normalised 
for transfection efficiency against p-galactosidase levels and their mean RLU values are given 
above each bar. n = 8 for each value, error bars show standard error of mean. Statistical 
significance was determined using one-way Anova with Bonferroni/Dunn post-hoc test. Significant 
induction by BNF treatment as compared to dmso treatment is marked: *P<0.001.
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6.3 Conclusions
(i) The empty reporter vector pSEAP2-promoter was not activated by p-naphthoflavone in HepG2 
cells. The introduction of the 1171bp element from the rat CYPlAl promoter resulted in a 2.5-fold 
induction of reporter gene expression by lOpM p-naphthoflavone treatment in ElepG2 cells 
transfected withplAl(-l/-1171)seap (Figure 6-1).
(ii) plAl(-l/-1171)seap reporter gene expression was shown to be induced by the CYPlAl 
inducer p-naphthoflavone specifically, at least in the panel of cytochrome P450 inducers that were 
tested (Figure 6-2).
(iii) Over the concentration range that was tested, plAl(-l/-1171)seap reporter gene expression 
was found to be significantly activated by P-naphthoflavone at concentrations of 0.05-100pM. 
Maximal induction was observed with a lOpM P-naphthoflavone treatment. Doses of 50pM and 
lOOpM P-naphthoflavone produced lower fold-inductions than at lOpM treatment, presumably due 
to cytotoxicity (Figure 6-3).
(iv) Fold-activation of plAl(-l/-1171)seap reporter gene expression in response to both p- 
naphthoflavone and a-naphthoflavone treatment was found to be elevated in HepG2 cells that had 
been cultured in media supplemented with DCC-treated serum, as compared to cells cultured in 
media supplemented with whole serum (Table 6-1).
(v) a-naphthoflavone was shown to significantly activate CYPlAl reporter gene transcription in 
HepG2 cells cultured in media supplemented with DCC-treated serum but not in media 
supplemented with normal serum. Co-administration of a range of a-naphthoflavone 
concentrations with lOpM p-naphthoflavone was not shown to significantly reduce the p- 
naphthoflavone induction response (Figure 6-4).
2 2 1
(vi) IpM PD98059 was shown to significantly reduce the transcriptional activation of CYPlAl- 
dependent reporter gene expression by lOpM p-naphthoflavone in HepG2 cells cultured in media 
supplemented with complete serum, but not in cells cultured in media supplemented with DCC- 
treated serum (Figure 6-5(a)). lOpM PD98059 was shown to significantly reduce the 
transcriptional activation of CYP 1A1 -dependent reporter gene expression by lOpM a- 
naphthoflavone treatment only in HepG2 cells cultured in media supplemented with DCC-treated 
serum (Figure 6-5(b)).
(vii) High PD98059 concentrations (lOOpM) were shown to significantly induce CYPlAl reporter 
gene transcription in HepG2 cells cultured in media supplemented with either complete serum or 
with DCC-treated serum (Figure 6-5(a)).
(viii) IpM 9-cis retinoic acid was not shown to significantly induce CYPlAl reporter gene 
transcription in HepG2 cells cultured in media supplemented with either normal serum or with 
DCC-treated serum (Figure 6-6)
(ix) 20pM EGF did not significantly modulate CYPlAl reporter gene expression in HepG2 cells 
cultured in media supplemented with either complete serum or DCC-treated serum (Figure 6-7).
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7. Discussion
7.1 Introduction
The liver microsomal cytochrome P450 enzymes that are involved in xenobiotic biotransformation 
reactions belong to three main P450 families, namely, CYPl, CYP2, and CYP3. Liver microsomes 
also contain P450 enzymes from the CYP4 family, enzymes which metabolise several fatty acids 
and eicosanoids but relatively few xenobiotics (Josephy, 1997; Gonzalez, 1992). Induction of 
cytochrome P450 activity by a xenobiotic can result in the increased metabolism of a second 
xenobiotic, if this second compound is a drug then the therapeutic effect of this drug may be 
decreased. An exaggerated pharmacological or toxicological response to a particular xenobiotic 
may be produced on exposure to a compound that inhibits cytochrome P450 (Cholerton et al., 
1992). It is therefore of great importance that drugs and other xenobiotics are assessed for their 
potential to induce or inhibit cytochrome P450, in order to predict or explain the following clinical 
or toxicological observations: (i) pharmacokinetic tolerance, (ii) drug-interactions, (iii) increases in 
liver weight and/or proliferation of the endoplastic reticulum or peroxisomes, and (iv) the formation 
of liver and thyroid tumours (Parkinson, 1996a).
Routinely P450 enzyme induction has been evaluated in laboratory animals using 14-day toxicity 
studies. In such studies the xenobiotic is administered to laboratory animals which are then killed and 
the organs of interest isolated. Levels of liver microsomal cytochrome P450 and other enzymes are 
determined, and compared to the enzyme levels of delivery vehicle control animals (Parkinson, 
1996a). The objective of this current project was to use reporter gene technology to develop rapid 
high-throughput in vitro assays, that could be used to screen large numbers of compounds, consuming 
only small quantities of test compound. Using these systems the potential of a compound to modulate 
CYP4A1 and CYPlAl expression levels. This thesis describes the development and validation of 
these reporter gene assays, and discusses the advantages and drawbacks of such systems.
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7.2 Development of In Vitro Methodoligies for the Investigation of Rat 
Liver Cytochrome P450 Gene Regulation: Implications for Toxicological 
Risk Assessment
7.2.1 Reporter Gene Assay Development
7.2,L1 Choice of Cell Line For Transient Transfections
The choice of cell line for the CYP4A1 and CYPlAl in vitro reporter gene assays was perhaps one 
of the most critical parameters in the development of these systems. Responsive elements isolated 
from the promoter regions of the rat CYP4A1 and rat CYPlAl genes were used for the 
construction of the reporter vectors. Initially, it was hoped that a rat hepatoma cell line could be 
used for analysing reporter gene transcription with these constructs and hence maintain any species 
specific responses. Many attempts were made to transiently transfect the rat hepatoma cell line, 
H4IIEC3, using both calcium-phosphate- and liposome-mediated methods for DNA transfection. 
Although this cell line had been used with success for reporter gene studies with the acyl CoA 
oxidase promoter (McNae, 1994) and for CYPlAl regulation studies (Fujii-Kuriyama et a l, 1992 
and Sterling et al, 1993), in my hands the transfection efficiency was found to be too low for such 
experiments (see section 4.2). The H4IIEC3 cells, obtained from ECACC, were of unknown 
passage number, these cells may therefore have been highly transformed and hence unsuitable for 
transfection studies.
Previously, Chinese hamster ovary (CHO) cells have been stably transfected with a reporter gene 
construct containing a PPRE and with expression vectors for PPAR and RXRa (Hoffmann and 
Tynes, 1995). A selected stable transformant was selected and used to produce a clonal cell line 
which was shown to be responsive to clofibric acid. In view of the results obtained by Hoffmann 
and Tynes, the CHO cell line was also tested for transient transfection efficiency. As with the
224
H4IIEC3 cell line the transfection efficiencies obtained were considered to be too low for transient 
transfection studies (see section 4.2).
Two hepatoma cell lines had been widely used in reporter gene studies on the DNA response elements 
and trans-QcXmg factors involved in the transcriptional response to peroxisome proliferators, namely the 
mouse Hepalclc? and the human HepG2 cell lines. Hepalclc? cells have been used in the 
identification and characterisation of peroxisome proliferator response elements (PPRE’s) in the 5'- 
fianking region of the acyl CoA oxidase gene (Tugwood et al, 1992; Bardot et al., 1993) and upstream 
of the CYP4A1 gene (Aldridge et al, 1995). HepG2 cells had been used in similar gene transfer studies 
with responsive elements isolated from the promoter regions of the CYP4A6 (Meurhoff et al, 1992) 
and peroxisomal bifunctional enzyme genes (Bardot et al, 1993, Bardot et al., 1995). A number of 
studies on the transcriptional activation of CYPlAl and on the function of the aromatic hydrocarbon 
receptor have also used hepalclc? (Fujisawa-Sehara et al, 1987; Fujii-Kuriyama et al, 1992; Elarper et 
al, 1994; Riddick et al, 1994) and HepG2 cells (Hines et al, 1988; Fukada et al, 1992; Sterling et al, 
1992; Boucher et al, 1993; Sterling et al, 1993; Boucher and Hines, 1995). Hepalclc? cells have been 
well characterised for their inducible aryl hydrocarbon hydroxylase activity (Hankinson, 1991). HepG2 
cells had also been shown to possess high bezo[a]pyrene-metabolising activity (Diamond et al, 1980) 
and to conserve the receptor mechanism regulating CYPlAl activity (Roberts et al, 1990). Using a 
calcium phosphate mediated DNA transfection method for the HepG2 cells and a liposome mediated 
DNA transfection method for Hepalclc? cells, both cell lines were determined to transfect with a 
suitably high efficiency (see section 4.2). HepG2 cells were chosen for use in the development of the 
CYP4A1 and CYPlAl reporter gene assays for the following reasons: (i) they transfected with a higher 
effeciency than Hepalclc? cells, (ii) DNA transfection mediated by calcium phosphate is significantly 
less expensive and more rapid than liposome mediated transfection and (iii) the high levels of reporter 
gene proteins produced by the HepG2 cells and the use of calcium phosphate mediated DNA 
transfection was better suited for development of high-throughput assays.
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7.2.1.1.1 Optimisation of Calcium Phosphate Mediated DNA Transfection In HepG2 Cells
The HepG2 cells used for transfection optimisation and all subsequent experiments all originated 
from the same stock of cells that had been cultured in large quantity on receipt from ECACC; these 
cells had then been pooled and stored in aliquots in liquid nitrogen. It was hoped that by using cells 
from the same pooled culture and hence at the same passage number, that any variation in response 
due to the cells could be minimised.
Initially, calcium phosphate mediated transfection of plasmid DNA into HepG2 cells was carried 
out using the method of Sambrook et al. (1989), on cells grown in 6-welI plates (see section 4.3). 
HepG2 cells were transfected with a plasmid that encoded the enzyme P-galactosidase and hence 
transfection efficiency was monitored by histochemical staining or by determination of enzyme 
activity (see section 2.12.4).
For reproducible and high transfection efficiency it was found that the method of plasmid DNA 
purification was of great importance. In agreement with the work of Weber et al (1995), a h i^ e r  
transfection efficiency was obtained using DNA purified by an anion-exchange chromatography 
method than by silica-based DNA adsorption (see section 2.5.7). This has been correlated to the 
higher levels of impurities that are found in DNA prepared by silica-based DNA adsorption and to 
the lipopolysaccharide content of these preparations (Weber et a l, 1995; Weber et a l, 1996).
The reproducibility and efficiency of transfection in HepG2 cells, using calcium phosphate-DNA 
co-precipitation, was further improved by optimisation of the following parameters: (i) temperature 
at which the precipitation reaction was carried out, (ii) DNA concentration of the precipitate and
(iii) precipitate formation reaction time. A very effective precipitate for DNA transfection was 
produced using only 25 pg of DNA/ml precipitate, with a short precipitate formation time of 1 
minute, at a temperature of 4°C (see section 4.3.6). This optimised method of forming the
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transfection precipitate was readily reproducible, quicker to perform than the standard method (see 
section 2.12.2.4) and resulted in higher transfection efficiencies in HepG2 cells.
The application of either DMSO or glycerol shocks to HepG2 cells incubated with transfection 
precipitate did not increase transfection efficiency as has been reported for other cell lines (Beckler 
e ta l, 1996).
7.2.1.1.2 Characterisation of HepG2 Cells
The transcriptional activation of the reporter construct p4Al(171/273)GCAT was investigated in 
HepG2 cells (see section 4.4) and compared to results of studies using this construct in Hepalclc? 
cells (Aldridge et al, 1995). In these experiments p4Al(171/273)GCAT was co-transfected with and 
without expression plasmids encoding for PPARa and RXRa. The pattern of induction in transfected 
HepG2 cells, in response to Wy-14,643, 9-cis retinoic acid and Wy-14,643 in combination with 9-cis 
retinoic acid, was found to be qualitatively almost the same as that seen in Hepalclc? cells. The 
major difference in induction response was observed in cells co-transfected with the PPARa 
expression plasmid and p4A1(171/273)GCAT. In HepG2 cells the presence of exogenous PPARa in 
the absence of added receptor ligands resulted in a 3.8-fold induction of transcription as compared to 
the control (transfected with the empty expression vector, pSG5). In Hepalclc? cells, co-transfection 
of the PPARa expression vector with p4A1(171/273)GCAT resulted in only a 1.5-fold higher level of 
activation than with co-transfection of PSG5. These results suggest that the HepG2 cells or their 
culture media contain higher levels of natural activators of PPAR/RXR heterodimers than Hepalclc? 
cells. The foetal calf serum used to supplement the media for these experiments would have 
originated from different sources and also explain the differences in response between the HepG2 and 
the Hepalclc? cells. Although the media used for the experiments in HepG2 cells contained foetal 
calf serum that had been treated by charcoal stripping, to remove hormones, fatty acids and nuclear 
receptor ligands, it is unlikely that all of these activating substances were removed completely. The
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particular batch of charcoal stripped serum used for an experiment may be result in a variation in 
response and in background activation of reporter gene transcription.
The peroxisome proliferators nafenopin, ciprofibrate and clofibric acid were tested for 
transcriptional activation of the p4Al(171/273)GCAT construct in HepG2 cells, in order to 
determine that the transcriptional activation response was not specific for Wy-14,643 and 9-cis 
retinoic acid. A statistically significant induction response to each of these compounds was 
achieved in transfected HepG2 cells (see section 4.4.2; Giddings et al., 1997). The element isolated 
from the promoter of the CYP4A1 gene was shown to be responsive to a number of peroxisome 
proliferators and hence was suitable for use in the development of a high-throughput assay to detect 
such compounds.
In the absence of co-transfected PPARa expression vector, the p4Al(171/273)GCAT showed no 
significant activation by Wy-14,643 in HepG2 cells (see Figure 4-7). Similarly treated cells that 
had been co-transfected with a PPARa expression vector showed a statistically significant 
activation of reporter gene expression. This would suggest that the HepG2 cells contained very 
little if any endogenous PPARa or that PPARa expressed by these cells is unable to ^mw-activate 
via the CYP4A1 promoter response element. The requirement for co-transfection of a PPARa 
expression vector is not unexpected, because HepG2 cells are a human hepatoma cell line and as 
discussed in section 1.3.2.2, humans are refractory in their response to peroxisome proliferators. 
PPARa mRNA and protein expression in liver is 10-fold lower in humans as compared to rats and 
mice. Differential splicing has been found to contribute to the low abundance of PPARa in human 
liver and leads to frequent deletion of exon 6, resulting in a truncated protein that lacks the carboxy 
terminal extension. This carboxy terminal extension is required for PPRE binding, for 
heterodimerisation with RXR, and for transactivation fimction (Hsu et al., 1998). In order to 
determine whether HepG2 cells had lost PPARa expression and to determine if they expressed the 
PPAR subtypes (3 and y, SDS-PAGE and Western blots were carried out using HepG2 cell lysates
228
and homogenates. Despite considerable efforts to optimise the Western blot procedure, the results 
of these experiments were most unsatisfactory and the levels of the PPAR sub-types in HepG2 cells 
remains undetermined. The major problem with the Western blotting seemed to be the lack of 
specificity shown by the antibodies. The antibodies that were used were obtained from Santa Cruz 
Biotechnology Inc. Other researchers have reported a lack of specificity with antibodies supplied 
by Santa Cruz Biotechnology Inc. (Dr Mark Hudson and Dr Matthew Golding, personal 
communication). In future, it may be possible to obtain better results if the HepG2 cell extracts are 
immunoprecipitated prior to SDS-PAGE and Western blotting.
HepG2 cells have previously been shown to possess high bezo [ajpyrene-metabolising activity 
(Diamond et a l, 1980) and to conserve the receptor mechanism regulating CYPlAl activity 
(Roberts et a l, 1990). Ethoxyresorufin (9-deethylation activity has also been reported to be induced 
in HepG2 cells by benz(a)anthracene (Grant et a l, 1988) and by p-naphthoflavone (Wang et a l, 
1997). Ethoxyresorufin 0-deethylation activity induced by p-naphthoflavone was investigated in 
our HepG2 cell bank, in order to determine whether these cells expressed all the necessary factors 
required for CYPlAl induction. EROD activity was found to be undetectable in untreated HepG2 
cell homogenates, in agreement with the results of Roberts et a l, 1990. P-naphthoflavone 
treatment was found to induce EROD activity; indicating that our HepG2 cells contained functional 
AH receptor and other factors, required for CYPlAl induction and rrawi'-activation of CYPIAI- 
dependent reporter gene activation. Induced EROD activity was only detected in HepG2 cell 
homogenates and not lysates, illustrating that the method of sample preparation is critical in 
retaining particular enzymatic activities.
7.2.1.1.3 High-Throughput Transient Transfection of HepG2 Cells
Initially chloramphenicol acetyl transferase (CAT) reporter gene vectors were used in transient 
transfections of HepG2 cells, along with a co-transfected p-galactosidase expression plasmid to
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enable normalisation for transfection efficiency. CAT levels were measured by ELISA and p- 
galactosidase levels by colorimetric assay (see section 2.12.4), these assays requiring a minimum of 
300pl of cell lysate per transfection. This required transfections to be carried out in plates with a 
minimum size of 35mm diameter, in order to produce enough HepG2 cell lysate for the assays. 
Transfections carried out in 35mm dishes consumed considerable amounts of plasmid DNA, media, 
and dosing compounds, and were time consuming to carry out and harvest. It was therefore 
desirable that the transfections should be miniaturised in order to reduce costs, increase sample 
throughput, and to use minimal quanities of test compound. The requirement for cell lysate was 
reduced by using a new chemiluminscent assay to determine p-galactosidase levels (see section 
2.12.4.5), which can determine enzyme activity using as little as lOpl of cell lysate. The 
development of chemiluminescent 1,2-dioxetane substrates for p-galactosidase has greatly 
improved the utility of lacZ as a transcriptional reporter by increasing the sensitivity of the assay 
and extending the dynamic range of detection. Using a luminometer for chemiluminescence signal 
detection, the assay is 50,000-fold more sensitive than the colorimetric assay (Ausubel et a l, 1996). 
A chemiluminscent substrate was also used to replace the colorimetric substrate in the CAT ELISA 
and this improved the dynamic range and sensitivity of the assay but a considerable amount of cell 
lysate was still required. In order to overcome this problem the reporter gene used was changed 
fi*om CAT to one encoding secretory alkaline phosphatase (SEAP). The SEAP gene encodes a 
truncated form of human placental alkaline phosphatase, which lacks a critical membrane anchoring 
domain, thereby allowing the protein to be efficiently secreted Jfrom transfected cells (Cullen and 
Malim, 1992). SEAP has several advantages over other reporter genes: (a) the kinetics of gene 
expression can be easily studied by repeated collection of medium from the same cultures, (b) 
transfected cells are not disturbed during measurement of SEAP activity and remain intact for 
further analysis (c) background from endogenous alkaline phosphatase activity in the culture 
medium is almost eliminated by inhibitor and heat treatment (see section 2.12.4.7), and (d) sample 
collection and assay can be automated using 96-well plates. SEAP levels were measured in 15pi
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media samples using the chemiluminscent alkaline phosphatase substrate 1,2-dioxetane CSPD. 
Dephosphorylation of CSPD results in a sustained “glow”-type luminescence that remains constant 
for up to 60 minutes (Bronstein et a l, 1994b). This chemiluminescence based SEAP assay has 
greater sensitivity and an increased linear dynamic range of detection than the original colorimetric 
procedure, which used the alkaline phosphatase substrate /?-nitrophenyl phosphate (Cullen and 
Malim, 1992).
By using the SEAP reporter gene instead of CAT and with chemiluminescence determination of 
both SEAP and p-galactosidase levels, it was possible to transfect HepG2 cells in 96-well culture 
plates and to rapidly measure SEAP and p-galactosidase levels in 96-well plates. The use of 96- 
well plates allowed for a greater throughput of samples, reduced the amount of media/reagent 
needed per sample tested and also required smaller quantities of test compound.
7.2.2 Detection of Peroxisome Proliferators Using CYP4A1 Reporter Gene Assay
Treatment of male rats with clofibric acid results in induction of CYP4A1, CYP4A2, and CYP4A3 
levels by up to 40-fold, as determined by measurement of lauric acid 12-hydroxylation (Sundseth 
and Waxman, 1991). CYP4A2 is expressed in the liver and kidney of male rats only, CYP4A3 is 
expressed in the same organs as CYP4A2 but is not sex-specific, and CYP4A1 is specifically 
expressed in the liver (Parkinson, 1996a). CYP4A enzymes are induced by a structurally diverse 
range of chemicals that include perfiuorodecanoic acid, phthalate ester plasticisers, 2,4- 
dichlorophenoxyacetic acid, ciprofibrate and other hypolipidaemic drugs, aspirin and other 
NSAIDS, nicotinic acid, dehydroepiandrosterone sulfate, and leukotriene receptor antagonists (see 
section 1.3.2.2; Parkinson, 1996a). Compounds that induce CYP4A enzymes share the common 
feature, namely that on administration to rats or mice they cause proliferation of liver peroxisomes. 
Chronic exposure to these compounds, known as peroxisome proliferators (PPs), leads to the 
development of liver tumours (see section 1.3.2.2.1; Rao and Reddy, 1991). The molecular
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mechanisms that lead to hepatocarcinogenesis have not yet been determined, it is therefore of great 
interest to pharmaceutical and chemical industries that they should be able to readily identify PPs. 
As the majority of PPs are non-genotoxic carcinogens they cannot be identified using standard 
genotoxicity tests.
The initial aim of my work was to develop and validate an in vitro assay that could detect whether a 
compound is a peroxisome proliferator. This was achieved using a peroxisome proliferator response 
element that had been previously isolated from the CYP4A1 gene promoter (Aldridge et a l, 1995). 
Reporter gene constructs containing the peroxisome proliferator response element (see Figure 1-8) 
were transiently transfected into HepG2 cells along with an expression vector for p-galactosidase, to 
allow for normalisation of transfection efficiency, and an expression vector for the transcription factor 
PPARa. As discussed above in section 7.2.1.1.2 the CAT reporter gene was initially used for these 
transfection studies and in order to increase the sample throughput of the system this was changed to 
use a SEAP reporter gene. Even though the expressed products encoded by these reporter genes are 
quite different, SEAP being secretory in nature and CAT remaining within the cells, the 
transcriptional responses to PPs were not changed (see section 5.2). In the range of compounds 
tested, p4A1(171/273)seap reporter gene expression was shown to be specifically induced by 
peroxisome proliferators and not by a number of other cytochrome P450 inducing agents (see section 
5.2). Fold activations were observed to vary between experiments and in order to rank the 
peroxisome proliferators in order of their ability to activate CYP4A1-dependent reporter gene 
transcription, fold-inductions were expressed as a percentage of a control. The standard inducer used 
was Wy-14,643, at a concentration of lOOpM. Out of the nine compounds tested the system ranked 
the peroxisome proliferators in the following order: linoleic acid < clofibrate < ETYA < clofibric acid 
< Wy-14,643 < ciprofibrate < bromopalmitate < nafenopin / bezafibrate (see Figure 5-8). The system 
was able to identify clofibrate as a PP, this compound itself is not a PP, but is the parent compound of 
the PP clofibric acid (Lake, 1995). The sytem did however elicit a response of equal magnitude to 
that produced by lOpM Wy-14,643, to 9-cw retinoic acid, a compound that is not a peroxisome
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proliferator (see Figure 4-7). This response is probably due to the formation of PPAR/RXR 
heterodimers and is absent in cells that have not been co-transfected with a PPARa expression vector. 
In order to distinguish between peroxisome proliferators and retinoic acid analogues it should be 
possible to co-transfect the CYP4A1 reporter gene construct with RXR into HepG2 cells; an 
induction of transcription should only occur on exposure of the cells to a retinoic acid analogue and 
not to a PP (see Figure 4-7).
BRL49653, an anti-diabetic thiazolidinedione that binds to PPARy with a IQ of approximately 40nM 
(Jurgen et aL, 1995), did not produce transcriptional activation of the CYP4A1 reporter gene 
construct in the presence of co-transfected PPARa in HepG2 cells (see Figure 5-5). This would 
suggest that the HepG2 cells do not express either sufficient PPARy, or that they express non­
functional PPARy, in order to form PPAR/RXR heterodimers. This result is not surprising since 
PPARy has been found to be expressed predominantly in adipose tissue and the immune system, at 
least in the rat (Braissant et a l , 1996).
The panel of nine PPs were also tested in HepG2 cells that had been co-transfected with and without 
the PPAR expression plasmid (see section 5.2.6). Out of this panel of compounds, only two were 
observed to induce reporter gene transcription in the absence of co-transfected PPARa expression 
vector, these were bezafibrate and bromopalmitate. As compared to solvent control, bezafibrate 
induced CYP4A1-dependent reporter gene transcription by 1.84-fold in the presence of exogenous 
PPARa, and by 1,58-fold in the absence of exogenous PPARa. Surprisingly, bromopalmitate 
produced a very high induction of reporter gene transcription in the absence of co-transfected PPAR 
expression vector, of the order 3.2-fold. The fold-induction by bromopalmitate was observed to be 
considerably lower in the presence of co-transfected PPARa expression vector than in its absence, 
with an activation of 2.4-fold. This would suggest that bromopalmitate and bezafibrate are activators 
of PPARp, as the HepG2 cells did not respond to the PPARy ligand BRL49653. It would also suggest 
that either the relative receptor sub-type levels affect the activation response (signalling cross-talk), or
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that perhaps PPARp/RXR heterodimers activate the CYP4A1 reporter construct more strongly than 
PPARo/RXR heterodimers. Using a co-activator-dependent receptor ligand assay (CARLA), 
bezafibrate has been identified as a very strong xPPARj3 ligand and has been shown to strongly 
activate CYP4A6-dependent and CYP4A1-dependent reporter gene transcription (Krey et al, 1997, 
Juge-Aubry et al, 1997). The binding affinity for the PPAR receptor sub-fypes by bezafibrate and 
brompalmitate could be determined by radioligand binding assays.
Recently there has been a great deal of interest in PPAR receptor sub-type ligands, not only for 
their detrimental effects as in the case of peroxisome proliferation but for their potential therapeutic 
effects. Many of the genes regulated by these ligand-activated transcription factors are involved in 
controlling lipid metabolism. PPARs have therefore been identified as molecular targets for the 
development of drug therapy for disorders such as diabetes, dyslipidaemia and obesity (Willson and 
Wahli, 1997). Leukotriene B4 (LTB4) has also been identified as a PPARa ligand, implicating this 
transcription factor in the control of inflammation (Serhan, 1996; Devchand et ah, 1996). A great 
deal of effort has been made to identify PPAR ligands and new screening technology has been 
developed. The CARLA system is able to detect the ligand-dependent binding of the co-activator 
steroid receptor co-activator protein (SRCl) to PPAR (Krey et a l, 1997). This system is successful 
in that all the compounds that were tested and found to induce PPAR-SRCl interaction, have also 
been shown to be active in mediating transcriptional activation. However, CARLA failed to show 
that bezafibrate, ciprofibrate and nafenopin induce strong PPAR-SRCl interactions, even though in
vitro they each strongly activate all three of the PPAR receptor subtypes (in HeLa cells). The CYP4A1
reporter system described herein was able to identify bezafibrate, ciprofibrate and nafenopin 
as activators of PPAR-mediated CYP4A1 transcription.
At the time that the CYP4A1-dependent reporter gene assay described in this thesis (also see paper by 
Giddings et al, 1997) was being developed, a similar system was under development for the detection 
of peroxisome proliferators using a reporter construct derived from the rat acyl-CoA oxidase promoter 
(Lee et al, 1997). In this system, a region of the rat acyl CoA oxidase promoter (-1273/-471) had 
been cloned into a CAT reporter gene construct and stably transfected into the rat hepatoma cell line
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H-4-II-E. This system was able to detect a number of peroxisome proliferators and showed no 
response to several genotoxic carcinogens used as negative controls. These stably transfected cells 
also showed a response to 9-cis retinoic acid, as was observed with the transiently transfected HepG2 
cells. With the use of stably transfected cells the time required to carry out the assay was only 48 
hours. However, the assay was limited by the use of a CAT reporter gene. Determination of CAT 
levels was carried out by CAT ELISA, an expensive and relatively time consuming assay.
7.2.3 Detection of C Y P lA l Inducing Compounds Using C Y P lA l Reporter Gene 
Assay
Treatment of rats with 3 -methy Icholanthrene results in an induction of CYPlAl and CY1A2 levels 
in the liver by a factor of over 20-fold. Liver microsomes from untreated rats contain virtually 
undetectable levels of CYPlAl. CYPIA enzymes are induced not only by 3-methyIcholanthrene 
and other polycyclic aromatic hydrocarbons but by flavones (e.g. p-naphthoflavone), 
polyhalogenated aromatic hydrocarbons (e.g. TCDD), and by certain drugs and food additives (see 
section 1.3.2.2). Induction of CYPlAl involves not only transcriptional activation of the CYPlAl 
gene but also stabilisation of the messenger RNA and newly synthesised protein. In the absence of 
an inducer, CYPlAl transcription is suppressed by a repressor protein (Parkinson, 1996b). 
CYPlAl is not only involved in drug interactions and toxic responses, but also is well known to be 
involved in the activation of pro-carcinogens into reactive species (see section 1.3.2.3). It is 
therefore of interest to the pharmaceutical and chemical industries that CYPlAl inducing agents 
can be readily identified.
Described in this thesis is the development and validation of an assay for the detection of CYPlAl 
transcription modulating compounds using a SEAP reporter construct containing the first 1171bp of 
the CYPlAl promoter (see Figure 1-11). As endogenous CYPlAl activity had been shown to be 
inducible in HepG2 cells by P-naphthoflavone (see section 4.4.4), the CYPlAl reporter construct
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was transiently transfected into HepG2 cells without any additional transcription factors. The 
CYPlAl reporter gene construct was shown to be specifically activated by the CYPlAl inducer p- 
naphthoflavone, by up to 4.5-fold, and was not activated by a number of other cytochrome P450 
inducers (see section 6.2.2).
The fold-activation of the CYPlAl reporter gene construct was found to be higher in HepG2 cells 
that had been cultured media supplemented in DCC-treated serum (charcoal stripped serum), as 
compared to cells that had been cultured in media supplemented with untreated serum. The 
normalised relative light unit values produced by the solvent control was not significantly lower in 
cells grown in media with DCC treated serum compared to cells grown in media with untreated 
serum. It would appear that inhibitory factor/factors were removed from the serum by charcoal 
stripping (seeTable 6-1).
a-naphthofiavone was shown to significantly activate CYPlAl reporter gene transcription in 
HepG2 cells cultured in media supplemented with DCC-treated serum but not in media 
supplemented with normal serum. Co-administration of a range of a-naphthofiavone 
concentrations with lOpM p-naphthoflavone was not shown to significantly reduce the 
transcriptional activation induced by p-naphthoflavone treatment. It was expected that at some 
concentrations a-naphthofiavone would significantly reduce the activaton of transcription produced 
by p-naphthoflavone treatment; as it has been reported that at low doses, a-naphthofiavone 
antagonises CYPlAl induction. Although at high doses a-naphthofiavone has been observed to act 
as a weak agonist of the AH receptor (Kikuchi et a l, 1998). It may be that the dosing schedule of 
the HepG2 cells was poorly designed, instead of co-administration of the compounds it may have 
been better to administer a-naphthoflavone first followed by p-naphthofiavone after a suitable 
incubation period. This may have allowed the a-naphthoflavone to bind AH receptor first and 
block p-naphthoflavone binding later.
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A functional retinoid responsive element has been recently characterised, located at -454bp in the 
human CYPlAl promoter. IpM 9-cis retinoic acid was not shown to significantly induce rat 
CYPlAl reporter gene transcription in HepG2 cells cultured in media supplemented with either 
untreated serum or with charcoal stripped serum. To fully investigate whether the CYPlAl 
reporter construct does contain a retinoid response element it would be necessary to carry out 
transfections with and without an expression plasmid for RXR. Cells would need to be dosed with 
a range of concentrations of 9-cis retinoic acid, with and without additional AH receptor ligand. 
Gel retardation analysis could be carried out using RXR proteins and radiolabelled oligonucleotides 
corresponding to elements isolated from the promoter of rat CYPlAl.
7.2.3A Modulation o f Aryl Hydrocarbon Receptor (AHR) and Mitogen-Activated 
Protein Kinase Kinase (MEK) Function By PD98059
In MCFIOA and MCFIOA-Neo (cell line has constituitively active MAPK cascade) cultures it has 
been reported that treatment with the MEK inhibitor, PD98059, strongly suppresses the TCDD 
induced accumilation of CYPlAl mRNA (see section 6.2.6; Reiners et aL, 1998). Reiners et aL 
(1998) also showed that PD98059 inhibited the binding of TCDD to AH receptor. From these 
results the authors postulated that the reduced mRNA levels noted in TCDD treated cultures 
reflected a PD98059-mediated supression of CYPlAl transcription. Using the CYPlAl reporter 
gene assay, IpM PD98059 was shown to significantly reduce the transcriptional activation of 
CYPlAl-dependent reporter gene expression by lOpM j3-naphthoflavone, in HepG2 cells cultured 
in media supplemented with complete serum. This reduction in transcriptional activation was not 
seen in similarly treated HepG2 cells that had been cultured in media supplemented with charcoal 
stripped serum. lOpM PD98059 was shown to significantly reduce the transcriptional activation of 
CYPlAl-dependent reporter gene expression by lOpM a-naphthoflavone treatment only in cells 
cultured in media supplemented with charcoal stripped serum. These results agree with the 
hypothesis put forward by Reiners et aL High PD98059 concentrations (lOOpM) were shown to
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significantly induce CYPlAl reporter gene transcription in HepG2 cells cultured in media
supplemented with either complete serum or with charcoal stripped serum. This would suggest that
PD98059 is a weak agonist of AHR and suppresses the transcriptional activation of CYPlAl
transcription by blocking the binding site for P-naphthoflavone. Figure 7-1 shows that the chemical
structure of PD98059 is remarkably similar to that of a-naphthoflavone. The structural similarity
between the MEK inhibitor PD98059 and the AH receptor ligands a- and p-naphthoflavone may be
providing us with a clue to the role of the AH receptor in cellular signalling. Stimulation of the
MEK/MAPK pathway can result in inhibition of cyclin dependent kinase activity and cell cycle
arrest (Pumiglia et al., 1997). The AH receptor has also been implicated in modulating cell cycle
progression (Ma and Whitlock, 1996). Supplementation of culture media with complete serum is
known to stimulate the MAPK cascade via membrane-bound receptors such as the growth factor
receptors (Troppmair et aL, 1994). The point at which PD98059 acts in the signal transduction
cascade stimulated by growth factors is illustrated in Figure 7-2 (Goetzl and An, 1998). j 
conclusion, the modulation of CYPlAl -dependent reporter gene transcription by PD98059 supports
the hypothesis made by Reiner et al. (1998), that PD98059 is an antagonist of AHR in addition to
being an inhibitor of MEK.
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Figure 7-1. Structures of PD98059, p-naphthof1avone and Related Flavonoids
p-naphthoflavone
(5,6-Bezof lauone)
PD98059
a-naphthoflavone 
(7 ,8-Benzoflavone)
flavanone
flavone
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Figure 7-2. Signal Transduction Cascade Stimulated By Growth Factors
Growth Factors, Lysophospholiplds 
and Other Ligands
RAS
R-PTK/NR-PTK
Raf
SOS PI3-K
IRS-1
GRB2 pllOp85
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Nuclear Activity
Gs, glycogen synthase; GSK-3, GS kinaseS; IRSl, insulin receptor substrate 1; MAPK, mitogen 
activated protein kinase; MAPKK, MAPK kinase; NR-PTK, R-PTK, receptor protein tyrosine 
kinase; non-receptor PTK; PI3-K, phosphatidylinositol 3-kinase; PPl-G, protein phosphatase.
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7.3 Conclusions and Further Work
Reporter gene assays for the detection of CYP4A1 and CYPlAl inducing compounds using 
transiently transfected HepG2 cells, have been developed and validated, and are described herein. 
Within a five day period a large number of compounds can be screened using only small quantities 
of test compound.
The SEAP reporter gene used for these systems allows reporter gene expression to be monitored 
without disturbing the cells and hence the kinetics of gene expression may be studied. The 
sensitivity, wide dynamic range, simplicity and format flexibility of the chemiluminescent assay for 
detection of the SEAP reporter gene product has significant advantages over other reporter gene 
assays. As the assay requires such small volumes of media sample it was possible to carry out 
transfections and SEAP level determinations in 96-well plates, thus simplifying the process. In 
future the whole system could be automated. The main drawback to these reporter gene assays is 
the high cost of the chemiluminscent reagents. Although a recently published paper has shown that 
it is possible to monitor SEAP levels in 1536-well plates, both sensitively and rapidly using the 
conventional inexpensive colorimetric assay, with reproducible results (Comley et aL, 1998). The 
work presented by these latter authors was carried out with the use of stably transfected cells that 
were seeded into 1536-well plates, the cells were then exposed to test compounds for only sixteen 
hours prior to SEAP quantitation. This would suggest that in future it would be possible to develop 
cell lines stably expressing the CYP4A1 and CYPlAl reporter constructs and to carry out the 
compound screening in 1536-well plates, allowing the assay time to be reduced down to under 
forty-eight hours. Further miniaturisation of the assays would reduce costs considerably, especially 
if SEAP was measured using a colorimetric assay. Stable cell lines would also negate the 
requirement for co-transfection of a p-galactosidase expression vector, as it would be unnecessary
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to normalise for transfection efficiency. Hence, costs would be lowered further because cell lysates 
would not need to be collected nor p-galactosidase levels determined.
The reporter construct p4AlBam+20CAT, containing a 5kb genomic fragment of the rat CYP4A1 
promoter, has been previously shown to be unresponsive to Wy-14,643 or 9-cis retinoic acid 
treatment, in Hepalclc? cells co-transfected with and without expression vectors encoding PPARa 
or RXRa (Aldridge et aL, 1995). P4AlBam+20CAT was similarly found to be unresponsive in 
HepG2 cells. The 5kb region of the CYP4A1 promoter, from which the PP responsive element 
used in the CYP4A1 reporter gene study was isolated, has not been sequenced or examined for the 
presence of other regulatory elements. This large fragment of the CYP4A1 promoter would 
provide an interesting area for future study; it may be possible to identify negative regulatory 
elements and other regulatory factors involved in the regulation of CYP4A1 expression.
Another area for possible future investigation is the molecular mechanism of CYPlAl induction by 
benzimidazole compounds such as omeprazole. These compounds are a different type of CYPlAl 
inducer from AH receptor ligands like TCDD (Curi-Pedrosa et aL, 1994). Recent experiments in 
HepG2 cells have shown that the tyrosine kinase inhibitor herbimycin-A and the tyrphostins block 
omeprazole induction of CYPlAl mRNA but not TCDD induced CYPlAl mRNA production 
(Kikuchi et aL, 1998). The data presented by Kikuchi and collègues would suggest that the 
omeprazole-mediated induction of CYPlAl involves activation of the AH receptor complex by 
signal transduction sytems and that it is distinct from induction mediated by AH receptor ligands. 
The molecular mechanisms involved in this possible alternative pathway of AH receptor activation 
remain to be elucidated.
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